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Killed vaccines of the adjuvant Corynebacterium parvum(Propioni-
bacteriuni acnes) have proved to be potent anti-tumour agents in a number
of experimental systems and are currently being assessed clinically,
either alone or as an adjunct to other cancer treatments. In animals,
systemically administered C■ parvum can exert a strong, non-specific
anti-tumour action which is thought to be mediated principally by
activated macrophages. The author describes in vitro experiments
analysing the possible pathways leading to the production of such acti¬
vated macrophages in C. parvum-treated CBA mice. The tumour studied
was a methylcholanthrene-induced fibrosarcoma.
It was found that spleen cells from mice treated intravenously, or
intraperitoneally (but not subcutaneously) with C. parvum could induce,
in vitro, anti-tumour cytotoxicity in normal, non-cytotoxic, murine peri¬
toneal macrophages, provided that C. parvum was also present. This re¬
quirement for the presence of C. parvum was shown to be a specific one,
other strains of C. parvum or other unrelated bacteria being ineffective.
The macrophage-activating cell was found to be radio-sensitive, but re¬
sistant to treatment with sodium aurothiomalate or anti-macrophage serum.
However, exposure of normal peritoneal macrophages to sodium aurothiomalate,
either before, or during activation with spleen cells, abrogated the
cytotoxic effects.
Nylon wool column separation of spleen cells into B cell-rich and
B cell-depleted fractions indicated a possible requirement for B cells
in the activation process. On the other hand a T cell requirement was
shown by the failure of spleen cells from C. parvum-treated T cell-de¬
prived mice to activate macrophages in vitro. Treatment of spleen cells
with anti-9 serum prior to the activation process yielded inconclusive
(ii)
evidence with regard to the T cell dependence of macrophage activation.
Spleen cells capable of activating macrophages in vitro did
not appear in the C. parvum-treated mouse until after day 6 post
C. parvum injection. This contrasted with the early appearance, by
day 3, of cytotoxic spleen and peritoneal cells in i.p.-treated mice.
This suggested the existence _in vivo of two separate pathways leading
to the stimulation of anti-tumour effector cells.
In vitro induction of anti-tumour activity could also be achieved
using locally-stimulated lymph node cells, or cell-free supernatants
from mixed cultures of C, parvum-sensitised spleen cells and C. parvum.
During the course of in vitro studies on C. parvum-activated
macrophages it was observed that such macrophages lost their cytotoxic
capacity on culture. This loss of activity could be delayed by the
addition of C. parvum to the cultures. This maintenance effect by C.
•parvum was found to be radioresistant, sensitive to sodium aurothio-
malate, T cell dependent, and at least partially specific.
The significance of these results and the possible mechanisms
underlying them have been discussed in relation to the existing know¬
ledge of C. parvum's biological and anti-tumour effects.
(iii)
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INTRODUCTIO N
1 . HOST RESISTANCE TO TUMOURS
A central objective of research into the therapy of cancer
is the elucidation of those features of tumours which distinguish
them from normal tissue and which enable them to escape the body's
usual homeostatic tissue restraints. Such differences between malig¬
nant cells and normal cells can then provide a basis for diagnostic
and therapeutic purposes, and, even for prophylaxis. However, it
is only in comparatively recent times that this concept of cancer
has attained universal acceptance since, apart from being supplied
by the body of nutrients and oxygen, tumours had often been regarded
as being autonomous, growing without regard to the well-being of
the organism as a whole. Nevertheless, it was well known that tumours
did not always progress inexorably and could in fact be held in check
or even repulsed by unknown homeostatic mechanisms. Much of this
evidence is anecdotal and concerns regression or progression of
tumours in individual cases. Prom an extensive review of cancer
literature between 1900 and 1965> Everson and Cole (1966) cite 176
cases sufficiently well documented to provide convincing proof of
spontaneous regression of established, untreated tumours. Some of
the regressions were permanent, others merely transient. In cases of
melanoma, for example, certain tumour nodules are frequently seen
to be regressing while others on the same limb are developing
(Bodenham, 1968). Many tumours such as breast carcinoma and mela¬
noma may suddenly reappear after many years of inactivity following
initial diagnosis and treatment of the primary lesion (Willis, 1973).
Occasional reports have appeared of cases in which tumour metastases
have regressed following surgical removal of the primary tumour
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(Rosenberg, Pox and Churchill, 1972) or following a febrile illness
or infection, particularly infections involving the tumour site or
its draining node (Nauts, Swift and Coley, 1946; Everson and Cole,
1966).
Direct evidence of one aspect of homeostatic tumour control came
with the clinical and experimental observations of Huggins illustrating
the hormone dependence of certain tumours of prostate, breast, thyroid
and kidney (Huggins and Hodges, 1941; Huggins, 1967). In addition
to hormonal control tumour cell growth may be governed locally by
tissue specific chalones (Bullough, 1975; Forscher and Monck, 1975).
Mere physical restraints may also play an important part in tumour
containment, tumour nodule size and subsequent metastatic spread
depending on angiogenesis (reviewed by Polkman, 1974) and tumour
invasiveness.
The idea that immune mechanisms might play a part in the resis¬
tance to and rejection of neoplasia developed as a consequence of
the awakening interest in immunological resistance to microbial
pathogens during the latter decades of last century. Central to
this idea was the expectation that tumour cells would be antigeni-
cally different from host tissue and, as with bacterial infection,
immunotherapeutic procedures could be developed against these foreign
antigens. The search for an effective immunotherapy of cancer con¬
tinues to this day. One such approach has involved the administration
of agents which potentiate specific and/or non-specific immunity.
The possible mechanisms involved in the anti-tumour effects of one
such agent Corynebacterium parvum provides the subject for this thesis.
The evidence for an active participation by the immune system in
-3-
the host's defence to tumours, and the prospects for successful
immunological intervention in cancer, particularly with agents such
as C. parvum. are outlined in the remainder of this introductory
review.
2. TUMOUR ANTIGENS
Unaware of the principles of allograft rejection and of histo¬
compatibility, researchers in the first quarter of this century
believed they were studying tumour-specific immunological responses
when they transplanted tumours. The unequivocal demonstration that
tumours could be antigenically different from their original host
had to await the development of in-bred strains of laboratory
animals during the 1940's.
2.1 Tumours induced by chemical carcinogens
Tumour associated transplantation antigens (TATA) were first
demonstrated on methylcholanthrene-induced sarcomas in mice (Gross,
1943; Foley, 1953; Prehn and Main, 1957). Ligation or excision
of tumour transplants in syngeneic mice resulted in resistance to
subsequent challenge by the same tumour. That the induced resis¬
tance was not due to histo-compatibility differences between tumour
and host was proved by experiments in mice bearing primary tumours
(Klein, Sjogren, Klein, and Hellstrbm, I960).
The TATA of chemically-induced neoplasms are generally unique,
in sharp contrast to those of virally-induced tumours. For example,
tumours induced independently in the same host do not cross react
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antigenically (Globerson and Feldman, 1964). However, evidence
for shared TATA among chemical induced tumours has been reported
(Heiner and Southam, 1967; Taranger et al.. 1972). Subsequent
infection of tumours with an oncogenic virus would also lead to
expression of virus associated tumour antigens (Stuck, Old and Boyse,
1964; Klein, 1969). Foetal antigens may also be expressed on
chemical-induced tumours (Baldwin, Glaves and Vose, 1972; Baldwin,
Embleton, Price and Vose, 1974).
2.2 Tumours induced by viruses
Tumours induced by the same virus share common TATA (Habel,
1961; Sjogren, Hellstrom and Klein, 1961; Klein and Klein, 1964).
DNA virus-induced TATA are distinct from the actual viral antigens
(Law, 1970). Differentiation between RNA virus antigens and tumour
antigens is difficult to establish since most of the tumour cells
produce infectious virions which bud from the cell surface (Law,
1970). However, there is evidence that there are virally determined
cell surface antigens distinct from the viral envelope antigens
(jonsson and Sjogren, 1965; Levy et al.. 1969; Lilly and Steeves,
1974). In addition to the common virus-associated antigen, tumours
such as the virus-induced mammary tumour may have other distinct
TATA (Vaage, 1968; Morton et al., 1969).
2.5 Differentiation antigens
Differentiation antigens represent the re-expression in a tumour
cell of certain genes which are normally only operative at a certain
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stage in the differentiation of a cell from its embryonic stage
to specialised cell. De-repression of genes may be a fundamental
process in malignant transformation. Two such differentiation
antigens are the TL and Gix antigens normally expressed on thy¬
mocytes from certain mouse strains, but absent from others. TL-
negative mice with leukaemia often express the TL antigen on their
leukaemic cells (Boyse, Old and Stockert, 1968). Similarly, the
Gix antigen can be induced in Gix-negative rat or mouse thymocytes
by infection with Gross murine leukaemia virus (MuLV) (Stockert,
Old and Boyse, 1971; Stockert et al., 1972). Both these systems
are thought to represent de-repression in negative strains of
mice of genes coding for TL or Gix. Many tumours express other
normal antigens and some do so in greater quantity than normal
tissue (Fogel and Sachs, 1962).
2.4 Embryonic (EA) or Foetal (FA) antigens
Embryonic or foetal antigens are expressed on many tumours
including virus-induced (Coggin et al., 1970; Ting et al., 1972)
and chemical-induced tumours (Baldwin et al., 1974). Certain embry¬
onic antigens may be common to several different tumours (Thomson
and Alexander, 1973; Ting et al.. 1972). Immunisation with foetal
tissue evokes immunity to subsequent tumour challenge in some systems
(Coggin et_al., 1970; Girardi et_al., 1973; Grant et al., 1974)
but not in others (Ting et al., 1972; Baldwin et al.. 1974). This
discrepancy may be due to the failure to select embryo cells during
the limited period in which these particular antigens appear in
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embryogenesis (Coggin et_al., 1970; Baldwin et al., 1972). Brawn
(1970) demonstrated that lymph node cells from multiparous mice
were cytotoxic in vitro to several methyl-cholanthrene-induced
sarcomas.
2.5 Antigens on human tumours
A distinctive feature of many human tumours is that they
carry cross-reacting organ or tissue-specific antigens. Thus
lymphocytes from individuals with a particular cancer can by cyto¬
toxic or growth inhibitory in vitro to tumour cells from another
individual provided it is of the same histologic type (Hellstrdm,
Hellstrom, Sjogren and Warner, 1971; Hellstrdm, Warner, Hellstrdm
and Sjogren, 1973). These antigens may be differentiation or em¬
bryonic antigens.
Two tumour-associated macromolecules have received a great
deal of attention in recent years, carcinoembryonic antigen (CEA)
and alpha-foetoprotein (AFP). These antigens can be detected in
the serum of cancer patients and, although of doubtful immunogeni-
city, would appear to be of value as cancer diagnostic aids (see
Zamchek and Kupchik, 1976; Mclntire and Waldmann,1976).
2.6 Immunogenicity
It is recognised that the so-called spontaneous tumours, tumours
of unknown aetiology, both in man and animals, are generally non-
immunogenic (Main and Prehn, 1957; Baldwin, 1966; Peters, 1975).
Immunogenicity is usually assessed by tumour transplantation into
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syngeneic animals previously exposed to that tumour. Only
immunogenic tumours will immunise against such subsequent challenge.
Chemical-induced tumours can also be non-immunogenic (Baldwin, 1973;
Baldwin and Embleton, 1969). Prehn. (1975) demonstrated that
both immunogenicity and the latent period between exposure of
tissue to the carcinogen and appearance of the tumour, were depen¬
dent on the dose of the carcinogen: as the concentration was de¬
creased the latent period lengthened and immunogenicity declined.
The fact that so much experimental work in tumour biology is
conducted using highly immunogenic tumours has resulted in consid¬
erable concern over the desirability of studying poorly immunogenic
tumours which would more closely reflect those neoplasms encountered
clinically (Klein and Klein, 1977; Hewitt, Blake and Walder, 1976;
Weiss, 1977).
3. TUMOUR IMMUNOLOGY
If so many tumours do possess neoantigens or TATA, and hence
are potential targets for the immune system, it would be expected
that immune mechanisms would play an important part in the host's
resistance to that neoplasm. Indeed, there is now a vast body of
evidence on the interaction of the immune system and malignant
tumours. Some of this is circumstantial, such as the clinical
observations of regression mentioned earlier, and which is indica¬
tive of host resistance but gives no insight into the mechanisms
involved. Other circumstantial evidence has come from histological




Many malignant tumours are infiltrated by lymphoreticular
cells: lymphocytes, macrophages, polymorphonuclear leucocytes,
plasma cells, mast cells. This stromal response to neoplasia has
been of interest to pathologists since the latter half of the 19th
century (see Underwood 1974 for review) and many believed the phen¬
omenon was indicative of host defence against the tumour (Da Fano,
1912; Murphy, 1926). Attempts to correlate lymphoreticular infil¬
tration with favourable prognosis have been successful with certain
tumours such as carcinoma of the breast (Hamlin, 1968) and oesophagus
(Takahashi, 1961) seminoma (Dixon and Moore, 1953) and many more
(Underwood, 1974). Both positive (Thompson, 1972) and negative
(Little, 1972) correlations have been reported for malignant melanoma.
Sinus hystiocytosis of draining lymph nodes of tumours has also been
reported (Black, Opler and Speer, 1954) but the diagnostic or
prognostic value of this observation is now in doubt (see Silverberg,
Frable and Brooks, 1973). A recent study using immunofluorescent
techniques showed that T cells predominate in the infiltrates of
primary human tumours but that B cells predominate in certain
metastases (Husby, Hoagland, Strickland and Williams, 1976). How¬
ever, many studies of human and animal tumours have also demon¬
strated the macrophage to be an important constituent (up to 50$>)
of tumour infiltrates (Evans, 1972; Gauci and Alexander, 1975;
Szymaniec and James, 1976; K. Moore and Moore, 1977). The magnitude
of the cellular infiltrate correlates well with tumour immunogeni-
city (Evans, 1972; K. Moore and Moore, 1977). The significance of the
high macrophage content of some tumours is discussed more fully below.
-9-
3.2 Immune surveillance
The last two decades has seen intensive research into the
role of the immune system in tumour biology. The most important
concept, and indeed the central dogma of tumour immunology in this
period, has been that of immune surveillance. This concept originally
phrased by Ehrlich (1909) and. later developed by Thomas (l959)»
Burnet (1964, 1967, 1970a, b, 1971) and others (Good and Finstad,
1969), was that tumours arise at a much more frequent rate than
clinical evidence would allow but that the majority of these tumours
are recognised as foreign and eliminated soon after initiation by
the immune system. Failure of this surveillance mechanism results
in malignant tumour growth. Thomas (1959) actually proposed that
the raison d'etre of cell-mediated immunity, as observed in allograft
rejection, was in fact a primary defence mechanism against neoplasia.
An important consequence of the theory, and one which ought
to provide much of its supporting evidence, is that individuals
with congenitally defective immunological responses or individuals
undergoing immunosuppressive therapy (e.g. transplant recipients)
should exhibit a greatly increased incidence of malignant tumours
(Good and Finstad, 1969; Keast, 1970; Gatti and Good, 1971; Waldmann
et al., 1972). Alternatively, the development of a malignant tumour
in an individual should have been associated with, or presaged by,
some immunological deficiency. It should be noted that initial
failure of immunosurveillance does not imply that an immune response
is not subsequently evoked by the tumour. Evidence dealing with the
immunology of established tumours will be dealt with in a later section.
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3.3 Immunodeficiency - Clinical Evidence
There have been several analyses of the proposed link between
immunodeficiency and cancer (Good and Finstad, 1969; Gatti and
Good, 1971; Kersey, Spector and Good, 1973a, b; Melief and
Schwartz, 1975). Patients with the Wiskott-Aldrich syndrome or
ataxia-telangiectasia exhibit, an increased incidence of lympho-
reticular tumours while patients with Bruton's agammaglolbulinaemia
have a greater chance of developing leukaemia (Kersey et al.. 1973b).
A few individuals with severe combined immunodeficiency (Kersey
et al., 1973b) and also those with the Chediak-Higashi syndrome
(Windhorst, Zelickson, and Good, 1966) have been reported to develop
lymphoreticular malignancy. Collation of cases at the Immunodefici¬
ency - Cancer register in Minnesota, USA showed that 58$ of patients
had lymphoreticular tumours, 17$ had leukaemias and 18$ had epi¬
thelial tumours (Kersey et al.. 1973a).
A higher incidence of malignancy has also been reported in
connection with certain genetic disorders such as Fanconi's anaemia
(Swift and Hirschhorn, 1966) and Klinefelter's syndrome (Fraumeni
and Miller, 1967), diseases in which no detectable immune deficit
has been detected. This observation may be accounted for by the
extraordinary susceptibility of fibroblasts from these patients
to in vitro viral transformation (Todaro, Green and Swift, 1966;
Mukerjee, Bowen and Anderson, 1970).
Individuals on immunosuppressive therapy also exhibit an
increased frequency of malignancy. Hoover and Fraumeni (1973),
analysing data from 6,297 renal-transplant recipients, observed
that the risk of developing one of the lymphomas was 35 times
-11-
higher than normal and that with the most prominent type, reticulum-
cell sarcoma, the risk was increased 350-fold. Skin and lip cancers
also had a statistically greater incidence in these individuals.
An unusual feature of the lymphomas and which has not been ade¬
quately explained (see Stutman, 1975a; Melief and Schwartz, 1975)?
was their extraordinary frequency in central nervous tissue.
The predominance of lymphoreticular malignancies in the above
studies detracts from the support they are alleged to give to the
immune surveillance concept; a greater incidence of all tumour
types would be expected in the absence of a healthy surveillance
system. Several explanations for the frequency of lymphoreticular
malignancy have been proposed. Schwartz (1975) has pointed out
that these tumours are normally very rare (Silverberg and Grant,
1970) and that their relatively high immunogenicity would ensure
early elimination by the immune system, unless it was depressed.
It has also been argued that chronic antigenic stimulation from
infection (or the graft itself in transplant recipients) may lead
to development of lymphoreticular malignancy (Ten Bensel, Stadlam
and Krivit, 1966; Krueger, 1972). This would arise because of the
lack of immunoregulatory feedback mechanisms (eg. T suppressor
cells) and/or activation of latent oncogenic viruses within acti¬
vated lymphocytes (Schwartz, 1972, 1975). In this respect it is
interesting that Lukes and Collins (1974) regard the reticulum-
cell sarcoma as consisting of cells morphologically similar to
antigen-stimulated lymphocytes and not reticulum cells.
It should be noted that in patients with other disease states,
such as rheumatoid arthritis and myasthenia gravis, and who are
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being treated with immunosuppressive drugs, the incidence of new
tumours is much less dramatic than in organ transplant recipients,
and in many studies no positive correlation has been found (Brendel,
Seifert, Lob et_al., 1972; Pirofsky et_al., 1972; see also Stutman,
1975a).
Association between cancer incidence and those periods of life
during which immune responses may be poorly developed or defective
such as in old age or the perinatal period, has often been quoted
in support of the immune surveillance theory (Gatti and Good,
1971; Keast, 1970). Doll and Kinlen (1970) agree that in general
there is a peak incidence of malignancy in infancy or childhood
and that following adolescence there is a fairly regular increase
to old age. However, they also quote many discrepancies; seminoma,
Hodgkin's disease, carcinoma of the cervix. In addition, it must
be remembered that many aged individuals are entirely immunocompe¬
tent (Hallgren et al.. 1975), and that immunological responses have
been detected in the human foetus (Silverstein and Lukes, 1962).
Doll and Kinlen (1970) went on to point out that tumour incidence
correlated more closely with length of exposure to carcinogens as
shown by leukaemia incidence in patients exposed to irradiation
for ankylosing spondylitis (Doll and Kinlen, 1970), cancer of lung
in asbestos workers (Knox, Holmes, Doll et al., 1968) and cancer of
bladder in workers exposed to naphylamine or benzidine (Case et al..
1954).
5.4 Development of tumours in thymectomised or ALS-treated animals
The literature contains many studies on the effects of neonatal
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thymectomy and anti-lymphocyte serum (ALS) on tumour development,
spontaneous as well as viral- and chemical-induced tumours.
An extensive review by Stutman (1975a) illustrated that many of
these reports provide conflicting results with respect to the
role of immunity in host defence of neoplasia. Many of the dis¬
crepancies between experiments may be accounted for by differences
in carcinogen used, dose, strain of animal and on the immuno¬
suppressive effects of the carcinogen.
3.4.1 Chemical-induced tumours
Mice thymectomised in early life and injected as young adults
with methylcholanthrene (MC) subcutaneously generally showed no
increased incidence of local tumours (Stutman, 1975a). In contrast,
thymectomy of mice together with exposure to chemicals such as
urethane resulted in an increase in lung adenoma formation (Ribacchi
and Giraldo, 1966; Trainin and Linker-Israeli, 1969, 1970). Grafting
of thymus back into these mice normalised the incidence of lung
adenoma (Trainin and Linker-Israeli, 1970). Results with ALS
follow much the same pattern as for thymectomy with data appearing
for and against immune surveillance (see Stutman, 1975a). One possible
explanation for the lack of effect in some experiments using these
procedures might be that the carcinogens are immunosuppressive any¬
way and no additional effects of immune deprivation would be observed
(Kripke and Borsos, 1974). However, Stutman (1973) was able to
distinguish between carcinogenic effects and immunosuppressive effects
by varying the dose of carcinogen used.
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3.4.2 Virus-induced, tumours
The thymus dependence of host resistance to many oncogenic
viruses has been demonstrated repeatedly. Neonatal thymectomy
enhances the tumour incidence resulting from oncogenic viruses
in hamsters (Yohn, Funk and Grace, 1968; Van Hoosier, Gyst and
Trentin, 1968), rats (Allison and Taylor, 1967; Vandeputte and De
Somer, 1965), and mice (Miller, Ting and Law, 1964; Law, 1966a, b;
Allison, 1970). Furthermore, experiments in which post-thymectomy
immune deficiency was restored confirmed that the immune system
plays a major part in the host resistance to polyoma virus onco¬
genesis (Law, 1966a, b; 1969; 1970).
Immunosuppression by ALS treatment has also enhanced tumour
induction in many experimental systems: in mice by adenovirus
o
(Allison, Berman and Levery, 1967); and polyma virus (Allison and
Law, 1968); in rats by polyma virus (Vandeputte, 1968); and in
hamsters by SV40 (Tevethia, Breesman, Lausch and Happ, 1968).
However, there are also ALS results discordant with these (see
Stutman, 1975a). Explanations for the discrepancies can probably
be found in the many variables affecting results of viral oncogene¬
sis and additionally there is the problem that immunosuppression can
lead to elevated, unchanged or decreased levels of interferon
(Glasgow, 1971). Experimental systems involving leukaemias and
lymphomas are also complicated by the possible effects of ALS on
the tumour target cells themselves.
Despite these problems it can be said that, in general, neo-
l\ ^
natal tymectomy or ALS treatment facilitates viral oncogenesis and
thus these results provide strong support for the immune surveillance
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theory. Klein (1973, 1975) has argued that the immune system's
competence to resist the effects of oncogenic viruses compared
to its relative inability to deal with chemical-induced tumours
could be explained by the relatively recent (in evolutionary terms)
appearance in the environment of such chemical carcinogens. Immune
protective mechanisms against tumour viruses may have evolved
over a long period of time and may be generally transmitted by
immune responsiveness genes (Klein, 1975).
An important distinction in studies of viral oncogenesis is
whether the observed thymus dependence of host resistance is direc¬
ted at the virus itself, at tumour antigens, or both. Dissociation
of anti-viral and anti-tumour immunity has been discerned in Marek's
disease of fowl (Powell and Rowell, 1977) and in an oncogenic herpes
virus system (Laufs and Steinke, 1976).
3.4.3 Spontaneous tumours
The influence of neonatal thymectomy on the development of
spontaneous tumours has also produced conflicting reports. Negative
correlations were found by Sanford et al. (1973) and Burstein and
Law (1971), whereas Cornelius (1971 ) found an increased incidence
of lymphoreticular sarcomas in thymectomised mice. Thymectomy has
been found to actually decrease the incidence and prolong the latent
period of virus-induced 'spontaneous' mammary tumours (Martinez,
1964; Law, 1969). The reasons for this phenomenon are not clear
but may involve hormonal or immunostimulation (vide infra) depen¬
dencies.
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3.5 Development of tumours in nude mice
Although, they can respond, to some antigens and. possess some
theta-positive cells, homozygous (nu/nu) nude mice, nevertheless,
have a greatly impaired immune system making them highly susceptible
to infection and incapable of rejecting allografts, and even xeno¬
grafts (Wortis, 1974). The risk of developing spontaneous tumours
should, therefore, be high in these animals following predictions
from the immune surveillance theory. However, observation of thous¬
ands of nude mice over their life span (7 months in conventional
housing and approaching that of normal mice in germfree or pathogen
free environments) only found an increased incidence of lymphoreticular
tumours (Outzen et al.. 1975; Rygaard and Povlsen, 1976). Reasons
why this tumour type is not acceptable evidence for the operation
of immune surveillance have been discussed in an earlier section.
There seems to be no increase in tumours induced in these mice
by polycyclic hydrocarbon carcinogens (Outzen et al., 1975; Stutman,
1974), and, with the exception of polyma virus-induced tumours, sus¬
ceptibility to viral oncogens is no greater than in control (nu/+)
mice (Stutman, 1975a). It must be recognised that nude mice may
have alternative defence mechanisms mediated by B cells and/or macro¬
phages. Stutman (1975b), for example, demonstrated that age-depen¬
dent resistance to polyoma virus in the nude mouse was mediated by
non-T cells.
3.6 Immunologically privileged sites
Various immunologically privileged sites are known in experimental
animals where first set allografts or xenografts are permitted. These
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sites are the brain, hamster cheek pouch, anterior chamber of the
eye, and the mouse mammary fat pad. Tumours might be expected to
arise more frequently or be induced more readily in these sites
in the absence of immunological surveillance. However, this
expectation is not fulfilled by the available evidence. Spontaneous
tumours of the brain are rare in laboratory mammals (Luginbuhl,
Frankhauser and McGrath, 1968) and induction of tumours in both
brain and hamster cheek pouch is often more difficult than in other
tissues. In addition, any resulting tumours develop either more
slowly than, or at a comparable rate to equivalent tumours in non-
immunologically priveleged sites (Stutman, 1975a).
3.7 Host-tumour immunological interactions
The existence of tumour associated antigens and of immune
responses to them, at least in experimental tumour systems, together
with the circumstantial clinical evidence provide a powerful case
for the involvement of immunological processes in the host's reaction
to malignant tumours. The evidence for an immunological surveillance
function as envisaged by, say, Burnet (l970a, b; 1971) is not, however,
entirely convincing but does not detract from the demonstration of
immune responses to established tumours. It is probable that a modi¬
fied immunosurveillance theory will emerge encompassing non-specific
anti-tumour effects mediated by macrophages and null cells (vide
infra) in addition to specific T cell effects.
There is now a vast literature on tumour immunology. The follow¬
ing sections briefly outline this knowledge and the ways in which it
has been obtained. Several techniques are available for the demon-
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stration of humoral and cell-mediated responses to tumours.
4. HUMORAL IMMUNITY
4.1 Immunofluorescent and antiglobulin binding; assays
Anti-tumour antibodies can be detected by immunofluorescent
techniques (Moller, 1961) either directly (Goldstein, Klein, Pearson
and Clifford, 1969) or indirectly (Klein, Clifford, Klein and
Stjernsward, 1966). For example, antibodies directed at melanoma
cells have been detected in the sera of melanoma patients (Morton,
Malmgren, Holmes and Ketchum, 1968). An alternative to this assay
is the radiolabelled anti-globulin binding test (Burdick, Cohen
and Wells, 1973; James et al.. 1976, 1977). The presence of
antibodies on tumour cells can lead to complement-dependent or
cellular-dependent growth inhibition or lysis of tumour cells as
demonstrated _in vitro (vide infra). The significance of anti-
tumour immunoglobulins in vivo is still in some doubt. Blocking
and enhancing antibodies and antigen-antibody complexes will be
discussed in a later section.
4.2 Complement fixation and complement-dependent cytotoxic antibody
Both complement-fixation (Eilber and Morton, 1970; Morton,
Eilber, Malmgren and Wood, 1970) and complement-dependent cytotoxic
antibody (Bloom, 1970; Fritze, Kern and Pilch, 1974) tests have been
used to assess anti-tumour antibodies in patients' sera. Complement-
fixing antibody levels may correlate with the clinical course of
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neoplastic disease as, for example, in the case of melanoma (Morton
et al., 1970), but in general, the significance of such assays to
in vivo events is open to criticism particularly since positive
results usually require use of xenogeneic serum for the complement
source.
Antibody-dependent cell-mediated (K cell) cytotoxicity is dealt
with under effector cells.
4.3 Inhibition of tumour mobility and re-aggregation
The presence of anti-tumour antibodies can also be detected by
their effect on in vitro tumour cell behaviour. Currie and Sime
(1973) showed that the in vitro movement of lymphoma cells could be
inhibited by serum from syngeneic mice immune to those lymphoma
cells. Currie (l976) also described a system in which tumour cell
aggregation in vitro is inhibited by the presence of tumour-immune
sera.
4.4 Lymphokines
A number of pharmacologically active, non-antibody substances,
known collectively as lymphokines (Dumonde et al., 1969) are produced
and released by immune lymphoid cells responding to specific antigen.
Many of these lymphokines, such as lymphocyte mitogenic factor,
lymphotoxin, skin reactive factor, chemotactic factor, macrophage
migration inhibitory factor, and macrophage activation factor, mediate
and regulate cellular immune responses including those to tumour cells.
(For a review on lymphokines see Dumonde et al., 1975). Some of
the above lymphokine effects are possibly mediated by the same
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molecular moiety, although in most cases they can only be classified
by biological function. For example, there is some evidence that
macrophage migration inhibitory factor and macrophage activation
factor are the same entity (Nathan, Remold and David, 1973).
Lymphokine preparations have been used successfully as intradermal
injections to treat cutaneous metastases in patients with adeno¬
carcinoma of the breast (Papermaster et al., 1974; 1976).
Another group of lymphocyte-derived mediators called transfer
factors can confer specific cell-mediated responses to a number of
antigens, including tumour cells, when injected into non-immune
recipients. Transfer of such responses has been demonstrated by
delayed hypersensitivity skin tests and various in vitro assays
such as lymphocyte transformation and macrophage migration inhibi¬
tion (Lawrence, 1969). A number of studies using transfer factor
preparations in cancer therapy have been reviewed by Lo Buglio and
Neidhart, (1974). Transfer factor as described by Lawrence (1969)
differs from immunogenic ERA, also derived from lymphocytes, and
which can transfer cellular and humoral immunity (Deckers and Pilch,
1971; Dodd, Scheetz and Rossio, 1973).
5. CELLULAR IMMUNITY
Several in vivo and in vitro assays are available for the
demonstration of cell-mediated tumour immunity.
5.1 In vivo Assays
5.1 .1 Neutralisation tests (¥inn assay) and adoptive immunisation
This assay, originally developed by Winn (1959) for studies on
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homograft immunity, generally involves inoculation of mixtures of
lymphocytes from tumour-immune animals and tumour cells into syn¬
geneic, suh-lethally X-irradiated recipients. This procedure was
shown to decrease the rate of growth of methylcholanthrene (MC)-
induced sarcomas (Klein et al., I960; Old et al., 1962). Virus-
immune lymphocytes could also protect mice against virally-induced
tumours (Sjogren, Hellstrom and Klein, 1961; Slettenmark and Klein,
1962). Mikulska Smith and Alexander (1966) found that transfer of
protection by spleen cells in a rat-sarcoma model was only possible
20 days or more following amputation of the tumour.
Other investigators have been able to adoptively immunise against
subsequent tumour challenge by injection of immune lymphoid cells
(Old et al.. 1962; Delorme and Alexander, 1964). Although somewhat
dubious ethically, equivalent experiments have been performed in
cancer patients in which autologous leucocytes were mixed with
autologous tumour cells and re-injected into the patients' skin.
(Southam, 1967). Inhibition of tumour nodule formation was observed
in 20 of 44 patients.
5.1.2 Delayed hypersensitivity
Delayed hypersensitivity skin tests have been employed extensively
to evaluate the immunocompetence of cancer patients by assessing
their reactivity to tumour cell extracts or non-tumour antigens. In
one such study using the skin-sensitising hapten dinitrochlorobenzene
(DNCB), hypersensitivity to this chemical, shortly after surgery, was
correlated with a lower rate of recurrence and improved survival
(Pinsky, Wanebo, Mike and Oettgen, 1976a). The use of DNCB as a
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therapeutic agent is discussed in a later section.
Autologous skin testing with extracts of a patient's own tumour
has been widely investigated and in some studies positive reactions
have correlated with remissions or otherwise favourable prognosis
(Bluming et al.. 1971; Char et al., 1973) but not in others (Gutterman
et al.. 1973).
5.2 In vitro Assays
5.2.1 Lymphocyte transformation (blastogenesis)
Assays of lymphocyte transformation provide another way of
investigating the cell-mediated response in tumour immunity.
Sensitised lymphocytes can be stimulated to form immunoblasts in
vitro by exposure to the sensitising antigen. Transformation also
takes please without previous sensitisation when lymphocytes are
exposed to cells carrying different major histocompatibility antigens
(Bain, Vos and Loewenstein, 1964; Button, 1965). This effect has
meant that in many studies it has been difficult to determine if
the observed transformation was due to prior sensitisation to
tumour antigens or to a primary immune recognition process. The
evidence tends to support the former concept. (Stjernsw&rd, Vanky
and Klein, 1973; Golub et al., 1972). For more information on
lymphocyte transformation tests and their associated problems consult
Oppenheim and Schecter (1976).
Incubation of patients' lymphocytes with autologous tumour cells
or tumour cell extracts have given positive results with many human
tumours (Herberman, 1974). In one study cells from lymph nodes
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draining patients' tumours were refractory to stimulation, in con¬
trast to the positive reaction of peripheral blood lymphocytes from
the same patient (Stjernsward and Vanky, 1972; Vanky, Stjernsward,
Nilsonne and Sundblad, 1973). This was probably due to inhibition
by excess antigen in the node since the lymph node cells could still
stimulate autologous peripheral lymphocytes. In another study
greater stimulation by autologous tumour cells was obtained in
patients with localised disease than in patients with systemic
disease (Mavligit, Ambus, Gutterman and Hersh, 1973).
Blastogenesis assays can also be used to detect the presence of
blocking factors in patients' sera. Gutterman et al.. (1973) have
shown that serum inhibition of blastogenesis correlated with good
prognosis in leukaemia. However, this has not proved to be the case
with other tumours where the observation generally reflects exten¬
sive disease and poor prognosis (Stjernsward et al., 1973).
5.2.2 Inhibition of leucocyte and macrophage migration
Among the lymphokines released by sensitised lymphocytes acti¬
vated in vitro by the appropriate antigen, is the macrophage (and
monocyte) migration inhibitory factor (MIF) which will retard the
migration of macrophages and monocytes from capillary tubes (Morley,
Wolstencroft and Dumonde, 1973; Rocklin, 1976). This phenomenon has
proved to be a very useful _in vitro correlate of delayed hypersensiti¬
vity and has frequently been used as an assessment of cell-mediated
immunity in tumour-bearers (Herberman, 1974).
In animal models, where macrophage populations can be readily
obtained from spleen and peritoneal cavity, the test has demonstrated
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tumour-specific immunity (Kronman et al., 1969; Vaage, Jones and
Brown, 1972). However, in humans, experimenters generally have to
use peripheral blood leucocytes as the source of their reactive
cells in one of two modifications of the assay. The first is
an indirect assay in which blood lymphocytes are cultured with
autologous tumour cells or tumour cell extracts and the culture
supernatant then tested for the presence of MIF using non-immune
guinea pig macrophages (Hilberg, Balcerzak and LoBuglio, 1973;
Wolberg and Goelzer, 1971). The other assay involves the direct
use, in capillary tubes, of human blood leucocytes as the source
for both migratory cells and prducer of MIF, and is more appropriately
called the leucocyte migration inhibitory test. This technique
has been used to. advantage by Cochran and his colleagues (1973)
in a study of melanoma and breast carcinoma patients and which showed
a correlation between lack of demonstrable MIF and the extent of
metastatic spread.
5.2.3 Inhibition of leucocyte adherence
Similar to the MIF and LIF assays is the leucocyte adherence
inhibition assay in which peripheral blood leucocytes are prevented
from adhering to glass by exposure to sensitising antigen (Halliday
and Miller, 1972; Maluish and Halliday, 1975). Hse of this test
in studies of melanoma and breast carcinoma indicated that patients
with small tumour burdens (stage I or II), in contrast to those
with large tumour burdens (stage III or IV), generally had peripheral
leucocytes which exhibited adherence inhibition when exposed to tumour
extracts (Grosser and Thomson, 1975; Marti and Thomson, 1976). The
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monocyte was shown to be the indicator cell manifesting non-adherence
and this reaction was associated with the binding of tumour antigen
via specific cytophilic anti-tumour IgG antibody on the monocyte
surface (Grosser, Marti, Proctor and Thomson, 1976; Marti, Grosser
and Thomson, 1976). Furthermore, the non-reactivity of monocytes
in patients with advanced cancer was attributed to the failure of
serum anti-tumour antibody to bind to monocytes because of an excess
of tumour antigen and immune complexes (Grosser and Thomson, 1976).
5.2.4 Colony inhibition and cytotoxicity assays
A number of in vitro assays have now been developed for the
assessment of cell-mediated immunity to tumours. These assays
generally consist of a period of incubation in which tumour cell
monolayers in Petri dishes or 96-well microculture plates are ex¬
posed to the test lymphoid cells, followed by some assessment of
remaining viable tumour cells. Growth inhibition (cytostasis), or
death or injury (cytotoxicity) of tumour target cells is determined
by the relative effects of normal (non-immune) lymphoid cells and
the test (tumour-bearer or tumour-immune) lymphoid cells. As there
are a number of reviews and articles dealing with thesein vitro
assays the following descriptions will be brief. (For more details
see: Perlmannand Holm, 1969; Cerottini and Brunner, 1974; Hellstrom
and Hellstro'm, 1974; Herberman, 1974; Baldwin, 1975; Herberman and
Oldham, 1975; Ting, Park, Nunn and Herberman, 1977).
The various assays differ principally in the way numbers of
viable cells are assessed at the end of the test. The earlier assays
involved visual counting of cells (Takasugi and Klein, 1970; Hellstrom
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et al., 1971), cell colonies (Hellstrom, 1967), or of cell nuclei
(Roseneauand Moon, 1961; Wilson, 1963; Ulrich and Keiler, 1969).
In addition to being tedious, these methods lacked objectivity
and have now, therefore, been largely superseded by a number of
assays utilising radioisotope cytoplasmic, DNA, or RWA labels such
as: sodium ( Cr)-chromate (Brunner et al., 1968); ( H)-proline
rz
(Bean et al., 1973); ( H)-thymidine (Jagarlamoody et_al., 1971 );
14- 125( c)-thymidine (Vainio et_al., 1964); 5-( l)iodo-2'-deoxyuridine
C^ITJDR: Cohen et al., 1971); (^H)-uridine (Hashimoto and Sudo,
1971); Technitium-99m (Barth et al.. 1972). These assays measure
either isotope released from dead or injured cells, or the isotope
incorporated into viable cells remaining at the end of the test.
Despite being convenient to use, the various radioisotope
.51 N
techniques do have disadvantages. The { CrJ method suffers from
a high spontaneous release of the label restricting the assay to
short term incubation periods of less than 20 hours. Some nucleic
3 3
acid labels, particularly ( H)-thymidine and ( H)-uridine can be
reutilised by other viable cells when released. The thymidine labels,
1 23
including the thymidine analogue ( IUDR), can be competitively
inhibited by cold thymidine or its derivatives released into the
culture system by dead or dying cells (Opitz et al., 1975; Kasahara
and Shioiri-Nakano, 1976; Evans and Booth, 1976). The label itself
can also be denatured in vitro (Marsh and Perry, 1964).
Other problems that have been encountered with microcytoxicity
assays in general have been: in vitro development of lymphocyte
activation ana/or suppression; non-specific cytotoxicity; loss of
activity of effector cells with prolonged culture; stimulation/feeder
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effects of lymphoid cells on target cells; inadequate controls
due to 'natural' cytotoxicity or target cell stimulation; and dis¬
crepancies in results when using established cell-lines as opposed
to short-term cultures of excised tumours (Baldwin, 1975; Herberman
and Oldham, 1975; Perlmann, Troye and Pape, 1977). These difficul¬
ties, more apparent in human cancer work, require that the chosen
assay be thoroughly investigated before it can be deemed reliable
for a particular study. References to studies employing in vitro
assessment of cell-mediated tumour immunity can be found in the papers
and reviews cited above.
5.3 Effector cells
5.3.1 Immunoblasts
Immunoblasts, highly mobile, large lymphoid blast cells with
cytoplasmic basophilia, pyroninophilia, prominent nucleoli and
frequent mitotic figures, appear in antigen-stimulated lymph nodes
from which they are subsequently released in large numbers into the
blood stream (Crowther, Hamilton Pairley and Sewell, 1969). They
contain and secrete antibody, and can be potent cytotoxic effector
cells in vitro, the cytotoxicity being mediated by the antibody.
Following inoculation of syngeneic tumour cells, immunoblasts are
present in the lymph for only a short period. Their reappearance
on extirpation of the growing tumour suggests that they are inhibited
from leaving local nodes by the tumour presence (Alexander and Hall,
1970). Immunoblasts responding to tumour antigens have been used
therapeutically in an experimental system (Delorme and Alexander, 1964).
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5.3.2 Lymphocytes
The evidence demonstrating the involvement of lymphocytes
in both the initiation and the effector phases of tumour immunity
is now considerable, and has been extensively reviewed (Perlmann
and Holm, 1969; Baldwin, 1973; Hellstrom and Hellstrom, 1974;
Cerottini and Brunner, 1974; Herberman, 1974). By using T cell-
deprived animals, anti-sera to T cells and macrophages, and various
cell separation procedures, it has been possible in these studies to
demonstrate dependency for T cells, or for T cells and B cells in
tumour immunity. However, proof that these cells can be cytotoxic
effector cells in vitro and in vivo has been more difficult to es¬
tablish unequivocally.
This is not the case in allograft immunity and in allogeneic
tumour immunity where the T -.cell has been affirmed as an autonomous
cytotoxic effector cell in vitro (Solstein , Wigzell, Blomgren and
Svedmyr, 1972; Golstein and Blomgren, 1973; Lohmann-Matthes and
Fischer, 1972). A similar role has also been claimed for T cells
in vivo (Sprent and Miller 1972; Cerottini and Brunner, 1974) but
the difficulty of excluding T cell-macrophage cooperation in vivo
in such cell transfer experiments necessitates that they only provide
evidence of T cell dependency.
Analyses of the cytotoxic effector cells in a number of syngeneic
tumour systems have now shown that T cells can be cytotoxic in the
absence of other cell types. In rats, cytotoxic cells directed at
Gross-virus-induced lymphoma cells were inhibited by anti-theta serum
but unaffected by removal of adherent cells and B cells (Djeu et al.,
1974). Currie and Gage (l973) isolated radiosensitive, non nylon-
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adherent (and therefore suggestive of T cells) cytotoxic cells from
regional lymph nodes of rats bearing a sarcoma. Leclerc, Gomard,
Plata and Levy (1973) have also demonstrated T cell effector cells
in the Moloney sarcoma virus (MSV) system. The MSV system has been
closely studied by Lamon and his group who found both T cells and B
cell dependent non-T cells capable of the in vitro killing of cells
expressing virally-induced antigen (Lamon, 1974). T cell activity
was greatest during the early part of tumour development and gradually
disappeared during regression, whereas the non-T cell activity was
present throughout the experiment and showed peak activity in re¬
gression. This heterogeneity in effector cell populations has also
been described in mice bearing syngeneic MC-induced sarcoma (Nelson,
1974). The non-T cell designation has been used above because of
the possibility that K cells are present in the T cell-depleted
populations (vide infra).
Cytotoxic T cell effectors have been observed in a number of
human tumour studies (Wybran et al», 1973). O'Toole et al.. (1973)
on the other hand only found non-T cell effectors in a study of
bladder cancer patients.
5.3.3 K cells (antibody-dependent cell-mediated cytotoxicity)
Target cells exposed to specific IgG antibody _in vitro become
susceptible to lysis by non-immune, C3 ana Fc receptor-bearing cells.
These cells can be macrophages or monocytes (Dennert and Lennox,
1973; Zighelboim et al.. 1973; Evans, 1975), or killer cells (K cells)
(Perlmann and Holm, 1969; Perlmann, Perlmann and Wigzell, 1972;
MacLennan, 1972a; Cerottini and Brunner, 1974). The ontogeny of K
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cells is still the matter of much debate. K cell-mediated cyto¬
toxicity can be surprisingly efficient with regard to the antibody
levels required. Perlmann et al., (1972), reported that some sera
-9 -11
were active at dilutions of 10 - 10
Elevated K cell activity has been observed in the spleens and
tumour-draining lymph nodes of MC-induced fibrosarcoma-bearing mice
(Calder, Irvine and Ghaffar, 1975; Ghaffar, Calder and Irvine, 1976a).
Antibody-dependent macrophage-mediated cytotoxicity is discussed in
the following section.
5.3.4 Macro-phages
The free macrophage and the fixed tissue macrophage (histiocyte)
represent the final differentiation stages in a cell series which has
progressed via bone marrow precursors, promonocytes and monocytes.
This cell series, collectively known as the mononuclear phagocyte
system (Van Purth, Langevoort and Schaberg, 1975), constitutes an
essential part of the reticuloendothelial system (RES) which is
involved in particle clearance and degradation. In addition to their
scavenging work, mononuclear phagocytes exhibit a multiplicity of
functions including wound healing, production and breakdown of
biologically important products and participation in immune responses
(for details see Van Purth, 1975; Nelson, 1976a).
Macrophage involvement in an immune response can occur at any
or alllevels; afferent, central or efferent. Por example, by phago-
cytosing and processing antigens they can initiate the primary
(Panijel and Cayeux, 1968; Gallily and Feldman, 1967) and sometimes
the secondary (Panijel and Cayeux, 1968; Feldman and Palmer, 1971)
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antibody responses. Macrophages or their products are involved
centrally in the cooperation of B and T cells in their response-to
antigens, and in lymphocyte activation and immunoregulation (Basten
and Mitchell, 1976; Nelson, 1976b). However, it is principally
the role of the macrophage as an effector cell which has interested
tumour biologists.
In vitro studies have consistently shown that macrophages can
affect the replication and viability of tumour cells (see reviews by
Levy and Wheelock, 1974; Lejeune, 1975; Alexander, 1976; Lohmann-Matthes,
1976; Evans and Alexander, 1976; Keller, 1976a; 1977). The observed
anti-tumour effects are dependent on the properties of target cells
and effector cells, and on their relative numbers, and may be manifested
as promotion of tumour cell growth, cytostasis, or cytolysis (Keller,
1976a; Cullen, unpublished observations). Cytotoxic effects observed
at higher effector to target ratios may give way to growth enhancing
effects at lower ratios (Keller, 1976a). Effector macrophages may be
specifically or non-specifically cytotoxic depending on the manner in
which they were activated. Activation is used here to indicate the
acquisition or stimulation of cytotoxic or cytostatic potential.
Specifically cytotoxic macrophages may be obtained from the peri¬
toneal cavities of mice immunised with allogeneic cells (Granger and
Weiser, 1964, 1966; Den Otter, Evans and Alexander, 1972, or with
syngeneic tumour cells (Evans and Alexander, 1970), and also from mice
bearing a growing subcutaneous tumour (Evans, 1973). Evidence that
macrophages exert an anti-tumour effect in vivo came from neutralisation
(Winn assay) studies in which immune lymphoid cells were mixed with
tumour cells and injected into normal animals. It was found that the
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subsequent inhibition of tumour development was mediated by host macro¬
phages and not by the injected lymphocytes (Evans and Alexander, 1970;
Zarling and Tevethia, 1973a, b).
This cooperation between normal, non-cytotoxic macrophages and immune
lymphocytes to produce macrophage-mediated cytotoxic effects has also been
demonstrated in vitro in both syngeneic (Evans and Alexander, 1970) and
allogeneic systems (Evans and Alexander, 1972a; Evans and Grant, 1972;
Lohmann-Matthes et_al., 1972; Pels and Den Otter, 1974). The immune
lymphocytes were said to "arm" the macrophages which were then specifi¬
cally cytotoxic for the immunising tumour cells (Evans and Alexander,
1970; 1972a, b). Specific arming of macrophages has also been achieved
in vitro by a T cell-dependent supernatant factor released by immune
lymphocytes cultured with the sensitising antigen (Evans and Alexander,
1971; Lohmann-Matthes, Ziegler and Fischer, 1973; Pels and Den Otter, 1974).
Macrophages can also bind (via their Fc receptors) and specifically
kill antibody-coated tumour cells (Dennert and Lennox, 1973; Zighelboim
et al., 1973; Evans, 1975; Evans and Alexander, 1976).
Following exposure to their specific target cells armed macro¬
phages become activated and can exert non-specific growth inhibitory
effects against a variety of target cells (Evans and Alexander, 1972a).
Non-specific cytotoxicity can also be induced in macrophages by a
variety of agents some of which, for example, double-stranded RNA
and endotoxin, can activate macrophages both in vivo and in vitro
(Evans and Alexander, 1976). In vivo activation has also been
obtained by administration of killed Corynebacterium oarvum (Scott,
1974c), pyran copolymer (Morahan and Kaplan, 1976) and Freund's
complete adjuvant (Hibbs, Lambert and Remington, 1972). Of particular
interest has been the observation that activated macrophages can be
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recovered from animals suffering persistent infection with, one of a
number of phylogenetically divergent organisms including: Toxoplasma
gondii, Besnoitia .jellisoni. Listeria monocytogenes (Hibbs et al.,
1971; 1972; Krahenbuhl and Remington, 1974); BOG (Hibbs, 1975a, b;
Evans et al., 1973; Cleveland, Meltzer and Zbar, 1974); a strain of
Pasteurella (Evans and Alexander, 1972a); Hippostrongylus brasiliensis
(Keller and Jones, 1971). It should be noted that, as suggested by
these observations, studies into the anti-tumour role of macrophages
often closely parallels work on the microbicidal effects of activated
macrophages (Mackaness and Blanden, 1967; Nelson, 1974; Mackaness,
1976).
Non-specifically cytotoxic macrophages may also be obtained by
incubating non-cytotoxic macrophages in the cell-free supernatant
from cultures of stimulated lymphocytes. The lymphocytes have been
stimulated in a variety of ways including exposure to sensitising
tumour antigens (Lohmann-Matthes et al., 1973), tumour unrelated-
antigen (Piessens, Churchill and David, 1975),concanavalin A (Pidler,
Darnell and Budmen, 1976) or the mixed lymphocyte reaction (Dimitriu
et al., 1975). The macrophage activating factor (MAE) is a lymphokine-
like molecule (Dumonde et al.,1975) and various investigators have
put its size in the range of 35,000-55,000 daltons (Nathan et al.,
1973; Lohmann-Matthes, 1976; Dy et al., 1976).
Several groups have observed that non-specifically activated
macrophages are capable of a considerable degree of non-immunologic
discernment in that they selectively kill or inhibit transformed
(malignant) cells (Hibbs, Lambert and Remington, 1972; Hibbs, 1973;
Holterman, Klein and Casale, 1973; Piessens et al., 1975; Keller,
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1974). However, for reasons as yet unknown, different tumour
lines vary in the degree of their susceptibility, and to further
complicate the issue, many normal tissue cells can be just as sens¬
itive as transformed cells to macrophage cytotoxicity (Kaplan,
Morahan and Regelson, 1974; Keller, 1974, 1975> 1976c; Jones,
McBride and Weir, 1975; Nathan and Terry, 1975). It has also been
reported that DNA synthesis of transformed lymphocytes can be inhi¬
bited by activated macrophages. (For a review on the non-specific
immunogrgulatory activities of macrophages see Nelson, 1976b). This
complexity may reflect the existence of sub-populations of macro¬
phages having different functions or different degrees of activity
(Walker, 1976; Wing, Gardner, Ryning and Remington, 1977). Calderon
and Unanue (1975) have described two fractions in cultures of the
same peritoneal cell population, one of which has a stimulatory
effect and the other an inhibitory effect on cell growth.
Macrophages are endowed with an extensive armoury with which to
exert their anti-tumour effects. These weapons may involve cell-
to-cell contact (Hibbs, 1974; Keller, 1976a; Piessens, 1977) and/or
secretory products (Davies and Allison, 1976). Extracellular killing
by labile, lytic factors has been described (Melsom, Sanner and
Seljelid, 1975; Sethi and Brandis, 1975). These factors could be
complement cleavage products such as C3a, which has been shown to
be cytolytic, and C3b which can be involved in secretion of hydro¬
lases (Ferluga et al., 1976; Schorlemmer, Davies and Allison, 1976).
Recent work showing that macrophage cytotoxicity can be abrogated
by protease inhibitors would suggest that proteases are involved
in target cell lysis (Hibbs et al., 1977).
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Many studies have stressed the importance of macrophage-target
cell contact for the expression of cytotoxic effects (Evans and
Alexander, 1970; Hibbs, 1974; Keller, 1976a; Piessens, 1977). Hibbs
(1974) showed that, following cell fusion between target cell and
macrophage, lysosomal enzymes were transferred to the target cell
which subsequently underwent lysis.
In addition to the cell-transfer experiments of Zarling and
Tevethia (1973a,b) described above, a number of other experiments
and observations have confirmed the role of macrophages in tumour-
host interactions. In the absence of a macrophage-free strain of
laboratory animal, macrophage depletion or inactivation must be
conducted using a macrophage poison such as carageenan or silica
(Keller, 1976b; Levy and Vheelock, 1975). Administration of these
agents on the day of tumour inoculation significantly enhanced tumour
growth and, since the lysosome stabilising agent polyvinylpyridine
N-cxide (PVUO) neutralised this effect, a role for macrophages in
host defence against tumour implantation was assumed (Keller,
1976b). However, the cellular and biochemical consequences of the
administration of silica and carageenan may offer alternative
explanations (Levy and Wheelock, 1975; Keller, 1976b). The observed
effects may have been due to release from lysed macrophages of
growth promoting substances or of factors which interfered with
lymphoid cell function (Keller, 1976b).
The anti-inflammatory agent sodium aurothiomalate has also been
utilised in studies of macrophage anti-tumour effects (McBride et al.,
1975b; James et al., 1976; Ghaffar et al., 1976b). This compound
inhibits lysosomal enzymes (Ennis et al., 1968) and suppresses
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phagocytosis and migration of macrophages (Jessop et al., 1973;
Vernon-Robert et al., 1973).
Further information on the anti-tumour role of macrophages
has derived from studies on the macrophage population of human and
experimental tumours. As mentioned earlier, infiltrating macrophages
can account for a considerable proportion of a tumour's bulk. This
has been demonstrated by disaggregating tumours enzymatically and
identifying macrophages by a variety of parameters (Evans, 1972,
1973; Pross and Kerbel, 1976; Szymaniec and James, 1976; Kerbel and
Pross, 1976; K. Moorre and Moore, 1977; M. Moore and Moore, 1977).
The capacity of a tumour to metastasise was shown to be inversely
proportional to its macrophage content in experimental tumours
(Eccles and Alexander, 1974) and, although only a preliminary survey,
also in some human tumours (Gauci and Alexander, 1975). It has also
been shown that the number of host infiltrating cells is directly
proportional to the immunogenicity of a particular tumour (Evans,
1972; K. Moore and Moore, 1977; M. Moore and Moore, 1977). Tumour-
derived macrophages have been shown, in some studies, to be cyto¬
toxic (Evans, 1973, 1975; Haskill et al., 1975, 1976). Furthermore,
macrophages are more numerous and more cytotoxic in regressing
Moloney sarcoma than in progressing tumours (Russell, Doe and Coch¬
rane, 1976; Russell and Mcintosh, 1977). These studies thus provide
strong corroboration of a significant role for macrophages in the
host's defence against tumour growth. Why such defences should
often prove inadequate is still largely a mystery. This paradox
will be returned to in the discussion on escape mechanisms.
-37-
5.3.5 Other effector cells
Besides B cells and T cells, a third heterogeneous group of
lymphoid cells (variously called null cells, N cells, nonselective
cytotoxic cells, or natural killer (NK) cells), have attracted
considerable interest as effectors of 'spontaneous' cell-mediated
cytotoxicity to a number of tumours (Kiessling, Klein and Wigzell,
1975; Herberman, Nunn and Lavrin, 1975; Kiuchi and Takasugi, 1976).
These cells appear to lack the conventional markers for T or B
cells, are non-adherent and non-phagocytic. Natural killer cell
activity has been associated with a cell population mediating K
cell activity in some human studies (Kalden, Peter, Roubin, and
Cesarrini, 1977) but not in mice (Kiessling et al., 1976; Herberman
et al.. 1975).
In addition a subpopulation of adherent peritoneal cells has
been isolated which is poorly phagocytic and which appears to account
quantitatively for the tumour inhibitory activity of the total cell
population from which they were derived (Nathan, Hill and Terry,
1976). These cells were present in untreated mice although BCG
treatment greatly increased their number (Nathan et al.. 1976).
These cells may be a subpopulation of B cells (Nathan, Asofsky and
Terry, 1977).
The non-specific effects of natural killer cells and macrophages
point to the existence of a primitive surveillance system which
possibly pre-dates the evolution of the vertebrate immune system as
it is now known (Holterman et al., 1976; Keller, 1977).
Another cell population with the demonstrated anti-tumour effects
is the neutrophil (Pickaver, Ratcliffe, Williams and Smith, 1972).
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6. IMMUNOLOGICAL ESCAPE OF TUMOURS
The preceding sections have described the battery of host
responses that can be demonstrated to act against tumour cells in
vitro and in vivo but which are often powerless to reject the growing
tumour. This paradox, perhaps best illustrated by the presence
within many tumours of cytotoxic host cells and by the phenomenon
of concomitant immunity, in which tumour-bearing animals may reject
a challenge with the same tumour in another site (Klein et al., I960).
Such enigmas have prompted discussion and explanation by many authors
(Klein, 1969, 1975; Woodruff, 1973; Jeejeebhoy, 1975).
One explanation might be that the tumour may only be weakly
immunogenic or even non-immunogenic. This could occur through
immunological selection pressures on tumour cells giving rise to
less immunogenic clones. Two possible mechanisms for such pheno-
typic modification of tumour cells are: antigenic modulation as
described by Boyse and Old (1969) for the thymus leukaemia (TL)
antigen in mice, and the shedding of antigens from the cell surface
(Currie and Alexander, 1974; Davey, Currie and Alexander, 1976).
Another possibility is that the tumour cells "sneak through"
the host defences. This concept arose from the observation that a
small or large tumour cell inoculum would grow, whereas an intermedi¬
ate cell dose was rejected (Old, Boyse, Clarke and Carswell, 1962).
An alternative, perhaps not unrelated to this sneaking through
effect, is that a weak immune response could actually promote tumour
growth. Attention was drawn to this phenomenon by Prehn who called
it immunostimulation (Prehn and Lappe', 1971; Prehn, 1972), and it has
since been demonstrated in both _in vitro and in vivo systems by a
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number of workers (Fidler, 1973; Medina and Heppner, 1973; Jeejeebhoy,
1974; Kail and Hellstrom, 1975).
However, the explanation of this failure of anti-tumour defences
that has received most attention is that factors derived from the
tumour or the host interfere directly, or via suppressor cells, to
inhibit, or block the response.. It has been known for most of this
century that prior injection of killed tumour cells, or tumour extracts
with the aim of eliciting protection against subsequent live tumour
challenge, frequently gives the opposite result, namely, enhancement or
facilitation of tumour growth (Snell et al., 1946; Voisin, 1971). It
was found that enhancement could be transferred by serum and that the
active agent was associated with immunoglobulins (Kaliss and Kandktsch,
1956).
The Hellstroms later showed that serum from tumour-bearing indi¬
viduals could specifically abrogate the in vitro cytotoxic effects of
lymphoid cells toward the appropriate target cells (i. Hellstrom and
Hellstrom, 1969; K.E. Hellstrom and Hellstrom, 1970, 1974, 1976).
This phenomenon has since been observed in many animal and human
tumour systems (Sjogren et al., 1971; Baldwin, Price and Robins,
1973; Plata and Levy, 1974; Blair and Lane, 1974). Blocking effects
by tumour-bearer serum have been noted in other assay systems such
as leucocyte adherence test (Grosser and Thomson, 1976) and the
lymphocyte transformation test (Stjernsward et al., 1973).
These serum blocking factors have now been shown to be antigen-
antibody complexes (Sjogren et al., 1971; Baldwin, Price and Robins,
1972b; Jose and Seshadri, 1974) which mediate their effects either
at the tumour cell surface by masking surface antigens, altering their
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distribution or causing their internalisation (Leonard, 1973), or by-
binding directly to the effector cells via Fc receptors (Baldwin _et
al., 1973; Blair and Lane, 1974; Gorczynski ejfcjal., 1975; Plata and
Levy, 1974). Inhibition of effector cell activity can also be mediated
by tumour antigen alone (Plata and Levy, 1974; Baldwin et al., 1973;
Yaage, 1973). The development of tumour enhancement following admin¬
istration of tumour antigen obviously has grave implications for
those clinicians using immunotherapy schedules involving such a
procedure.
Complimentary to these studies are those demonstrating that
blocking effects can be neutralised by the addition of excess anti¬
body (i. Hellstrom and Hellstrom, 1970; Bansal and Sjogren, 1971 ;
Robins and Baldwin, 1974). This effect would suggest that therapy
comprising the passive transfer of anti-tumour antibodies might be
beneficial.
In addition to antigen and immune complexes various other factors
with immunosuppressive activity have been found in the sera of cancer
patients and tumour-bearing animals. For example, in association
with certain tumours increased levels can occur of alpha foetoprotein
(Murgita and Tomasi, 1975a, b) and alpha-2-globulins which have
immunosuppressive properties (Cooperband et al., 1976; Glaser and
Nelkin, 1972). The active principle of the alpha-2-globulin factor
has been shown to be a peptide of molecular weight, 6,000 - 8,000
Daltons (oocbino et al., 1973). Small molecular weight immunosuppres¬
sive factors have also been found in tumour-bearers by other workers
(Nimberg et al., 1975; Yamazaki et al., 1973).
The origin of these suppressive factors has not always been clear.
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Macrophages, for example, can produce a range of immunoregulatory
products (Nelson, 1976b). Viruses or mycoplasma carried by tumour
cells, or extraneous bacterial contamination can also lead to en¬
hancement (Kamo, Patel and Friedman, 1976), or suppression of immune
responses (Kateley, Kamo, Kaplan and Friedman, 1974; Bonnard et al.,
1976; Kampschmidt and Schultz, 1963). However, there is evidence
from cell culture studies that tumour cells per se do release
immunosuppressive factors (¥erner et al.. 1973; Fauve et al., 1974;
Wong, Mankovitz and Kennedy, 1974). It should also be noted that
some tumours can evidently produce prostaglandins, another group
of immuno-regulatory agents (Plescia et al.. 1975; Sykes and Maddox,
1972).
The detailed mechanisms by which these blocking factors mediate
immunosuppression are not yet known, but it seems likely that some,
particularly antigen or antigen-antibody complexes, operate through
the suppressor cell system. Cells capable of suppressing the immune
reactivity have been found in many tumour systems (Gershon, 1974;
Treves et al.. 1974; Kolsch, Stumpf and Weber, 1975; Fujimoto et al., 1976
a,b). The suppression may be antigen specific (Fujimoto et al., 1976a,b)
or non-specific (Kirchner et al., 1974a,b; 1975; 1976). Suppressor cells
have been identified as T cells (Folch and Waksman, 1974a,b; Fujimoto
et al., 1976a,b), macrophages (Kirchner et al., 1976), or B cells (Gorc-
zynski, 1974). Macrophage-mediated suppression may in fact be the re¬
sult of a T cell signal cytophilic for macrophages (Taylor and Basten, 1976).
In addition to the suppressor cell system, tumour-associated or
tumour-derived suppressive factors could affect directly the perfor¬
mance of effector T cells, K cells and macrophages by blocking Fc
receptors, or receptors for immunoregulatory signals. For compre¬
hensive reviews of tumour-mediated immunosuppression see James
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(1977) and Kamo and Friedman (1977).
7. IMMUNOTHERAPY
Success of the conventional cancer treatments,surgery and radio¬
therapy, are subject to certain limitations. Surgical excision may
prove impossible if the tumour has originated in, or spread to, a vital
organ, and radiotherapy is limited by the relative radiosensitivity
of the tumour tissues. In addition, both therapies can be immuno¬
suppressive. For example, depressed in vitro lymphocyte blastogenic
responses to mitogens have been observed following surgery (Park
et al., 1971) and anaesthesia (Bruce and Wingard, 1971). The immuno¬
suppressive effects of whole-body irradiation of animals is well
documented (Micklem and Loutet, 1966; Anderson and Warner, 1976),
and in man even localised irradiation, for example of the chest
wall in breast cancer, can result in prolonged depression of blood
lymphocyte levels (Stjernsward et_al., 1972). However, both surgery
and radiotherapy have a more serious limitation in that they are
often powerless to deal with tumours which have already metastasised.
Disseminated cancer thus requires a systemic approach to treatment.
Chemotherapy and immunotherapy are, potentially at least, capable of
fulfilling this role.
To be successful an anti-cancer drug must exhibit a differential
cytotoxicity, at the dose used, between tumour cells and normal tissue,
and this generally means exploiting differences in metabolism or cell
kinetics. An example of the former mode is the use of L-asparaginase
in the treatment of leukaemia (Beard et al., 1970). Unfortunately,
the value of this treatment is limited by the development of resistant
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cells with asparagine synthetase activity, possibly due to gene de¬
repression in response to the presence of asparaginase (Haskell and
Cannellos, 1970). Where the difference in drug sensitivity (the
therapeutic index) has been sufficiently high, chemotherapy has been
strikingly successful, particularly in the treatment of Burkitt's
lymphoma (Burkitt and Wright, 1970), acute lymphoblastic leukaemia,
Hodgkin's disease and choriocarcinoma (McElwain, 1976). Many anti¬
cancer drugs act through an interference of cell division and thus,
unfortunately, host cells, such as bone marrow cells and lymphoid
tissue, with high rates of proliferation will also be affected, leading
to immunosuppression (Hersh and Freireich, 1968).
Absence of target selectivity in the available chemotherapeutic
drugs has led to a resurgence of interest in immunotherapy which should,
in theory, provide the desired specificity. To be successful any
immunotherapeutic procedure must potentiate specific and/or non¬
specific immune responses to the tumour cells in order to overcome
the various escape mechanisms outlined in section 6 above. The
modes of immunotherapy outlined below have been developed during
the past 100 years and have been employed alone or in combination
with surgery, radiotherapy or chemotherapy. An overview of early
work in this field may be gleaned from articles by Snell et al.,
(1946); Nauts, Swift and Coley (1946); Southam (1961); Yoisin (1971);
Currie (1972); and Gutterman et al., (1974).
7.1 Specific active immunotherapy
This involves injection of inactivated autologous tumour cells
or tumour extracts (Bloom et al., 1973; Currie, 1973; Ikonopisov et al.,
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1970). This method carries the possible hazard of enhancement
(vide supra). A modification of this form of therapy involves
increasing the immunogenicity of tumour cells by treating them
with neuraminidase (Currie and Bagshawe, 1969; Simmons et_al., 1971)
or by coupling various agents such as xenogeneic globulins to them
(Cza.ikowski et al., 1967).
7.2 Specific passive immunotherapy
Specific passive immunotherapy is achieved by the transfer of
immune syngeneic, allogeneic or xenogeneic serum (Murray, 1958;
Bansal and Sjogren, 1972). In addition to possible cytotoxic
effects on the tumour cells, this therapy mode could have the advan¬
tage of counteracting serum blocking factors (vide supra). Anti-
tumour immunoglobulins have also been used as carriers of other
therapeutic agents. For example, melanoma patients treated with
chlorambucil bound to goat or rabbit anti-human melanoma globulins
had prolonged survival when compared trith patients on either chemo¬
therapy or antiserum alone (Ghose et al., 1972, 1975, 1977).
7.3 Specific adoptive therapy
Specific adoptive therapy using immune lymphoid cells has also
been investigated (Nadler and Moore, 1969). This trial involved
cross-immunisation of pairs of patients with tumour, and thus lympho¬
cytes subsequently exchanged would also recognise HLA antigens.
This technique has recently been given new impetus with the develop¬
ment of methods of _in vitro sensitisation of lymphoid cells to tumour
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cells (K.E. Hellstrom and Hellstrom, 1976; Treves, Cohen, Schecter
and Peldman, 1976).
An alternative to the use of lymphocytes is to transfer lympho¬
cyte derived mediators of immunity such as transfer factor or immuno¬
genic SNA (Lawrence, 1969; Lo Buglio and Neidhart, 1974), or lympho-
kine preparations (Papermaster et_al., 1976). The lymphokine
preparation was used to treat cutaneous metastatic lesions and
seems to operate in a similar way to DNCB when used as an anti-
tumour agent. DNCB, a skin sensitising agent, is used to induce
delayed hypersensitivity reactions in the vicinity of neoplastic
skin lesions resulting in an inflammatory response in the tumour,
with subsequent regression (Klein and Holterman, 1972).
7.4 Non-specific immunotherapy
Non-specific anti-tumour effects using a large number of varied
biological and chemical agents have now been claimed. It was known
in the nineteenth century that tumour regressions sometimes followed
acute bacterial infection, particularly erysipelas (Coley, 1891) and
this formed the basis of attempts at deliberate infection with Strep¬
tococci in cancer patients (Coley, 1893). Coley and others eventually
progressed to the use of killed preparations of mixtures of various
bacteria which became known as Coley's toxins (reviewed by Nauts,
Swift and Coley, 1946). A lyophilised preparation of Streptococcus
haemolyticus (OK-432) has been shown to inhibit the growth of trans¬
planted tumours (Okamoto et al., 1966; Ishi, Yamaoka, Toh and
Kikuchi, 1976).
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Other micro-organisms with reported anti-tumour properties
include Bordetella pertussis (Likhite, 1974); Bacillus Calmette-
Guerin (BCG) or its methanolic extraction residue - MER (Weiss,
Bonhag and De Ome, 1967; Old, Clarke and Benacerraf, 1959; Zhar,
Bernstein, Tanaka and Rapp, 1970); anaerobic corynebacteria such
as Corynebacterium parvum (Woodruff and Boak, 1966; Scott, 1974c;
Milas, Hunter and Withers, 1974b; Ghaffar, Cullen, Dunbar and
Woodruff, 1974); Listeria monocytogenes, Toxoplasma gondii, Besnoitia
.jellisoni (Hibbs et al., 1971 , 1972; Krahenbuhl and Remington, 1974);
spores from non-pathogenic Clostridia species (Mose and Mose, 1964;
Thiele, Arison and Boxer, 1964). In addition, there are a number
of preparations of yeast or fungal origin-lentinan, zymosan, pseudo-
nigeran - which contain anti-tumour glucose polymers - glucans
(Bradner, Clarke and Stock, 1958; Chihara et al., 1969, 1970; Bomford
and Moreno, 1977; Cook et al., 1977). Many micro-organisms also
produce metabolites (e.g. L-asparaginase, neuraminidase), antibiotics
and endotoxins which could have anti-tumour effects (see review by
Rosenkranz, 1973).
Anti-tumour effects have also been demonstrated using natural
or synthetic polyanions such as double-stranded RNA or Polyinosinic-
Polycytidylic acid (Poly I-C) (Parr, Wheeler and Alexander, 1973)
and Pyran - a copolymer of divinyl ether and maleic anhydride
(Morahan and Kaplan, 1976; Schultz et al., 1977b).
The antihelminthic drug levamisole has aroused a great deal of
interest in oncologists because of its ability to augment immuno¬
logical functions and would thus seem to be of value as supportive
therapy in various treatment schedules, including those using chemo-
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therapy or agents such, as C. -par-vum (Symoens and Rosenthal, 1977).
Although the mechanism of action of many of these agents is
not known in detail, it is probable that some act through a stimu¬
lation of the mononuclear phagocytic system and potentiation of
immune responses. In some cases, for example BCG and C. rarvum,
both specific and non-specific immune stimulation can occur. Poten¬
tiation of specific responses can reflect the existence of antigenic
determinants common to both microorganisms and tumour cell. Further
details on the anti-tumour effects of BCG and C. parvum and on the
mechanisms underlying these effects are discussed below.
7.5 Combination therapy
Apart from a few isolated and anecdotal cases, immunotherapy
has generally proved unsuccessful in treating cancer in man. The
success obtained in animal models is perhaps misleading since cures
can often be achieved in these systems using conventional therapies.
However, despite the present scepticism of the value of immunotherapy
many workers remain enthusiastic about its potential, particularly
for those regimens using immunopotentiators such as BCG and C. -parvum
(Gutterman, 1977; Weiss, 1977). Judgement ought to await the outcome
of the numerous, worldwide, ongoing trials which are using immunological
manipulation.
It is now recognised that immunotherapy is most likely to succeed
when the tumour load is very small and consequently this mode of
therapy is best employed together with substantial reduction of the
tumour mass by using surgery, radiotherapy and chemotherapy. Main¬
tenance following cytoreduction can be achieved with a combination of
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drug therapy and immunotherapy. Such combined attacks on tumours
have led to encouraging results in animal models and in man. For
example, Haddow and Alexander, (1964) showed that treatment with
autologous tumour cells led to radio-sensitisation of growing rat
fibrosarcomas. Glynn et al. (1969) found that a combination of
adoptive immunotherapy with cyclophosphamide was much more effective
than either treatment alone in treating Moloney-virus lymphomas.
Many combination trials have used, or are using, BCG or C.
parvum. The first successful clinical trial employing BCG was that
of Mathe""and his group who reported that immunotherapy (BCG and/or
vaccination from a pool of inactivated leukaemia cells) following
intensive cytoreduction significantly prolonged the disease-free
interval compared to patients untreated after cytoreduction (Mathe'
et al., 1969). In contrast, two other trials using BCG therapy for
the maintenance of remission have given negative results (Medical
Research Council, 1971; Heyn et_al., 1973). However, the protocol
in these trials did not employ the cytoreduction techniques as used
in the Mathe study. It has also been shown that different strains
of BCG can have different anti-tumour activities (Hawrylko and
Mackaness, 1973; Fortner, Hanna and Coggin, 1974).
Studies in other tumour systems have also claimed improvement
using BCG. Morton et al. (1970) showed that intralesional inoculation
of BCG caused regression of melanoma skin nodules. Gutterman et al.
(1976) reported that combination treatment schedules using BCG and
chemotherapy could prolong remission and survival of patients with
melanoma, breast cancer and acute leukaemia. Favourable results
using BCG in melanoma patients have also been reported by Ikonopisov
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(1972) and Spitler, Levin and Wybran (1976). However, negative
results have been obtained by Pinsky et al. (1976b), and in another
study using BCG together with autologous irradiated tumour cells,
the immunotherapy actually resulted in acceleration of recurrence
(Mclllmurray et al.. 1977).
Assessment of BCG therapy has proved encouraging for a number
of other tumours: lung cancer (McKneally et al.. 1976; Pouillart
et al.. 1976; Holmes et al.. 1977) and in cancer of the colon and
rectum (Mavligit et al.. 1976).
The methanol extraction residue (MER.) of BCG, which has the
advantage over BCG of being a non-viable vaccine, has featured in
several tumour studies and shown to be of therapeutic value in
animals (Minden, Wainberg and Weiss, 1974; Cohen et al., 1970)
and in man (Moertel et al.. 1975; Robinson et al., 1975). See also
articles by Weiss (1977) and Ribi et al. (1976).
The only extensive clinical trials using C. narvum reported on
to date have been those of Israel and his associates (Israel, 1973,
1975; Israel and Halpern, 1972; Israel et al., 1975). These reports
claim beneficial effects from the use of C. uarvum. Several pre¬
liminary phase I studies have recently been published which provide
information on dose tolerance, immune responsiveness, serum Ig
levels and side effects (Fisher et al.. 1976a; Cheng et al., 1976;
Minton et al., 1976; Woodruff et al.. 1975; James et al.. 1975).
8. MECHANISMS UNDERLYING THE ANTI-TUMOUR EFFECTS OF BCG AND C. PARVUM
Although BCG and C. "parvum are at present the most widely used
and studied of the many'non-specific' immunotherapeutic agents, the
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mechanisms underlying their anti-tumour effects have not been completely
analysed. The following section provides a synopsis of some of the
existing knowledge.
8.1 BCG
The anti-tumour effects of BCG therapy have been observed in
animals with established tumours (Nathanson, 1972; Zbar, Bernstein,
Tanaka and Rapp, 1970; Zbar and Tanaka, 1971) and in animals receiving
tumour transplants following BCG treatment (Old, Clarke and Benacerraf,
1959; Lemonde et_al., 1971; Weiss, Bonhag and Leslie, 1966).
Prophylaxis with BCG has even extended to reduction in the incidence
of radiation or carcinogen induced malignancies (Wilsson, Revesz and
Stjernsward, 1965; Piessens et al., 1971 ). However, it should be
noted that BCG is not always effective against tumours (Eilber,
Holmes and Morton, 1971; Lemonde et al.. 1971; Baldwin and Pimm,
1973a; Old et al.. 1961) and can even facilitate their growth (Bansal
and Sjogren, 1973; Old et al., 1961; Mclllmurray et al., 1977).
BCG appears to be most effective when in contact with the
tumour cells. Thus tumour cells mixed with BCG fail to form tumour
nodules when injected (Zbar et al., 1970; Bartlett, Zbar and Rapp,
1972; Baldwin and Pimm, 1973b) and established tumours regress when
BCG is injected into the tumour (Zbar et_al., 1972; Zbar, Ribi and
Rapp, 1973; Nathanson, 1972; Zbar and Tanaka, 1971).
The success of BCG therapy is dependent on the immunogenicity
of the tumour, strongly immunogenic tumours being most strongly
inhibited (Baldwin and Pimm, 1973b).
Other factors determining the outcome of BCG theray are the
method of preparation, dose, and strain of BCG used. Differences
in the virulence and anti-tumour effectiveness of various BCG
strains have been reported (Hawrylko and Mackaness, 1973; Mathe,
Halle-Pannenko and Bourut, 1973; Fortner, Hanna and Coggin, 1974;
Mackaness, Auclair and Lagrange, 1973).
In addition to the anti-tumour effects, BCG administration can
have a number of consequences such as stimulation of the reticulo¬
endothelial system (Biozzi, Stiffel, Halpern and Mouton, I960;
Old et_al., 1961; Balner, Old and Clarke, 1961), increased non¬
specific resistance to other bacterial infection (Blanden, Lefford
and Mackaness, 1969; Dubos and Schaedler, 1957), accelerated graft
rejection (Balner, Old and Clarke, 1962; Vitale and Allegretti,
1963), and stimulation of humoral and cellular immunity to antigenic
challenge (Miller, Mackaness and Lagrange, 1973).
Many of these effects may be associated with, or mediated by,
BCG-activated macrophages. In addition to the general stimulation
of the EES, the macrophage functions of chemotaxis, pinocytosis and
random migration are elevated in BCG treated animals (Poplack, Sher,
Chaparas and Blaese, 1976; Meltzer, Jones and Boetcher, 1975). Bone
marrow macrophage colony formation is also transiently enhanced by
BCG inoculation in mice (Fisher et al., 1974).
The significance of macrophages in the anti-tumour action of
BCG has emerged from several other lines of research. Macrophages,
cytotoxic for tumour cells in vitro have been isolated from BCG-
treated animals (Cleveland, Meltzer and Zbar, 1974; Hibbs, 1975a,
b). Hibbs (1974) has demonstrated that macrophages activated by
BCG kill tumour target cells _in vitro by transfer of lysosomes into,
the tumour cells following cell-to-cell contact. Circumstantia
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evidence that macrophages may be involved in the anti-tumour effects
comes from the observation that BCG is effective in athymic nude
mice (Pimm and Baldwin, 1975) and in T cell-deprived rats (Moore,
Lawrence and Nisbet, 1975, 1976). These results are in contrast to
others in which BCG—mediated anti-tumour effects required the devel¬
opment of a T cell-dependent immune reaction to BCG (Zbar, Bernstein
and Rapp, 1971; Bartlett, Zbar and Rapp, 1972; Chung, Zbar and Rapp,
1973).
Macrophages may not be the only anti-tumour effector cells
mediating BCG's effects. T cells, K cells, B cells and natural
killer (ffiC) cells may all play a part. A recent report describes
increased NK cell activity following BCG administration (Wolfe,
Tracey and Henney, 1976; see also Parr, 1976).
In experiments where BCG is given intralesionally or together
with irradiated tumour cells, specific anti-tumour immunity may be
augmented (Hawrylko, 1975; Hanna et_al., 1973; Scott and Bomford,
1976). This effect and the observation that some tumours share
common antigens with mycobacteria (Borsos and Rapp, 1973; Minden,
McClatchy, Wainberg and Weiss, 1974; Bucana and Hanna, 1974; Minden,
Sharpton and McClatchy, 1976) indicates that in some situations BCG
can be considered to be a specific as well as a non-specific agent.
Note also that lymphocytes cytotoxic to human tumour cells in vitro
were obtained by in vitro culture of normal lymphocytes with various
bacterial extracts (Sharma et al., 1977). The design of this exper¬
iment was such that lymphocytes could have been responding to histo-
compatability antigens on the tumour target cells and consequently
a syngeneic model will be required for confirmation of the result.
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8.2 C ♦ -parvum
8.2.1 Following the demonstration of marked EES stimulation by a
killed vaccine of C, parvum (Halpern et al., 1964), and in view of
the known anti-tumour effects of other EE'S stimulants such as BCG,
Woodruff and Boak (1966) examined the effect of a single intra¬
venous (i.v.) injection of C. parvum vaccine on the growth of
syngeneic tumour transplants. The treatment significantly delayed
appearance of tumour nodules. The value of C. parvum and that of
another strain, Corynebacterium granulosum, as anti-tumour agents
has since been repeatedly affirmed both in a variety of animal
tumour systems (Halpern et al.. 1966; Milas et al., 1974a; Fisher
et al.. 1970; Ghaffar et al.. 1974; Scott, 1974c; Olivotto and
Bomford, 1974; Mazurek et al.. 1976; Bast and Bast, 1976) and in
man (Israel and Halpern, 1972; Israel, 1976). In the animal exper¬
iments C. narvum administered before or after tumour transplant
generally resulted in a delay in the appearance of tumour, retard¬
ation of tumour growth and prolongation of survival.
Systemic protection against tumour challenge could be obtained
with C. parvum given by the intravenous or intraperitoneal (i.p.)
routes but not by the subcutaneous (s.c.) route (Woodruff and Inchley,
1971; Woodruff, Inchley and Dunbar, 1972; Scott, 1974c). Subcutaneous
or intradermal application of C. parvum resulted in marked growth
inhibition provided that the injection was sufficiently near the
tumour site to engage the draining lymph node (Likhite and Halpern,
1974; Scott, 1974b; Woodruff and Dunbar, 1975). Systemic adminis¬
tration of C. parvum and C. granulosum has, in one model, led to
complete regression of artificial pulmonary fibrosarcoma metastases
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(Milas et al., 1974a,c; 1975a) but this is a rare observation and
is not generally found in other models (Scott, 1974c). Lasting
regressions however, do often follow administration of C. parvum
directly into the tumour (Likhite and Halpern, 1974; Paslin et al.,
1974; Scott, 1974b, Milas et al., 1975a).
Promotion of tumour growth as a result of C. narvum therapy
has only rarely been observed and only under particular circumstances.
Bomford (l977) has recently identified several situations which can
result in tumour enhancement by C. mrvum. Intravenous C. parvum
given before low doses (around the TD50) of tumour given subcutaneously
led to enhanced growth. This promotion effect increased with
higher doses of C. parvum. Enhancement of leukaemic 1210 in allo¬
geneic mice by C. parvum therapy has also been reported (Mantovani
et al., 1976; Berd and Mitchell, 1976). This effect was associated
with suppression of antibody-mediated and cell-mediated cytotoxicity
(Berd and Mitchell, 1976). In another study using two lymphomas
which regress spontaneously in normal mice, regression was abrogated
by administration of C. parvum (Woodruff and Warner, 1977).
8.2.2 Combined therapy
Combination of C. parvum therapy with chemotherapy (Currie and
Bagshawe, 1970; Woodruff and Dunbar, 1975; Fisher et al., 1975),
radiotherapy (Milas et al., 1975b; Suit et al.. 1975) or surgery
(Proctor et al., 1975) resulted in anti-tumour reactions which were
more effective than any individual treatment.
A number of specific active therapy modalities have been inves¬
tigated but with varying success. Subcutaneous injection of X-irradi-
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ated cells together with C. narvum evokes a strong protective effect
against subsequent tumour challenge (Scott, 1975). In contrast,
administration of C. parvum several days before immunisation with
irradiated tumour cells abolished the protection normally afforded,
by the immunisation procedure (Smith and Scott, 1972; Voodruff,
Ghaffar, Dunbar and Whitehead, 1976a). No improvement followed the
use of combinations of C. uarvum therapy and irradiated tumour cells
in other tumour systems (Likhite and Halpern, 1973; Scott, 1974a;
Proctor et al., 1973). Synergistic anti-tumour combinations have
been reported using C# uarvum together with neuraminidase-treated
cells (Woodruff and Dunbar, 1973) or cells coated with heterospecific
anti-tumour globulin (Woodruff and Inchley, 1971; Woodruff, Inchley
and Dunbar, 1972).
8.2.3 Toxicity
A number of authors have recorded toxicity using i.v. or i.p.
C. narvum in both high (Woodruff and Dunbar, 1973) and routinely used
doses (Scott, 1974a; Fisher et al., 1970; Milas, Hunter and Withers,
1974b). Several phase I human cancer studies have reported side
effects such as pyrexia and chills, vomiting and headache occurring
shortly after or during intravenous infusion with C. narvum (Woodruff
et al., 1975; Fisher et al., 1976a, Cheng et al., 1976; Minton et al.,
1976). Earlier animal experiments tended to use doses which are now
regarded as being large and so consequently carried a greater risk
of toxic effects. More recent studies tend to us© smaller doses
which also reflect more accurately the doses used in humans. Scott
and Warner (1976) have shown that weekly small doses of i.v. injected
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C. parvum gave a good anti-tumour effect but without suppression of
T cell function (vide infra).
8.2.4 Stimulation of mononuclear -phagocytes
Several aspects of cellular and humoral immunity are affected
by the administration of C. parvum. Intravenous or intraperitoneal
injection of C. parvum or C. granulosum results in a powerful stimu¬
lation of the RES with consequent hepatosplenomegaly, increased
lung weight, increased lymph node weight, and rapid clearance of
particulate matter from the blood stream (Halpern et al., 1964
Adlam and Scott, 1973; O'Neill, Henderson and White, 1973; Milas,
Basic, Kogelnik and Withers, 1975c). Macrophages from C. parvum-
treated animals exhibit the biochemical and morphological features
of activation (Wilkinson et al., 1973; Olivotto and Bomford, 1974;
Adams, Biesecker and Koss, 1973). A consequence of the increased
macrophage activity is the improved resistance of animals to infec¬
tion (Adlam, Broughton and Scott, 1972; Collins and Scott, 1974).
A lipid fraction isolated from C. parvum is chemotactic for
macrophages and appears to account for the early activation of
macrophages as assessed by carbon clearance (Russell, Mclnroy,
Wilkinson and White, 1976; Otu, Russell and White, 1977). Anti-
tumour activity may be due in part to the lipid fraction (McBride,
Dawes and Tuach, 1976).
Another early effect of C. parvum administration is a stimulation
of bone marrow macrophage colony formation (Wclmark, Levine and
Fisher, 1974; Baum and Breese, 1976).
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8.2.5 Adjuvant activity
C. parvum. administration to mice and men increases the serum
levels of certain immunoglobulin classes and subclasses including
antibodies to tumour (James et al.. 1975, 1976, 1977). Under approp¬
riate conditions antibody responses to both T cell dependent and
T cell independent antigens can be augmented (Howard, Christie
and Scott, 1973; Warr and James, 1975; Sljivic and Watson, 1977).
C. parvum has also been shown to be mitogenic for B cells (Zola,
1975). Both adjuvant and mitogenic activities required the parti¬
cipation of macrophages. A phenomenon which is probably related to
adjuvanticity in C. narvum-treated animals is that of sequestration
and retention of lymphocytes in nodes (lymphocyte trapping) (Frost
and Lance, 1973).
8.2.6 Effects on cellular immunity
Systemic administration of C. parvum depresses many T cell-
mediated phenomena such as the graft-versus-host reaction (Howard
et al., 1967; Scott, 1972a); delayed hypersensitivity (Allwood and
Asherson, 1972; Scott, 1974d); homograft reaction (Castro, 1974a;
Milas et al., 1975c); phytohaemagglutinin-responsiveness and the
mixed lymphocyte reaction (Scott, 1972a). In addition, infection
with Trichinella spiralis may be enhanced by C. parvum treatment
(Ruitenberg and Steerenberg, 1973). These immunosuppressive features
of C. parvum appear to be mediated by macrophages (Scott, 1972b;
Kirchner, Holden and Herberman, 1975). Local administration of




The non-specific aspect of systemically administered C. parvum
appears to he effected by macrophages. This conclusion is based princi¬
pally on the observed general stimulation of macrophage activity (vide
supra) and macrophage cytotoxicity towards tumour cells in vitro (Basic
et al.. 1975; Olivotto and Bomford, 1974; Ghaffar et al., 1974, 1975)
following C« parvum injection. The importance of the macrophage as
effector cell is further supported by the observation that systemic
C. parvum is also effective against tumours in T cell-deprived mice
(Woodruff, Dunbar and Ghaffar, 1975; Scott, 1974a), in athymic nude
mice (Woodruff and Warner, 1977) and in ALS-treated mice (Castro,
1974b). Cytotoxic macrophages have been recovered from T cell-deprived
and nude mice treated systemically with C. parvum (Ghaffar et al.,
1975). On the other hand, the marked anti-tumour effect usually mani¬
fested by local application of C. parvum does not appear in T cell-
deprived and nude mice (Scott, 1974b; Woodruff and Dunbar, 1975;
Woodruff and Warner, 1977).
Strong, specific, systemic, T cell-dependent anti-tumour immunity
can result from the injection of C. parvum locally, intralesionally, or
mixed with irradiated cells and given s.c. (Bomford, 1975; Scott, 1974b,
1975; Woodruff and Dunbar, 1975). This specific immunity is probably
cell-mediated and directed at tumour associated transplant antigens
(Bomford, 1975; Scott, 1975). Development of specific immunity seems
to be partly dependent on the immune response to C. parvum itself
when C. parvum is given locally or in admixture with irradiated cells
(Scott, 1974b), but not when given intratumour (Scott, 1975). It is
clear that C. parvum administration can, depending on circumstances,
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initiate non-specific or specific anti-tumour responses.
Another consequence of the administration of C. carvum, and one
which may have an important bearing on the in vivo development of
activated macrophages and anti-tumour responses in man and animals,
is the activation of both classical and alternate pathways of comple¬
ment, (McBride, Weir, Ka.v et al,, 1975c; Biran, Moake, Reed et_al.,
1976).
Recent studies on the distribution and persistence of C♦ -parvum
in the body have, to some extent, helped to. explain some of the above
observations. Thus biologically active strains of C. parvum persist
in the body for much longer periods than inactive strains and C. parvum
injected subcutaneously tends to remain at the inoculation site whereas
C. -parvum injected i.v. or i.p. is distributed to the lungs, spleen,
■liver, gut and bone marrow (Dimitrov et al.. 1977; Sadler et al., 1977;
Scott and Milas, 1977).
PURPOSE AND SCOPE OF THE STUD Y
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PURPOSE AND SCOPE OF THE STUDY
The final sections of the foregoing introduction provide a
brief outline of our knowledge to date of the effects of C. -parvum
administration in man and in animals, and of the possible mechanisms
underlying its anti-tumour properties. At the commencement of this
study, in the autumn of 1974, .a great deal of this knowledge had
already been obtained. For example, the importance of macrophages
as anti-tumour effector cells could be deduced, as outlined above,
from the RES stimulating capacity of C. parvum, the observation of
anti-tumour effects in T cell-deprived and nude mice, the stimulation
of bone marrow macrophage colony formation, and the cytotoxicity of
peritoneal macrophages from C. -parvum-treated T cell-normal and T
cell-deprived mice. However, the precise mechanisms leading to
activation of this macrophage anti-tumour effect were not known. It
was as an attempt to bridge this gap in knowledge that this study
evolved.
On the basis of published work in other systems, several possible
pathways might have led to the production of cytotoxic macrophages in
C. parvum-treated animals.
a) Macrophages could be activated directly by C. -parvum. Direct
activation in vitro had been observed using double-stranded
RHA and endotoxin (Alexander and Evans, 1971 ) and by a fraction
obtained from Mycobacterium smegmatis (juy and Chedid, 1975).
Circumstantial evidence of a direct effect of C. parvum on
macrophages was already available from the work of Wolmark,
Levine and Fisher (1974) showing a dramatic rise in the number
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of bone marrow macrophage colony-forming units, peaking at 48
hours, following C. parvum administration. This early effect
of C. parvum suggested a direct effect on macrophage precursors.
b) In view of the well known adjuvant effect of C. parvum (Howard
et al., 1973) antibodies to C. parvum and/or tumour cells could
play an important part in macrophage activation. Activation
might then occur through the formation of immune complexes (Evans,
1975) , or through activation of complement (see McBride et al.,
1975c). Complement cleavage products were known to be chemo-
tactic for macrophages and to be associated with various features
of activated macrophages (see Snyderman and Mergenhagen, 1976).
c) The possibility had also to be considered that many of the C.
■parvum results were actually due to an antibody-dependent
macrophage-mediated cytotoxicity as described, for example, by
Dennert and Lennox (1973).
d) Macrophages might also be activated by sensitised lymphocytes
or their products as described by several groups (Evans and
Alexander, 1972a, b; Lohmann-Matthes et al., 1972; Pels and Den
Otter, 1974; Hibbs, 1975a, b).
An investigation of three of these possibilities (a, b and d),
using _in vitro techniques, formed the initial objective of the
project. The experimental design and the choice of materials and
methods were dictated largely by previous, and by current, work on
the anti-tumour effects of C. parvum carried out under the direction of
Sir Michael Woodruff in the Department of Surgery, Edinburgh University.
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Dr Abdul Ghaffar and myself had developed an in vitro system utili¬
sing 96-well microculture plates to study the effects of lymphoid
cells from C. parvum-treated mice on monolayers of methylcholan-
threne (MC)-induced fibrosarcoma cells. Anti-tumour activity was
1 25
assessed by measuring incorporation of IUDR into the tumour cells
following their exposure to lymphoid cells. The reasonsfor this
choice of method are detailed in Materials and Methods.
These in vitro studies (Ghaffar et al., 1974, 1975) had already
provided useful information on the mechanism of action of C♦ -parvum.
Thus, as in other reports (e.g. Olivotto and Bomford, 1974), the
principal effector cell appeared to be the activated macrophage.
Furthermore, the anti-tumour effects were mediated by intact macro¬
phages and not by factors released into the culture medium. Attempts
to probe the mechanism leading to the production of activated.macro¬
phages met with no success. Thus, macrophages could not be stimulated
in vitro by exposure to C. narvum, either alone, or in combination
with lymph node cells from C. -parvum-treated mice. This finding
together with the observation that the production of C. -parvum-
activated macrophages was T cell-independent, indicated that the
mechanism involved differed from the macrophage-arming system described
by Evans and Alexander (l972a, b).
However, these negative findings had been obtained from only
limited experimentation and a re-examination of this work eventually
confirmed that macrophages could be activated _in vitro by lymphocytes
from C. parvum-treated mice. An analysis of this mechanism, using
methods then in current use such as T cell-deprivation of mice,
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x-irradiation, gold salts, and antisera to T cells and macrophages,
formed the bulk of the project reported in this thesis.
In parallel to this study, but not entirely divorced from it,
was an investigation of the observation that C. •parvum-activated
macrophages quickly lost their cytotoxic potential when cultured
in vitro but that this loss of activity could be delayed by the
presence of C. -parvum. The findings of this study are reported in
Results, Part 2.
MATERIALS AND METHOD S
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MICE
Mice of the CBA/Ca strain were inbred in the Department of
Surgery, Edinburgh University- Breeding pairs were originally
obtained from the Laboratory Animal Centre, Carshalton, Surrey,
England.
Only female mice, 9 to 12 weeks old were used. Experimental
mice were housed in plastic boxes lined with wood shavings, 3 to
6 mice per box. Water and mouse cake (McGregor & Co. (Leith) Ltd.,
Edinburgh) were available to animals ad libitum. The mouse room
had a 10 hour day and was maintained at an average temperature of
21°C with continual air exchange to ensure adequate ventilation.
T CELL-DEPRIVED MICE (B MICE)
CBA/Ca mice were thymectomized at the age of 4 to 6 weeks.
Ten days later these mice were given a potentially lethal dose
(850 Rad) of whole body x-irradiation followed by an intravenous
g
injection of 5 x 10 viable isogenic bone marrow cells. Mice were
not used experimentally for at least 6 weeks following this proced¬
ure. The criteria for thymic deficiency in such mice (Woodruff,
Dunbar and Ghaffar, 1973) were that they failed to mount known T
cell-dependent immune reactions such as the production of antibody
to sheep erythrocytes, and the rejection of H-2 incompatible skin
allografts. All experimental B mice were examined when sacrificed




RFMI-1640 medium buffered with 20mM HEPES* and supplemented
with 10$ heat-inactivated foetal calf serum (ECS), 2mM glutamine,
-1 -1
100 units ml penicillin, and lOOpig ml streptomycin was used
for tumour cell propagation and for the anti-tumour assays. The
medium, glutamine and FCS were obtained from Gibco-Biocult, Glasgow,
Scotland and the antibiotics in the form of Crystamycin from Glaxo
Laboratories Ltd., Greenford, England. Details of the composition
of RPMI-1640 are given in the appendix.
Wash Medium
This medium, used for washing tumour cells, lymphoid cells and
cell monolayers, was composed as for growth medium but with only
5$ FCS.
Phosphate-buffered saline (PBS)
Phosphate-buffered saline (pH 7.4), when used, was Dulbecco's
formulation (see appendix) and was obtained from Oxoia, London.
Tumour
The tumour studied was a fibrosarcoma, originally induced in
the thigh of a female CBA mouse with a single intramuscular injec-
1
*HEPES = W-2-hydroxyethylpiperazine-N -2-ethanesulphonic acid
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tion of 0.5mg 3-methylcholanthrene suspended in 0.1 ml trioctanion
(Sigma Chemical Co., St. Louis, Mo., U.S.A.). The tumour, which is
stored as single cell suspensions in liquid nitrogen, is now in its
g
18th transplantation generation. 1 x 10 of the stored cells are
injected subcutaneously into the thigh of a CBA mouse to give one
more transplantation passage before using the tumour in tissue
culture.
The tumour, which has a TD50 of about 30 viable cells (Woodruff
and Dunbar, 1974), is immunogenic in CBA mice, a single subcutaneous
(s.c.) injection of irradiated (22,000 rad) cells completely pro-
4
tecting against challenge with 10 viable tumour cells 14 days later
(Woodruff and Dunbar, 1973).
Preparation of tumour cell suspensions from solid tumour
Tumour cell suspensions were prepared by the following method
based on that of Woodruff and Boak (1966) and originally adapted
from Boyse (i960).
(1) 14-18 days following subcutaneous injection in the thigh of
g
1x10 stored tumour cells, when the tumour was about 14mm
in diameter, the mouse was killed and the tumour was excised
aseptically.
(2) The tumour was transferred immediately to a sterile glass
universal container containing 10ml of a concentrated anti¬
biotic solution (lO^ units ml ^ penicillin, 10^ }ig ml-''
3 —1
streptomycin, and 5x10 units ml mycostatin (Gibco-
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Biocult), in RPMI-1640 medium). The use of antibiotics in
such high concentration is an effective way of reducing
possible microbial contamination to a minimum (Paul, 1970).
(3) After 10 minutes at room temperature in the antibiotic solu-
tion, the tumour was cut up into small pieces (2-4mm ) with
a pair of scalpels (No. 10 blades), discarding necrotic
tissue in the process, and transferred to a universal con¬
tainer containing 2.4mg ml-'' pronase (Calbiochem Ltd.,
Bishops Stortford, Herts., England) and 0.04mg ml deoxy-
ribonuclease (DNA-ase; Sigma Chemical Co.) in Dulbecco's
PBS. DNA-ase is important in the digestion system as it
breaks down viscous nuclear protein which would otherwise
cause clumping of cells and interfere with settlement.
(4) Digestion was allowed to continue with frequent vigorous
shaking for 30 minutes in a 37°C water bath. Large pieces
of tumour were then allowed to settle and supernatant was
drawn off by pipette and transferred to another universal
for centrifugation (l80g for 7 minutes). The tumour cells
were washed a total of three times in PBS containing 0.04 mg
ml DNA-ase. Cells were finally suspended in RPMI-1640
growth medium.
(5) Steps 3 and 4 were repeated until most of the tumour had been
digested. This method normally yields 92-97$ viable cells.
In vitro propagation of tumour cells
Tumour cells were grown in monolayer in glass tissue culture
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"bottles (40cm ); 4 x 10 viable cells in 10ml KPMI growth medium
5
per bottle for the initial passage, and 8 x 10 cells per bottle
for subsequent passages. Cells were usually subcultured on every
second day, the cell monolayers being dislodged by firmly tapping
the glass bottle. Single cell suspensions were obtained by gently
aspirating dislodged cells in a 5ml pipette.
Tumour cells were maintained in culture for 18-20 days before
use in the assay system as it was found that cell adherence to
plastic culture plates improved after this time. This period in
culture also ensures the complete loss of any macrophages and lympho¬
cytes present in the original tumour suspension. The cultured cells
do not lose their capacity to produce a tumour when injected into
mice.
The anti-tumour assays were carried out in 96-well microculture
plates (Linbro, IS-FB-96, obtained from Flow Laboratories, Irvine,
Scotland). Plates were incubated at 37°C in a humid atmosphere
enriched with 5% CO^. In one experiment 35mm diameter plastic
Petri dishes (a/s Nunc, Denmark) were used in place of microculture
plates.
It should be noted that the MC-induced tumour cell line used
in this study has been screened for the presence of viruses and
other microorganisms by a number of procedures including standard
culture techniques, electron microscopy, immunofluorescence, RNA
incorporation studies and reverse transcriptase assays. Tumour
cells from both short (3 days) and long-term (8 months) culture
lines have so far proved to be free of microbial contamination as
judged by these tests (James et_al., 1978). Such screening of tumour
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cells is essential for immunological studies in view of the known
influence of microorganisms and their products on immune responses
(Kamo and Friedman, 1977). The 18-20 day culture of tumour cells
before use in the anti-tumour assays would in itself reduce the
possibility of one common type of tumour cell contaminant, lactate
dehydrogenase elevating (iDH)- virus, which has a poor survival under
tissue culture conditions (Riley, 1968).
EFFECTOR CELLS
Spleen Cells
Untreated (control) and adjuvant-treated mice were killed by
ether inhalation and their spleens excised aseptically. Spleens
were gently disrupted in cold (4°C) RFMI wash medium in loose-
fitting, hand-operated glass homogenisers. After allowing large
clumps of cells and splenic debris to settle for about 1 minute,
the supernatant spleen cell suspensions were transferred to 10ml
plastic centrifuge tubes and spun at 240g for 5 minutes. Spleen
cell pellets were resuspended in 10ml fresh wash medium and respun,
This washing procedure was repeated once more before resuspending
the cells in cold RPMI growth medium, and making a nucleated cell
count in a Neubauer haemocytometer.
Spleen cells were then incubated at 37°C in large culture flasks
(surface area 120cm ) for a total of 3 hours to remove adherent cells,
7
particularly macrophages. Each flask contained a maximum of 5 x 10
cells in 30ml RPMI growth medium and, midway through the incubation,
flasks were shaken to resuspend non-adherent cells and turned through
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180° to ensure as complete a removal of glass-adherent cells as poss¬
ible. Following incubation, non-adherent cells were transferred to
centrifuge tubes, washed once, resuspended in growth medium and nuc¬
leated cells counted.
Lymnh Node Cells
Mice treated by the intraperitoneal route had their inguinal,
brachial and axillary nodes excised, and mice treated by the subcut¬
aneous route had only those nodes local to the injection site removed.
Nodes from untreated mice served as controls. Non glass-adherent
lymph node cell suspensions were made according to the procedure
described for spleen cells.
PREPARATION OF MACROPHAGE MONOLAYERS
Experiments on the in vitro activation of anti-tumour activity
in normal macrophages
Peritoneal exudate cells (PEC) were obtained by washing the
peritoneal cavity of ether-killed normal (i.e. untreated) mice with
two injected 2.5ml aliquots of RPMI-1640 medium containing per ml,
10 units preservative-free heparin (Evans Medical Ltd., Liverpool,
England), 100 units penicillin, and 100 pg streptomycin. Washings
g
were withdrawn by syringe after massaging the abdomen. 5-4 x 10
PEC were usually obtained in this way from each mouse.
Cells were washed three times in cold RPMI wash medium, a
nucleated cell count made, and cells seeded in 96-well microculture
4 1
plates to give 8x10 cells in 0.1 ml volumes per well. After 1y
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to 2 hours incubation at 37°C, wells were washed three times with
0.3ml volumes of wash medium to remove non-adherent cells. To aid
this removal of unwanted cells, plates were shaken for 60-second
periods on a Cooke Microtiter AM 69 Microshaker (Dynatech Labs.
Ltd., Billingshurst, Sussex, England).
This method gives monolayers consisting predominantly of
macrophages as determined by morphology, phagocytosis, adherence,
and histochemical staining. Macrophages were enumerated using the
following tests:
(1 ) Saline containing 0.1$ neutral red added to adherent cell
monolayers resulted in the rapid uptake of the dye to macro¬
phages (Gesner and Howard, 1967).
(2) Phagocytic cells were identified by first incubating monolayers
with C. oarvum overnight. Monolayers were then washed thoroughly
with PBS to remove extracellular bacteria, fixed in methanol,
and stained with Gram's stain. Cells (stained red) which had
phagocytosed bacteria (stained blue) were then easily enumerated.
(3) Differential counts were made of stained monolayers using (a)
Leishman's stain and (b) Kaplow's method for myeloperoxidase
(Kaplow, 1965).
On the basis of these tests it was found that the macrophage
was the predominant monolayer cell, generally accounting for 92 -
97$ of adherent cells. Other cells present in the monolayers were
mostly lymphocytes with an occasional granulocyte (^1$).
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Experiments on the in vitro behaviour of peritoneal macrophages
which had been stimulated in vivo by C. pairum
Macrophage monolayers were prepared as above from the peritoneal
exudate of untreated mice and of mice which had been injected (usu¬
ally 10 days before) intraperitoneally with 1 .4mg C. parvum.
ANTI-SERA
Theta-1 .2 (QC3H) Anti-Serum
The mouse theta (©) alloantigen, first described by Reif and
Allen (1963, 1964), has been found in brain, on epidermal cells
(Scheid et al., 1972), fibroblasts (Stern, 1973), thymocytes and, to
a lesser extent, in spleen and lymph nodes. The relatively low levels
of theta in the peripheral lymphoid organs compared to the thymus,
suggested a use for theta as a surface marker to distinguish thymus-
derived lymphocytes (T cells) from thymus-independent lymphocytes
(B cells)(Schlesinger and Yron, 1969; Raff, 1969). Theta antigen
is the expression of one of two alleles: Thy-1.1 (qaKR) found in AER
and RE mice and Thy-1.2 (©C3H) found in most other inbred strains
including CBA (Reif and Allen, 1966).
Anti-sera cytotoxic for theta-bearing lymphocytes were used in
this study to remove the T cell population from spleen cells. Anti-
Thy-1.2 serum was prepared by the following method adapted from Reif
and Allen (1966).
A suspension of thymocytes was prepared by gently disrupting
female CBA thymuses in a loosely fitting glass homogeniser. Cells
were suspended in Dulbecco's PBS containing 0.05mg DNA-ase and washed
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twice with; this medium. 10 x 10 thymocytes were then injected intra-
peritoneally into each AKR. female mouse, the inoculation of thymocytes
being repeated on days 2, 21 , 30, 38 and 36. Mice were bled out on
day 70 and the serum separated and heat inactivated (56°C for 30
minutes). Fifty per cent cytotoxic titres of the anti-serum to CBA
spleen cells, and to thymocytes, were determined using the following
assay:
(1) Doubling dilutions of anti-serum were prepared in plastic tubes
using RFMI 1640 medium (without FCS) as diluent (0.1ml volumes).
g
(2) 1 x 10 spleen cells or thymocytes in 0.2ml were added to each
tube and the tubes vortexed.
(3) Tubes were left at room temperature (20°C) for 15 minutes.
(4) 0.1 ml of 1:4 dilution of agarose-absorbed guinea pig complement
(see below for details) were added to each tube which was then
vortexed. A tube without anti-serum was included to act as
complement control. Tubes were incubated for 1 hour in a 37°C '
water bath.
(5) 0.1ml trypan blue (see appendix) were added to each tube which
was vortexed and left at 37°C for 5 minutes.
(6) 0.1ml formalin were added to each tube. The number of dead
cells (those which had taken up trypan blue) was expressed as a
percentage of the total number of cells per tube and plotted with
respect to serum dilution. Figure 1 (a) illustrates the results
using anti-9 serum raised by the method described above and
figure 1 (b) the results using a commercial anti-9 serum
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In order to kill theta-bearing cells in spleen populations
it is necessary to use the anti-serum at a concentration which is on
a cytotoxic plateau (Raff, 1971). Thus from Fig. la> the anti-theta
serum was used at a final concentration of 1:8. Spleen cells depleted
of glass-adherent cells were treated with anti-serum and complement
as above, but scaling up the volumes and numbers of cells. Following
the treatment the spleen cells were washed twice, resuspended in growth
6 —1
medium, and their concentration adjusted to give 4x10 cells ml
ready for use in the activation assay. Control groups of spleen cells
treated only with complement were also included in the test.
Guinea Pig Complement
Normal guinea pig serum is generally toxic for mouse thymus
(e.g. Schlesinger, 1965) and accordingly has to be absorbed with
murine tissue before use as a complement source. An alternative to
the use of mouse cells for absorption was described by Cohen and
Schlesinger (l970) in which cytotoxicity to murine thymus cells can
be effectively absorbed with a carbohydrate source such as agarose.
Guinea pigs were anaesthetised (Nembutal) and bled by cardiac
puncture. Serum was diluted 1:2 with RPMI-1640 (without FCS) and
80mg agarose (Agarose A37, L'Industrie Biologique Francais, Genne-
villiers, France) for every original 1ml of serum added. Serum plus
agarose was placed in a refrigerator. The container was inverted six
times and this was repeated at 5-10 minute intervals for 1 hour. The
serum was then centrifuged in a cold room (4°C) at 1500g and the
supernatant serum transferred to a glass universal container and stored
at -20°C until use.
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Anti-macrophage Serum
Rabbit anti-mouse macrophage serum was prepared using the
method of Unanue (1968). Peritoneal exudate cells from CBA female
g
mice were cultured in 35mm plastic Petri dishes (approx. 15 x 10
cells/dish) for a period of three days at 37°C in a humid atmosphere
enriched with 5$ CO^. The monolayers were washed (two medium changes)
at 30 minutes, 24 hours and 48 hours. This culture method effectively
removes most mast cells, polymorphonuclear leucocytes and lympho¬
cytes (See Eirsch et al., 1969) leaving a population which is more than
95$ macrophage. After three days in culture the cell monolayers were
washed twice with medium, detached with a "rubber policeman" and washed
twice in Dulbecco's PBS. New Zealand White rabbits were immunized
and bled according to the following protocol:
g
Day 0 12 x 10 CBA macrophages in complete Preund's adjuvant
injected into each rabbit, the injections being distributed
between four sites: hind footpads (0.15ml each) and forearms
(0.3ml each).
g
Day 28 6 x 10 CBA macrophages in Dulbecco's PBS (0.6ml) intra¬
venously (ear).
g
Day 35 50 ml bled and 6 x 10 macrophages in Dulbecco's PBS
injected intravenously (ear).
Day 42 Rabbits bled out.
The serum was heated at 56°C for 30 minutes, sterilised by
Millipore (0.2jum) filtration and stored at -20°C. Each 1ml of anti-
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serum was absorbed with 4 x 10 CBA thymocytes for 30 minutes at
4°C. Cells were pelleted by centrifuging at 240g for 5 minutes and
the serum transferred to another tube containing a second batch of
rj
4 x 10 CBA thymocytes. This tube was left overnight at 4 C. Fifty
per cent cytotoxic titres to thymocytes and cultured peritoneal
macrophages were carried out on the anti-macrophage serum using the
method described above for anti-theta serum, using guinea pig serum
as complement source. The. batch of anti-macrophage serum used in
this study had 50$ cytotoxic titres of 1:512 against macrophages
and 1:4 against thymocytes.
ADJUVANTS
Formalin-killed suspensions of Corymebacterium parvum strain
CN6134> containing 7 mg dry weight of organisms per ml were obtained
as a gift from the Wellcome Research Laboratories, Beckenham, Kent.
In one in vitro experiment, two other corynebacteria, C. parvum
NCTC 10390 and Propionibacterium freudenreichii NCTC 10470, were
compared with C. parvum CN6134. Formalin-killed suspensions of these
bacteria, prepared as previously described (McBride, Dawes, Dunbar,
Ghaffar and Woodruff, 1975a), were kindly provided by Dr. W.H. McBride
of the Department of Bacteriology, University of Edinburgh.
It is recognised that "C. parvum" is a general designation for
a heterogeneous group of anaerobic bacteria that have proved difficult
to classify. These bacteria can be divided into four taxonomic groups
(I - IV) on the basis of serology, cell wall composition, and DNA
homology (Johnson and Cummins, 1972; Cummins and Johnson, 1974).
As a result of such studies it has been proposed that the "C. parvum"
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bacteria be in fact classified under Pronionibacterium (Douglas and
Gunter, 1946; Johnson and Cummins, 1972; Cummins and Johnson, 1974).
However, as there remains controversy over the true taxonomic posi¬
tion of these bacteria (see McBride et al.. 1975a), the classical
name C. narvum has been retained in this study. Adopting the
taxonomic grouping of Johnson, and Cummins (1972), the C♦ narvum
strains 6134 and 10390 used in this study have been placed in groups
I and II respectively (McBride et al., 1975a).
Freeze-dried BCG (Bacille-Calmette-Guerin)vaccine, containing,
g
when reconstituted, approximately 9 x 10 organisms per ml, was
purchased from Glaxo Laboratories, Greenford, Middlesex, and
a Bordetella -pertussis suspension containing 4 x 10^ killed organ¬
isms per ml was purchased from Wellcome Reagents Ltd., Beckenham,
Kent.
The dose used per mouse of a bacterial adjuvant was 0.2ml of
the original suspension and in most experiments this was administered
intraperitoneally. In experiments employing the subcutaneous route,
the dose was divided equally between two sites, the right foreleg and
the right hindleg. Intravenous injections were given via a large tail
vein, the tail having first been warmed in warm water.
When used in vitro the bacteria first had to be thoroughly
washed to remove all traces of preserving chemicals. This involved
washing 0.1ml aliquots of the bacterial suspensions six times in
10ml volumes of PBS. Washed bacteria were resuspended in RPMI growth
medium to give a stock containing one tenth of the concentration of
the original suspension. The stock suspensions were further diluted
1:100 before use in an experiment. Thus, C. parvum CW6134 was finally
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diluted to give 7p.g nil ^ and 0.1ml of this was added to each well of
a microculture plate. Washed preparations of C. parvum strain 10390
and P. freudenreichii strain 10470 were standardised to the C. parvum
strain 6134 preparation by optical density.
Freund's complete and incomplete adjuvants, obtained from Difco
Laboratories, Detroit, Michigan, U.S.A., were injected i.p. at a dose
of 0.1ml per mouse. These adjuvants were not tested in vitro.
GOLD SALT TBEATMENT
The effect of sodium aurothiomalate ('Myocrisin', containing
45^ metallic gold; May and Baker Ltd., Dagenham, Essex) on the
in vitro stimulation of anti-tumour cytotoxicity in normal
macrophages, was studied _in vitro and _in vivo.
In the in vivo experiments the following regimen of injections
was followed:
Group 1 1 mg gold salt in 0.2ml saline i.p. on days -8, -6, -4
and -1 . 1.4mg C. parvum i.p. on day -7.
Group 2 1 mg gold salt in 0.2ml saline i.p. on days -8, -6, -4
and -1 .
Group 3 1 .4mg C. parvum i.p. on day -7.
Group 4 No treatment.
Mice were killed on day 0 and their spleens harvested.
1 This schedule was determined by the results of a previous
investigation (McBride, Tuach and Marmion, 1975) using the same
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fibrosarcoma used in this study, which had shown that, in order to
abrogate the inflammatory response to C. parvum and its _in vivo
anti-tumour action, it was necessary to administer the gold salt as
a series of injections starting before the C. parvum injection.
For the in vitro experiments various concentrations of sodium
aurothiomalate (10, 20 and 50jig) were added to wells, either during
macrophage adherence, or during the macrophage activation process.
The in vitro effect of gold salt on the maintenance of anti-
tumour cytotoxicity by C. parvum in macrophages from C. parvum-
treated mice was also investigated.
X-IRRADIATION
Mice were irradiated in perspex boxes at a dose of 60 rad per
minute using a 230 kV Westinghouse X-ray machine, operating at 15ma
with a half-value layer of 1 .2mm Cu under conditions of maximum
back scatter. Spleen and peritoneal exudate cells in 60mm diameter
plastic Petri dishes were irradiated at the same dose rate.
SEPARATION OF SPLEEN T AND B LYMPHOCYTES ON NYLON WOOL COLUMNS
Spleen cell separation was carried out using a nylon wool
column filtration method, based on that described by Julius, Simpson
and Herzenberg (1973). This, and other studies (Eisen, Wedner and
Parker, 1972; Greaves and Brown, 1974; Handwerger and Schwartz, 1974)
have shown that the effluent cell population from the column is
enriched with T lymphocytes and the nylon adherent population with B
lymphocytes (Handwerger and Schwartz, 1974).
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About 10g of the nylon wool (LP-1 Leuko-Pak, Leukocyte filter,
Penwall Laboratories, Morton Grove, Illinois, U.S.A.) was soaked in
250ml distilled, deionised water and kept at 57°C for three days,
changing the water each day. This washing improves post separation
viability of cells in culture (Julius et_al., 1973; Greaves and
Brown, 1974).
The washed wool was dried and 600 mg quantities were packed to
the 5ml mark in the barrels of 5ml plastic syringes. The packed
syringes were wrapped in Kraft paper and autoclaved. Sterile plastic
2-way taps were fitted to the syringe barrels and the nylon wool
columns rinsed with 25ml warm (37°C) RPMI wash medium, drained of
excess medium, sealed, and equilibrated at 37°C for 1 hour. 1 x 10^
non-adherent, glass-incubated spleen cells (vide supra) in 2ml wash
medium were loaded onto the column and washed into the wool with
lml of warm wash medium. Columns, which were maintained in a vertical
position throughout the separation procedures, were incubated for 1
hour at 37°C.
Non-adherent cells were then eluted slowly be adding 15ml warm
(37°C) wash medium drop by drop to the top of the column. Effluent
cells were centrifuged at 240g for 7 minutes, resuspended in 2ml
medium and loaded onto a fresh column. This was incubated for 30
minutes at 37°C and non-adherent cells recovered by washing the
column slowly, as above.
Immunoglobulin-bearing cells which had been retained in the first
and second columns were recovered by eluting with 25ml cold (4°C)
wash medium and by simultaneous agitation of the nylon wool.
The separated cell populations were centrifuged, resuspended in
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RPMI growth, medium, and viable, nucleated cells counted in a haemo-
cytometer. The relative numbers of B lymphocytes in the two separated
populations and in the original untreated spleen population, were
assessed by Mr T. Varley of the Department of Surgery, University of
Edinburgh, using an indirect immunofluorescence staining method for
cells carrying surface immunoglobulin light chains. Briefly, the
method, which has been fully described elsewhere (McCormick, Nelson,
Tunstall and James, 1973) involved incubating cells for 30 minutes
at room temperature (20°C) with rabbit anti-mouse light chain serum
followed by washing and 30 minutes incubation with fluorescein-con-
jugated goat anti-rabbit serum. Stained cells were then washed,
deposited on microscope slides in a Shandon cytocentrifuge, and then
air dried and mounted in barbitone (50^ glycerol) buffer (pH 8.6).
Slides were examined alternately with incident blue violet illumination
and dark ground illumination.
CHOICE OF IN VITRO ASSAY
A number of methods utilizing monolayers of target cells in
tissue culture have now been developed to assess antibody-mediated
and cell-mediated immunity to animal and human tumours. These assays
measure either inhibition of growth of target cells (cytostasis) or
actual killing or injury of target cells (cytotoxicity). In the
latter assay, detachment of cells from the substrate is generally
taken as a correlate of cytotoxicity, detached cells usually being
seen to be dead or injured (Roseneau and Moon, 1961; Biberfield et al.,
1968; Ax et al.. 1968 and Oldham et al., 1973). However, all assays,
cytotoxic or cytostatic, have in common an assessment of numbers of
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cells remaining at the end of a test. The early work in this field
involved visual counting of cells (Takasugi and Klein, 1970;
Hellstrom et al., 1971), cell colonies (Hellstrom, 1967) or of
cell nuclei (Roseneauand Moon, 1961; Wilson, 1963; Ulrich and
Keiler, 1969). Such methods were tedious and lacked objectivity,
it sometimes being difficult to distinguish morphologically between
target cells and adherent lymphoid cells or to count accurately
cells which had clumped in culture. These difficulties can be avoi¬
ded by using an electronic counting system (Takasugi et al., 1973)
or by labelling of target cells with radio-isotopes. Sodium (^Cr)-
chromate-labelled cells have been used in assays for antibody-induced
lysis (Sanderson, 1964; Wigzell, 1965) and cell-mediated lysis
(Holm and Perlmann, 1967; Brunner et_al., 1968). The chromate is
reduced on binding to cellular constituents and thus, during lysis
, 51
of target cells, the 80-957° Cr released is in a non-reutilizable
form (Bunting et al., 1963; Holm and Perlmann, 1967). Unfortunately
the usefulness of the technique is marred by the relatively high
51
spontaneous release of Cr, restricting assays to short incubation
periods, generally between 3 and 10 hours. In assays requiring incu¬
bation periods in excess of 24 hours several methods have been developed
which use nuclear DNA labels: ^-Thymidine (Vainio et al., 1964);
•^H-Thymidine (Jagarlamoody et al., 1971) and 5-(^^l) Iodo-2-deoxy-
uridine (^^IUDR; Cohen et al., 1971 ). IUDR is a structural ana¬
logue of thymidine and as such can be incorporated into the DNA of
3
dividing cells. An RNA label, H-Uridine, has also been used
(Hashimoto and Sudo, 1971) but has the disadvantage that it is re¬
leased spontaneously and can be reutilized. Reutilization is also a
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14 3
problem with, the DNA labels C-thymidine and H-thymidine but is
125 f
not apparently a significant factor in assays using IUDR (Cohen
et_al., 1971; le Mevel et al., 1973 and Seeger et_al., 1974).
125 14 3
IUDR has a further advantage over C- and H- labels in that
being a gamma-emitter, labelled cells do not require special prepa¬
ration prior to scintillation counting.
1 25
Because of these advantages it was decided to use IUDR
labelling in this study. It remained to choose between labelling
the target cells (fibrosarcoma tumour cells) before or after their
exposure to the effector cells (adherent peritoneal exudate cells
in this study). The first procedure (pre-labelling) provides a
measure of injury or death of target cells but the second fails to
distinguish between such effects and mere growth inhibition (cyto-
stasis) of targets. Since cytostasis may be just as important an
anti-tumour mechanism as cytotoxicity and since the precise nature
of C. parvum's anti-tumour effects were not known, it was decided
to use the post-labelling technique. This procedure had the added
1 25
advantage that the tumour cells are exposed to IUDR for a minimum
period of time, thus reducing its reported chemical and radiation
toxicity (Morris and Cramer, 1968; Hofer and Hughes, 1971; Porteous,
1971; le Mevel et al., 1973). (See also section below on incorpora-
125 \tion kinetics and toxicity of IUDR).
METHOD OF QUANTITATING TUMOUR CELLS IN MONOLAYERS USING
125i-iododeoxyuridihe
125
I-Iododeoxyuridine obtained from the Radiochemical Centre,
Amersham, England was diluted with RPMI-1640 medium containing 100
•84-
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unit ml penicillin and lOOpg ml streptomycin to give a stock
solution with radioactive concentration of 50p.Ci ml and this was
stored at 4°C until use.
1 25
Quantitation of IUDR-labelled tumour cells remaining in a
monolayer at the end of an experiment was carried out using the
following procedure which was. standard for the majority of experiments
in this study.
Cell monolayers in wells of microculture plates (hinhro, IS-FB-96)
were gently washed twice with 0.2ml volumes of RPMI-1640 wash medium
125(vide supra) to remove unincorporated IUDR and non-adherent cells.
Medium was withdrawn from wells using a plastic 10ml syringe and 19
gauge needle from which the point had been cut off. Care was taken
to ensure as little disruption of the cell sheet as possible, and,
to aid this, wells were never completely emptied, a film of medium
(approx. 0.02-0.03ml/well) covering the cells at all times. Plates
were then left to dry thoroughly at 37°C and sprayed with a plastic
aerosol preparation such as Trycolac MK IV (Aerosol Marketing and
Chemical Co. Ltd., London, England) to fix cells to the wells. Indi¬
vidual wells were then cut out with a hot wire and the radioactivity
counted using a LKB-Wallac 1280 Ultrogamma scintillation spectrometer
(LKB Instruments Ltd., S. Croydon, Surrey, England).
INCORPORATION KINETICS AND TOXICITY OF 1 25I-IODODEOXYURIDINE
Experiments were conducted to determine the best tumour cell
125




Various concentrations of tumour cells were seeded in 0.1ml
volumes in wells of microculture plates and incubated for 18 hours
at 37°C. 0.1ml volumes of ^ ^IUDR were then added to the wells and
the plates incubated for varying periods up to 48 hours before
washing the wells and assessing isotope incorporation as described
1 25
in the preceding section. The variation of incorporated IUDR
1 25with increasing labelling time for each of the four IUDR concen¬
trations used is given in figures2(a) - 2(d). Each observation is
the geometric mean of the counts from four replicate wells.
Several points emerge from this experiment:
(1) As expected, the radioactive count generally increases with
1 25
increasing cell density and increasing IUDR concentration.
This is more apparent from figures 3(a) - 3(c) which show the
variation in counts with increasing concentration of isotope,
after 20 hours incubation.
(2) Incorporation reaches a maximum after 20-31 hours incubation
and thereafter decreases.
(3) The low counts at 48 hours suggest that the label was starting
to prove toxic for the cells.
Toxicity
1 25
The toxicity of IUDR for 1C fibrosarcoma cells was tested in
3
a further experiment in which 4x10 cells per well were seeded in
-1 125




























































































































CULTURE. Tumourcellslabelledfor18h rs,washedandincubat dforv ryingperiods
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period of 18 hours. The cell monolayers were then iwashed 3 times to
remove unincorporated label and the plate incubated for various
periods up to 72 hours. At the end of each period, adherent cells
were harvested with 0.25% trypsin, washed once, pelleted and radio¬
activity assessed in the gamma counter. Loss of radioactivity from
the monolayers with incubation is shown in Figure 4. Cells have
either released isotope, or become detached from the monolayers.
From these, and other similar experiments not shown, it was
1 25
decided to label tumour cells in the anti-tumour assay with IUDR
at 1 .25p.Ci ml over a period of about 20 hours. This isotope
concentration was chosen because it gave fairly high counts and
because any gain in incorporation levels obtained with the 1 ,75p.Ci ml
concentration was outweighed by increased costs and, again, the desire
to reduce any possible toxic effects. From Figure 3 it can be seen
125 -1that at 20 hours and with a IUDR concentration of 1.25pCi ml ,
original cell density has little effect on incorporation. Therefore,
3it was arbitrarily decided to use 4 x 10 tumour cells per well in
future experiments.
IN VITRO ACTIVATION OF ANTI-TUMOUR CYTOTOXICITY IN MORMAL MACROPHAGES
For the majority of experiments, in vitro activation of macro¬
phages was achieved by incubating macrophage monolayers together
with C. parvum and spleen cells from C. narvum-treated mice. The
following protocol, evolved from a series of pilot experiments, proved
to be the most effective in producing activation of anti-tumour cyto¬
toxicity.
5
4 x 10 non-adherent spleen cells, obtained from mice injected
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i.p. 6 to 12 days before with 1 .4mg C. narvum (6134), were added
to macrophage monolayers in wells of microculture plates, together
with 0.1p.g washed C. narvum (6134). The volume of growth medium
in each well was maintained at 0.2ml throughout the experiment.
Plates were incubated overnight at 37°C in a humid atmosphere
containing 5f° CO^. After 20 hours wells were washed three times
with 0.3ml volumes of wash medium to remove spleen cells and unphago-
cytosed C. oarvum. This was aided by placing the plates on a Cooke
3
AM 69 microshaker between washes. 4x10 cultured tumour cells in
0.2ml growth medium were then added to each well and the plates
incubated. 24 hours later 0.1ml was discarded from each well and
1 23
replaced with 0.1ml growth medium containing 0.25piCi IUDR.
Following a final incubation of 20 hours, wells were washed and
1 25
IUDR incorporation assessed.as described above. Generally, the
cytotoxicity obtained using spleen cells from C. -parvum-treated
mice was compared with that using normal spleen cells.
Each plate in an experiment carried additional controls which
assessed the cytotoxicity of the various activation components in
alternative combinations and individually: Spleen cells +_ C. uarvum:
macrophages + C. parvum; C. -parvum; spleen cells + macrophages. The
spleen cell controls were necessary since the washing process always
left a small (<0.1^) persistant population of adhering cells in the
wells.
EXPERIMENTS ON THE IF VITRO BEHAVIOUR OF MACROPHAGES FROM C. PARTEM
TREATED MICE
Macrophage monolayers were prepared as described above using
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peritoneal exudate from normal and C. parvum-treated mice.
After various incutation periods 0.7ug C, parvum 6134 (or its
equivalent in other bacterial adjuvants) was added to each well.
Control wells received growth medium only. Plates were incubated
for a further 24 hours before washing and shaking to remove bacteria.
3
4 x 10 tumour cells were added to each well, and cytotoxicity was
assessed as before. In some experiments cytotoxicity was measured
in the continued presence of C. parvum.
PRESENTATION OF RESULTS AND STATISTICAL ANALYSIS
The geometric mean (GM) was calculated of the counts per
minute from each experimental group of wells and recorded along
with one standard error from the mean. The number of replicate
wells in an experimental group was never less than three, and in
most experiments was five. Mice were in groups of three to six.
The significance of data was assessed by the standard two tail
Student's 't' test. P values greater than 0.05 were considered to
be not significant. AH statistical manipulations were performed
using a Wang (Model 154) programmable electronic calculator (Wang
Laboratories Inc., Tewksbury, Massachusetts, U.S.A.) and Geigy
scientific tables (Documenta Geigy, 7th edition: published by J.R.
Geigy S.A., Basle, Switzerland).
Some results have been expressed as a cytotoxic index (Cl)
calculated using the following formula:
~GM OP COUNTS PROM TEST GROUP
GM OP COUNTS PROM CONTROL GROUP
It should be.noted that the term cytotoxic has been used throughout
-89-
this thesis in a general sense to cover possible cytostatic, cyto-
125
cidal and. cytolytic effects since the IUDR labelling technique
fails to distinguish between such effects.
In experiments studying the maintenance of cytotoxicity in
cultured macrophages by C. oarvum some results have been expressed
as a cytotoxic stimulation index (CSI):
"GM OF COUNTS FROM NELLS NITH C. PARVUM
GM OF COUNTS FROM NELLS NITHOUT C. PARVUM
The CSI provides a measure of the extent to which the presence of
C, -parvum sustains the anti-tumour activity of cultured macrophages.
RESULTS PART 1
IN VITRO ACTIVATION OP ANTI-TUMOUR CYTOTOXICITY
IN NORMAL MACROPHAGES
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As described in the introduction, the purpose of this study-
was to attempt to elucidate the mechanism, or mechanisms by which
G■ parrum exerts its anti-tumour activity. Previous in vitro work
(Ghaffar et al., 1974, 1975; Olivotto and Bomford, 1974) has made
some progress towards a solution of this problem by demonstrating
that the macrophage was the principal cytotoxic cell in peritoneal
exudate from C. parvum-treated mice. The following in vitro
experiments investigated possible ways in which this anti-tumour
activity in macrophages might be brought about by C. -parvum. The
simplest model would require exposure of macrophages or macrophage
precursors to C. parvum which might then lead to anti-tumour acti¬
vation directly. Other mechanisms would involve T and/ or B lympho¬
cytes, possibly operating via released factors or immunoglobulin
specific for C. parvum antigens. It should be noted that the term
activation used in this thesis simply implies stimulation of the
capacity of macrophages to exhibit a cytotoxic reaction to the target
fibrosarcoma cells. The term cytotoxic has been used in a general
sense to include cytolytic, cytocidal and cytostatic effects since
the post-labelling assay system used fails to distinguish between
killing of target cells or mere inhibition of cell division.
1. ATTEMPTS TO STIMULATE MACROPHAGES IN VITRO DIBECTLY BY EXPOSURE
TO C. PARVXJM
A simple mechanism for activation seemed a reasonable supposition
particularly since Alexander and Evans (1971) had reported on the
anti-tumour behaviour of macrophages exposed _in vitro to small
amounts of double stranded KNA or endotoxin. Similarly, Juy and
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Chedid, (1975) were able to obtain growth inhibition of tumour cells
by macrophages previously exposed to a fraction obtained from Myco¬
bacterium smegmatis.
Accordingly, experiments were conducted in which monolayers
of peritoneal macrophages were incubated in the presence of various
concentrations of a washed preparation of C. narvum 6134 for various
time intervals up to 10 days. Tumour cells were then added to the
125
monolayers and anti-tumour activity assessed by ITJDR incorporation
48 hours later. None of these experiments (table 1) gave rise to
macrophages exhibiting the degree of cytotoxicity known to occur in
the peritoneal macrophages of C. narvum-treated mice (see table 20).
Nevertheless slight activation was observed in certain groups, par¬
ticularly those using greater amounts of C. oarvum, but otherwise
there was no consistent pattern.
Experiments were also conducted in which adherent peritoneal
cells were incubated simultaneously with C. uarvum and serum from
C. parvum-treated mice. Sera were tested from mice which had re¬
ceived 1.4mg C. parvum intraperitoneally 4, 10 or 24 days previously.
The rationale of this experiment was that formation of antigen/
antibody complexes might activate macrophages (see Introduction,
section 5.3). However, this approach also failed to induce anti-
tumour activity (data not shown).
However, these results do not rule out a case for direct acti¬
vation of macrophages in vivo. It is possible that macrophages which
have ingested C. parvum may play a role in stimulating the maturation
and release of promonocytes from bone marrow and that the resultant
mature monocytes are the anti-tumour effector cells _in vivo or
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in vitro. It has been shown that a subcutaneous (Wolmark, Levine
and Fisher, 1974) or an intraperitoneal (Baum and Breese, 1976)
inoculation of C. -parvum results in a dramatic yet transient rise
in the number of macrophage colony-forming cells from bone marrow.
The number of colonies reached a maximum at 2 days suggesting that
macrophage precursors may be the initial target in C. narvum therapy.
Macrophages derived from the bone marrow of tumour-bearing and C.
parvum/cyclophosphamide-treated tumour-bearing mice exhibited cyto¬
toxicity to tumour cells in vitro (Fisher and Volmark, 1976; Fisher
et al, 1976b, c).
2. ANTI-TUMOUR CYTOTIXICITY OF PERITONEAL MACROPHAGES FOLLOWING
SIMULTANEOUS INCUBATION WITH C. PARVUM AMD LYMPHOID CELLS FROM
C. PARVUM-TREATED MICE
C. parvum had failed to activate macrophages on its own and thus
a more complex model was envisaged in which macrophages might require
the co-operation of T cells or B cells, or both. Evans and Alexander
(1972a, b) describe such a mechanism in which lymphocytes from mice
sensitised to BCG and other antigens render macrophages from normal
mice cytotoxic in the presence of the specific antigen.
It was likely that a similar mechanism operated with C. parvum
and this possibility was investigated by incubating macrophage mono¬
layers simultaneously with C. parvum and glass-incubated spleen cells
from mice previously injected intraperitoneally with C. parvum.
Spleen cells and C. parvum were then removed from the monolayers by
vigorous washing 24 hours later and replaced with tumour cells to
test for cytotoxic activation.
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Results from a preliminary experiment were encouraging and
further experiments were pursued to ascertain the best protocol for
activation. This was achieved in part by empiric means, determining
the ideal time course, concentrations of spleen cells and C. parvum
to be used per well, and in part by arbitrary selection, for example,
of numbers of PE and tumour cells. The formula arrived at for
activation (described more fully in Materials and Methods) was (per
\ 4 5
well): 8 x 10 PE cells, 4 x 10 non-adherent spleen cells, and
0.7y-g washed C. -parvum. The extent of activation was assessed using
3
4 x 10 tumour cells per well. This concentration of PEC was selec¬
ted because it was known from previous work using PEC from C,
parvum-treated mice, to give a strong in vitro cytotoxic effect
(Ghaffar et al.. 1974). The actual adherent effector to tumour
target ratio was about 6:1 following the loss of non-adherent PE
cells during the washing process.
Table 2 gives the results of a typical experiment using spleen
cells from mice injected i.p. 10 days before with 1.4mg C. parvum.
It can be seen (line 1, table 2) that only one macrophage treatment
resulted in an anti-tumour reaction, namely C. parvum-sensitised
spleen cells plus C. parvum. The presence of C♦ parvum or spleen
cells alone was not sufficient to induce activation. The cytotoxic
index (CI_), compares the effects of normal spleen cells with C.
parvum-sensitised spleen cells in the anti-tumour assay: the higher
the CI the greater the cytotoxic effect. Where a particular treat-
1 25ment resulted in an increased uptake of IUDR by tumour cells,
when compared with the normal controls, this has been represented in
tables as a negative cytotoxic index (neg).





Spleen+macrophage +C.parvum Spleen-tmacrophage Spleen+G.parvum Spleen
17,553(16,1175-18,701) 18,862(16,58)4.-21,lp 2) 18,6311(16,521-21,018) 16,593(111-,11-20-19,09lj.)
2,211).( ,770-2,768) 30,071(26,811-33,727) 12,755( 1,133-11)-,61) 20,213(17,1).10-23,lj.66)
87 Neg. 32 Neg.
<0.001 N.S.
AdditionalControls Macrophage+C.parvum:16,695(ll|->771-18,868) Macrophage:12,671)-(10,6L|_9-15*83) Tumoural ne:16,181).(3,ij.57-19,1)-61).) (a)Comparisonusi gSt dent'sHiPte tofheffecspleec llfr munt ated miceandC.parvum-treatedmi .Pvalu sgreaterth n0.05w rconsid rnot significant(N.S.)
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Several other points should he noted when studying this and
subsequent tables:
(1) All presented data, unless otherwise indicated, signify
the counts per minute obtained with tumour cells present.
(2) The washing procedure fails to remove all lymphoid cells
and thus the possible cytotoxic effects of this residual
population have been controlled (eg. lines 2 and 4 in
table 2).
(3) All experiments included controls to assess the effects of
macrophages with or without C. parvum. This is an essential
control since there was an everpresent possibility of in vivo
activation of macrophages as a result of infection in the
mouse colony. It was frequently observed that normal unstimu¬
lated macrophages actually enhanced the incorporation of DMA
into tumour cells.
(4) Macrophages or persistently adherent lymphoid cells do not
125themselves take up IUDR to any great extent, the counts
per minute per well rarely being more than 200 - 300 counts.
Such controls have been omitted from the tables.
(5) C. -parvum itself does not affect the proliferation of tumour
1 23
cells nor of their uptake of IUDR.
3.1 EFFECT OF ROUTE OF ADMINISTRATION AMD TIME OF INJECTION OF C.
PARVUM ON THE ABILITY OF SPLEEN CELLS TO ACTIVATE MACROPRAGES
ID VITRO
In initial experiments C. narvum was administered 10 days before
harvesting spleen cells. This timing had been selected since it was
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known that the in vitro expression of anti-tumour cytotoxicity of
FE and other lymphoid cells was at a maximum 4 to 14 days following
i.p. injection (Ghaffar and Cullen, 1977). However, it was of
interest to know in what way the in vitro activation of macrophages
would he affected by different timings and in particular by other
routes of administration as it was known that the in vivo anti-
tumour effect of C. narvum was dependent on whether it was given
subcutaneously, intravenously or intraperitoneally.
Accordingly, groups of mice were injected with C. parvum,
either subcutaneously, intraperitoneally or intravenously, at
various times (42, 28, 21, 14 and 7 days) before harvesting their
spleens for use in the activation assay. The extent of macrophage
cytotoxic activation induced by the various spleen samples has been
summarised in the form of cytotoxic indices in figure 5. Spleens
from the i.p. groups of mice gave good activation up to 21 days
following injection. This capacity of i.p. sensitised spleen cells
to activate macrophages is not present on day 4 following injection
(data not shown) and thus it reaches a maximum very quickly indeed
between day 5 and day 7.
The intravenous route led to activation during the first "two
weeks following injections but by the third week the effect had
rapidly disappeared. The subcutaneous route was essentially ineffec¬
tive as a route for sensitising spleen cells which could activate
macrophages.
These results correlate closely with in vivo studies which
show that C. parvum causes tumour inhibition when given by the i.p.
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OF THIS CAPACITY WITH TIME.
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Woodruff et al., 1972; Scott, 1974c). It should, "be noted that anti¬
body titres to C. parvum following i.p. administration are consider¬
ably greater than those following s.c. administration (James et al.,
1976). In addition, the gradual loss of the capacity of C. parvum-
sensitised spleen cells to activate macrophages parallels recent work
on the effects of route and time of C. parvum administration on
the in vitro anti-tumour effects of lymphoid cells (Krahenbuhl,
Lambert and Remington, 1976; Ghaffar and Cullen, 1977). Such corre¬
lations might imply that the mechanism of in vitro activation
of macrophages being studied could be operating in vivo.
3.2 In vitro activation of macrophages by C. parvum and lymph node
cells from C. parvum-treated mice
This experiment set out to demonstrate that cells from the
lymph nodes of C. parvum-sensitised mice could also activate macro¬
phages in vitro. Mice were injected i.p. or s.c. with 1 .4mg C.
•parvum on day -11. The s.c. inoculation was divided equally between
two sites, right foreleg and right hindleg, and only the draining
nodes (inguinal, brachial and axillary) from these sites were excised.
All inguinal, brachial and axillary nodes were excised in the i.p.
and untreated control groups. As with spleen cells, lymph node cells
(LNC) were glass-incubated for a total of 3 hours to remove adherent
cells before being used in the activation assay. Three concentrations
5 /of LNC were used: 16, 8 and 4x10 per well (cf. spleen cell concen¬
trations used above of 4 x 10^ per well).
The results obtained with 16 x 105 LN cells per well, and shown
in table 3(a), indicated that in vitro activation could be achieved
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using such cells but that LNC from i.p.-treated animals were not
as effective as those from s.c.-treated animals. The comparative
ineffectiveness of LNC from the i.p.-treated group may have been
because peripheral nodes only were taken; mesenteric node lympho¬
cytes may have given better results. Table 3(b) summarises the
results obtained using the lower LNC to macrophage ratios. It can
be seen that significant anti-tumour activity was only obtained
using the high (l6 x 1(P LNC per well) ratio, four times as many
cells as would be required for a similar effect using spleen celUs
from i.p.-treated mice.
These results together with those on the effect of route and
time of C. -parvum administration (figure 5) on in vitro macrophage
activation account for the failure of a previous experiment reported
by.our group (Ghaffar et al.. 1975) in which the ratio of LNC to
PEC was only 10:1 and not 20:1 , and the mice had been injected, not
only by the less effective i.p. route, but on day -28, by which time
the capacity of the lymphocytes to activate would be greatly diminished.
4. CONFIRMATION THAT IN VITRO MACROPHAGE ACTIVATION IS EFFECTED BY
THE LYMPHOCYTE POPULATION OF SPLEENS FROM C. PARVUM-TREATED MICE
Experiments so far had shown that spleen cells depleted of
glass-adherent cells could activate anti-tumour cytotoxicity in
normal macrophages in the presence of C. narvum. It had been
assumed at this stage that, (a) the spleen cells involved were lympho¬
cytes and, (b) that they were not directly responsible for the observed
cytotoxic effects. However, the possibility could not be excluded
that some macrophages or macrophage precursors were surviving the
-97a-
TABLE 3(a) IN VITRO ACTIVATION OF ANTI-TUMOUR CYTOTOXICITY
IN MACROPHAGES BY C.PARVUM AND LYMPH NODE CELLS






































































Macrophage + C .parvum 1 0,866(1 0,1+23-11 ,328)
Macrophages 11 ,700(10,801-12,652)
(a) Comparison of LNC from normal mice with LNC from mice
treated sc or ip with C.parvum.
(b) LNC used at 1 6 x 10~Vper well (cf. experiments using
spleen cells, 1+ x 10r per well.)
(c) See notes on Table 3(h) for details of C.parvum adminis¬
tration .
TABLE3(b)





























(a)Pourmicepegroupusedinthisexperiment. (b)Subcutaneousroute:0.7mgG.parvum( .1lineachoftwosi es,rightfo eland righthindleg.Onlythdrainingodes(ingu al,brachialndaxillary)fromt e twoinjecti nsitesereex ised. (c)Intraperitonealrout :1.I4mgG.parvum(0.2l)pem use.Allinguin l,bra h and axillarynodeswereexcis d.
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glass incubation and. that they were either contributing to the
cytotoxicity or were the actual activating cells. Several methods
involving x-irradiation, gold salt and anti-macrophage serum were
employed to investigate these possibilities.
4.1 In vitro activation of macrophages: effect of in vitro x-
irradiation of suleen cells
The extreme radiosensitivity of lymphocytes and the lymphopoietic
system is well recognised (Trowel, 1952; Berdjis, 1971; Anderson and
Warner, 1976) and consequently x- or gamma-irradiation has often
been employed to kill or inactivate lymphocytes in experimental
systems (hitter et al., 1975; Denham et al., 1970). Many macrophage
functions, on the other hand, are regarded as being radioresistant
(Muramatsu, Morita and Sohmura, 1966; Geiger and Gal lily, 1974).
However, these are generalisations and in reality the cells of the
immune system, both lymphocytes and monocyte-macrophages, do contain
sub-populations of radiosensitive and radioresistant cells. Further¬
more, the sensitivity of a particular immune response depends very
much on the circumstances and on the nature of the antigens involved
(for review see Taliafero, Taliafero and Jaroslow, 1964; Berdjis,
1971; Anderson and Warner, 1976).
Spleen cells from untreated or C. parvum-treated mice were pre¬
pared in the usual way but, before incubation on glass, cells were
first exposed to x-irradiation doses of 200 or 400 rad.
Data in table 4 reveal a marked reduction in anti-tumour cyto¬
toxicity following exposure of spleen cells to 200r and complete
abrogation of cytotoxicity after 400r, indicating that the macrophage




































(a)Spleenc llswereirradiatedpriortoin ubationgl s (b)(Comparisonfp leecellsfromno maland,.arvum-tr atedic ;Pv lugrea rth 0.05wereconsiderednotsignificant(N.S.)
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activating cell was radiosensitive and thus possibly a lymphocyte
or macrophage precursor.
4.2 In vitro x-irradiation of PE cells (Table 5)
In order to eliminate the possibility that peritoneal lymphocytes
persisting in wells alongside macrophages were contributing to the
activation process, or to the cytotoxic effects directly, PEC were
irradiated prior to seeding in microculture plates. It was found
that this treatment caused a slight drop in the level of cytotoxicity,
and although this drop was significant statistically, it was apparent
that the capacity of macrophages to be activated was relatively
radioresistant, at least to a dose of 800r. The possibility that
radioresistant T helper cells or cytotoxic T cells were still playing
a significant part could not be formally excluded but was considered
unlikely (see Discussion - effects of x-irradiation).
4.3 Whole-body x-irradiation of spleen cell donor mice
Consistent with the above observation, and further supporting
the role of the macrophage as cytotoxic effector cell, are the results
reported by Woodruff, Ghaffar and Whitehead (1976b) showing the
effects of whole-body and in vitro x-irradiation on the in vitro
anti-tumour activity of PE and spleen cells from C. narvum-treated
mice. They found that irradiation (whole-body or in vitro) failed
to abrogate cytotoxicity if activation of effector cells had already
occurred. However, whole-body irradiation of 400 rad in the case
of PEC and 800 rad in the case of spleen cells, given either 4 days
before or immediately before administration of C. narvum, completely
TABLE5INVITROX-IRRADIATIONOFPE ITONEALEXU TE( .E.)CEL S: EFFECTONTHEINVITROACTIVATI NFNTI-TUMOURY OTOX CITYIMACROPHAGES
InVitro TestGroup
InVitro






























(a)Comparisonfspleecellsfromnor alnd.p rvum-treatedmic . (b)Effectofirradiationncytotoxicity:Inc lumn4.omparisonf200R d(1,535counts/minute) and800Ra(2,897counts/minute)withno -irrad ationg o p(6 1counts/mi t ). Irradiationcausessignificantdr picytot xicity:200Rad,<0. 58<( 01.






































(a)Comparisonofspleencellsfromnor ala dC.parvum-treatedice:Palu sgre terth n0.05wereconsid redotsignificant(N.S.)(b)Effectofirradiationfspleenc llsocy otoxicity:Inc lumn1+,c mparisonfthe irradiatedgroupswiththn n-irradiatedg oupsshowssignificantd crea escytotoxicity
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abolished the cytotoiic effects.
The results in table 6 show the effect of in vitro macrophage
activation of giving 200 or 400 rad whole-body irradiation to mice
one hour before administration of C. parvum. Cytotoxicity was
reduced in both irradiated groups but not completely abrogated.
This correlates well with the reduction in.cytotoxicity of spleen
cells in Woodruff et al. (1976b) following whole-body doses of 200
and 400 rad; 800 rad was required to abolish cytotoxicity.
These results using x-irradiation established that the processes
in C. oarvum-treated mice which led to cytotoxic cells or to spleen
cells capable of activating macrophages in vitro, involved a radio¬
sensitive cell population, but it was not yet clear whether these
cells were lymphocytes or macrophage precursors.
4.4 Treatment of spleen cells with anti-macrophage serum: no effect
on the in vitro activation of macrophages
Although incubation on glass undoubtedly removed the bulk of
splenic macrophages, the possibility did exist that a few macro¬
phages, or monocytes, were still present when spleen suspensions were
added to peritoneal macrophage monolayers. Such persistent splenic
macrophages may have been contributing to the observed anti-tumour
effects. To counter this possibility, glass-incubated spleen cells
were treated for 1 hour at 37°C with guinea pig serum (as complement
source) and either normal rabbit serum, or rabbit anti-macrophage
serum (AMS). This thymocyte-absorbed AMS had high specificity for
peritoneal macrophages, shown by a 50^ cytotoxic titre of 1:512.
There was some residual reactivity against thymocytes indicated by a
-101-
50fo cytotoxic titre of 1 :4. AMS was used at a final dilution of
1:64, known to give 100$ cytotoxicity against peritonei macro¬
phages but virtually no activity against thymocytes.
The results (table 7(a)) demonstrated that anti-macrophage
serum treatment of spleen cells from C. narvum-treated mice did
not affect their capacity to activate macrophages in vitro. If
it is assumed that splenic macrophages and monocytes share an anti-
gen(s) with peritoneal macrophages then this evidence clearly indi¬
cates that the observed anti-tumour effects could not be due to macro¬
phages or monocytes persisting in the spleen cell suspensions following
glass-adherence. The premise of common antigenicity between macro¬
phages of different sites is supported by several workers. Feldman,
Tubergen, Pollock and Unanue (1972) demonstrated in the guinea pig
that an anti-peritoneal macrophage serum reacted with up to 5C$
of splenic macrophages but only 10$ peripheral blood monocytes.
Montfort and Perez-Tamayo (1971) found a rat peritoneal macrophage
antigen(s) common to peripheral monocytes and macrophages in acute
inflammatory exudates. An alveolar macrophage serum had specificity
for fixed tissue macrophages but not blood monocytes (Martinez and
Montfort, 1973).
There is evidence to suggest that anti-macrophage sera are
directed at a differentiation antigen(s) associated with cell
maturation (Virolainen et al., 1971) which would account for the poor
specificity of AMS for monocytes reported by Feldman et al., (1972)
and Martinez and Montfort (1973). The reactivity against monocytes,
of the AMS used in the above experiments, is not known, therefore,
it is possible that some monocytes could have reached the microculture
TABLE7(a)
INVITROACTIVATIONOFN I-TUM URY OTOXICITYIMACR PHAGES










NormalRabbit Serum+ GuineaPig Complement
Spleen+Macrophage +C.parvum Spleen+Macrophage Spleen+C. arvum Spleen
52,131(50,182-54, 56) 51,235Ui9,2l|.2-53,308) 51,399(14-8,203-51^,806 38,210(35,371-41,276)





RabbitAnti- MacrophageSerum + GuineaPig Complement
Spleen+Macrophage +C.parvum Spleen+Macrophage Spleen+C.parvum Spleen
14.3,100(lp0,585-lp5,770) 14-3,931( 4.3,058-144,821) 14.5,726(1^,757-14-8,901 104-,794,(40,1 49-14 9,606)











(a)Followingincubatioongl ssf r3h urs,spleencellw eincubat dt7Cf r1houri thepresenceofguineaigserum(ascompl entso rce)a dith rnor alrabbits um,r rabbitanti-macrophageserum.Finalse umdiluti nssedwer1:64fon r alrabbit rabbitanti-macrophage,nd1:16foguineapiserum.(b)Comparisonofspleecellsfromnor alnd.pa vum-treatedmic .Pva uesgr t rth n O.Ofjwereconsiderednotsignificant.






















(a)Treatedanduntreatespl ncellsddetotumourcn lay rs4x10Jcells/w ll) andcytotoxicityassessedI4.8hourlate . (b)Spleenc llstreat dwithnormalrabbitora ti-macrophageserufind lu i nof 1:61).togetherwithuin apigs rumafinaldilutionf1:16fh ra37°C•
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wells.
The effect of anti-macrophage serum on the direct cytotoxicity
of spleen cells to tumour cells in vitro is shown in table 7(b).
Treatment with guinea pig complement and either normal rabbit serum,
or AMS, markedly reduced the anti-tumour activity of spleen cells
from C. naryum-treated mice, particularly at the lower effector to
target ratios. These results indicate that the macrophage population
of spleen cells was being effectively eliminated by the serum pre-
treatments and thus confirmed that macrophages were not the activating
cell type.
4.5 In vitro activation of macrophages: effect of gold salt treatment
of spleen cell donors
Gold salts, recognised anti-inflammatory compounds (Walz et al.,
1974), are known to localise in the reticuloendothelial system and
at sites of inflammation (Swartz et al., I960; Persellin and Ziff,
1966). Lysosome-s are actively involved in the destructioncf articu¬
lar cartilage in rheumatoid arthritis (Dingle, 1969; Chayen and
Bitensky, 1971) and it has been postulated that the therapeutic
effects of gold salts may be due to the inactivation of macrophage
lysosomal enzymes. Ennis et al., (1968) demonstrated that gold
thiomalate and gold thioglucose could inhibit the lysosome enzymes
acid phosphatase, J3-glucuronidase and cathepsin, by reversibly
binding to enzyme sulphydryl groups, but did not affect actual
release of the enzymes from lysosomes. It has also been shown that
sodium aurothiomalate suppresses phagocytosis and migration of
macrophages, (jessop et al., 1973; Vernon-Roberts et al., 1973).
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These effects of gold compounds on macrophages have been used
to advantage in studies aimed at elucidating the role of macrophages
in the anti-tumour effect of C. naryum (James et al., 1976; McBride
et al., 1975b; Ghaffar et al., 1976b). It was, therefore, natural to
extend this work to investigate the effects of gold salt on the in
vitro activation of macrophages.
Normal mice and C. naryum-treated mice were given multiple 1 mg
doses of sodium aurothiomalate(as described in Materials and Methods)
and their spleens were excised and processed in the usual way, for
testing in the activation assay. Table 8 shows that in vivo gold
treatment completely abrogates the stimulation by C. parvum of
spleens capable of activating macrophages in vitro. This result is
in complete agreement with previous work showing the antagonism of
gold salt treatment for C. parvum's anti-tumour effects, whether
measured in vivo (McBride et al.. 1975b) or in vitro (Ghaffar et al..
1976b).
4.6 In vitro activation of macrophages: effect of the presence of
gold salt in vitro
The influence of in vitro sodium aurothiomalate on the activation
of normal macrophages by C. parvum and C. uarvum-sensitised spleen
cells was investigated. The gold compound was added at one of three
stages of the activation assay: during initial macrophage adherence;
during activation; and during the incubation of spleen cells to remove
the glass-adherent population. The gold was removed by thorough
washing before proceeding with the next stage of the assay. This
TABLE8










Spleen+Macrophage C.parvum Spleen+Macrophage Spleen+C.parvum Spleen
6,626(6,253-7,021) 5,0114(14,751-5,291) 2,313(2,022-2,6^5) 2,657(2,1^70-2,860)
178(173-1814) 8,532(8,286-8,7814) 2,370(2,062-2,725) 14,008(3,391-14,738)




Spleen+Macrophage C.parvum Spleen+Macrophage Spleen+C.parvum Spleen
10,261(9,655-10,906) 5,961(5,385-6,598) 3,288(3,057-3,537) 3,736(3,258-14,281].)






10,020(9,11-85-10,581].) 6,010(5,726-6,309) 5,1+50( 4-,906-6,051^5
(a)1mgsodiumauroth omalateadministeredipd ys-8,6I4a d1 (b)Comparisonofnormaland.parvu -treatedg oups;Pv l eseat rtha0.05wer considerednotsignificant
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was particularly important in those groups receiving gold salt in
the microculture wells since it was known that this compound is very
toxic for the fibrosarcoma tumour cells being used.
The results obtained with the various treatments are summarised
thiomalate had been present during macrophage adherence or during
the activation process. Prior treatment of spleen cells with gold
salt had no effect , lending further support to the anti-macrophage
serum evidence that splenic monocytes or macrophages that escape
the glass-adherence procedure do not contribute significantly to
the cytotoxic effects, either directly or as activators of normal
macrophages. These results demonstrated that sodium aurothiomalate
exerts its effects at the level of the macrophage,, both in vitro and
in vivo. However, it was not clear whether gold salt interferes with
the expression of macrophage cytotoxicity or with the activation process
itself (in vitro and in vivo). The former seems more likely in view
of the observation that the _in vitro cytotoxicity of PEC stimulated
by C. -parvum in vivo could be blocked by gold salt (Ghaffar et_al.,
1976b). The mechanism of this abrogation may depend on the inhibition
of lysosomal enzymes (as discussed above) which may mediate the observed
effects. It has been shown that the cytotoxic effects of BCG-stimu-
lated macrophages can be inhibited by stabilising lysosome membranes
with hydrocortisone or by inactivating the lysosomal enzymes before
they are exocytosed into target cells (Hibbs, 1974).
in table 9 (some of the control data have been omitted for sake of
clarity). There was no anti-tumour sodium auro-


































5. IN VITRO ACTIVATION OF NORMAL MACROPHAGES: FURTHER CHARACTERI¬
SATION OF THE MECHANISM
The following experiments were designed, to determine (a) the
identity of the activating cells, and (b) the manner in which acti¬
vation was effected, i.e. whether by cell-to-cell contact or by a
soluble factor(s) released into the culture medium.
5.1 Identification of the activating lymphocytes
The bulk of evidence would favour a role for T cells, both in
systems measuring activation by intracellular killing of microbes or,
by anti-tumour cytotoxicity. It has been shown that resistance to
infection with Listeria monocytogenes is effected through a collabo¬
ration between., antigen-stimulated lymphoid cells and macrophages which
could then kill, in a non-specific way, intracellular organisms
(Mackaness, 1969; Blanden, Lefford and Mackaness, 1969). The co¬
operating cell was later identified as a T cell(Lane and Unanue,
1972; Blanden and Langman, 1972; North, 1973).
Similar conclusions were reached by Evans and Alexander (1970,
1972 a, b) using an anti-tumour system. They found that normal macro¬
phages could be activated to specific growth inhibition of target
lymphoma cells in vitro, either by direct contact of hyperimmune
lymphoid cells and macrophages, or by incubating macrophages with
a factor from mixed cultures of lymphoma-immune spleen cells and the
specific lymphoma cells. This factor was called specific macrophage
arming factor (SMAP). Similar results in allogeneic systems have
now been described by other groups (Lohmann-Matthes, Ziegler and
Fischer, 1973; Zembala, Ptak and Eanczakowska, 1973; Pels and Den
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Otter, 1974). Of particular relevance to this thesis is the work
demonstrating the in vitro stimulation of non-specific cytotoxicity
in macrophages by supernatant factors derived from culturing lymphoid
cells immune to BCG (Evans, Cox and Alexander, 1973; Piessens,
Churchill and David, 1975) or C. narvum (Christie and Bomford, 1975)
with the specific immunising antigen.
As in the bacterial systems, macrophage activation was found
to be a T cell-dependent phenomenon (Evans et al., 1972; Grant et al.,
1973; Lohmann-Matthes et al., 1973; Christie and Bomford, 1975).
B[owever, there have been reports of macrophage activation systems
in which B lymphocytes have played a role (Wilton, Rosenstreich and
Oppenheim, 1975; Yamazaki, Shinoda and Mizuno, 1975).
In order to delineate the possible roles of B cells and T cells
in the activation of macrophages by C. -parvum, experiments were set
up in which spleen cells from C. narvum-treated mice were either
treated with anti-Thy-1.2 serum to remove T cell activity or passed
through nylon wool columns to remove immunoglobulin-bearing cells
(B cells). Experiments using spleen cells from C. parvum-treated
thymectomised-irradiated-bone marrow reconstituted mice were also
set up.
5.2 Anti-Thy-1.2 serum treatment of spleen cells
Spleen cells from untreated and C. parvum-treated mice were
depleted of glass-adherent cells and incubated with anti-Thy-1.2
serum and guinea pig serum as complement source. The effect of this
treatment on the capacity of C. parvum-immune spleen cells to acti¬
vate normal macrophages is given in detail in table 10 from one such





Spleenc lls + Macrophages + C.parvum
None NormalAKR+C1 Anti-Thy1.2+C1 Complement()
611,290(63,11-08-66,186) 62,393(61,931-62,860) 60,114.8(69,31 7-60,969) 67,060( 6,668-67,l|lt6)




<0.001 <0.001 <0.001 <0.001
Spleenc lls + Macrophages
None NormalAKR+C1 Anti-Thy1.2+C1
69,306(66,660-62,196) 67,292(66,1kO-68,14.67) 66,830(611,1188-67,206)




Spleenc lls + C.parvum
None NormalAKR+C1 Anti-Thy1-2+C1
ill,281i(36,693-li6,677) 36,820(31,736-li0,li30) 60,27ll(ll7,632-63,062)




Ijil,686(14.1,l|ii7-118,178) 14.6,126(14.3,127-14.9,332) 63,198(li9,260-67, 161)




(a)SeeM t rialsande hods ctionford a lsfs rumtre tment. (b)Comparisonfs leecellsfromnor alandC.parvum-tr atedic :Pv lugreat rth 0.05wereconsider dnotsig ificant(N.S.).
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Inthisexperimentacommercialpreparationfnti-Thy-1.2seruw s usedatfinaldil tionof1:(G.D.SearlendCoLtd ,HighWyc mbe, England).
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experiment, and in summary from other experiments in table 11.
Activation was reduced in all experiments by anti-Thy-1.2 serum
treatment but, unfortunately, the results were difficult to analyse
since normal serum treatment was generally as effective, and in some
experiments more so, in ablating activation. This effect of normal
serum was surprising since, at the dilution used, this serum was
known to exhibit virtually no toxicity to normal CBA spleen cells
and thymocytes. These results might be explained by postulating that
a non-T cell population was also involved in activation and that
serum treatment, if not actually killing these cells, was interfering
with their function, possibly by blocking receptors.
5.2 Effect of T cell deprivation of spleen cell donor mice
Spleen cells from immunologically intact and T cell-deprived
mice were tested in the activation assay at various times (3, 6, 8
and 12 days) following i.p. C. parvum injection. Results using
spleens taken 8 days after C. parvum (table 12) show that lymphocytes
in T cell-deprived mice do not acquire the capacity to activate
macrophages _in vitro. The time course of activation by spleen cells
is summarised in figure 6 as cytotoxic indices. By 12 days post
C■ parvum injection spleen cells from T cell-deprived mice can cause
some activation of cytotoxicity. It is tantalising to speculate that
activation might have been greater had spleens been harvested
several days later. This slight activation with day 12 spleen cells
may reflect the presence in T cell-deprived mice of a residual T
cell population which may even be expanded in the response to C.
-parvum. These results parellel closely those reported by Bomford
(a)







Spleen+Macrophage +C.parvum Spleen+Macrophage Spleen+C.parvum Spleen
1k,011( ,£88-16,91 -2) 18,61+8(17,2I4.7-20,162) 6,920(6,4£1-7,ll-23) 9,9114(8,926-11,079)
2,£6£(2,373-2,773) 1£,42£(14,433-16,486) £,030(4,02£-6,286) 10,949(10,30£-11,634)
82 17 27 Neg
CC0.001 N.S. N.S.
TCell Deprived
Spleen+Macrophage +C.parvum Spleen+Macrophage Spleen+C.parvum Spleen
10,92k'(9,323-12,800) 13,078(11,£61-14,79£) £,447(4,604-6443) 3,963(3,223-4,873)








(a)SeeMat rialsndMethodssectionfordetailsfthiprocedure (b)Comparisonfspleence lsfrountreatedmica dC.parvum-treatedmic Pvaluesgreaterthan0.0£wereconsider dnotsignificant
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and Christie (1975) using a similar test system.
It is of interest that in vivo activation of macrophages by
C. parvum is not affected by T cell depletion (Ghaffar et al., 1975;
Bomford and Christie, 1975). This was confirmed by assessing spleen
cells, which had not been glass-incubated, for direct cytotoxicity
to tumour target cells.
3
4 x 10 tumour cells were seeded in wells of microculture plates
and, after 1-y hours incubation at 37°C, spleen cells at various
effector to target ratios were added to the wells. 48 hours later
plates were shaken to resuspend the bulk of the spleen cells which
were then removed. Cytotoxicity was then assessed by incubating
125
the tumour cells with IUDR for 20 hours. Anti-tumour potential
appears by day 3 in both normal and T-deprived mouse spleens but
reaches a peak first (day 6) inthe latter group (table 13). By.day
12 the activity is declining in T cell-deprived mice and at a maximum
in the normal group. It was obvious from this experiment and others
(Ghaffar et al., 1974) that in vivo activation by C. -parvum is an
early event differing in its time course to that of the development
of lymphocyte potential to activate in vitro. A possible explanation
of why spleen cells in T cell-deprived mice reached a peak of
cytotoxicity earlier than those in T cell-normal mice, could be that
the T cell-deprived mice were simply deficient in suppressor T cells.
5.4 Nylon wool column depletion of spleen immunoglobulin (ig)-
bearing cells
Separation of non-glass-adherent spleen cells into B cell
depleted and B cell enriched fractions was achieved by two consecutive






























(a)Tumourcellsseededinw ll4x10lls/well).5hourbefothadditionf spleencells.A£t rI4.8hoursthplatewsh kenandlash dncbefo theadditionof^IUDR.Is topeinc rp rationw scoun ed18h rlate (b)Intheinterestsofclarity,geometricm anI4.ounarpr s ntedwithouti standarderrors.
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incubations in nylon wool columns. The effluent cell population
from such columns has been shown to be greatly depleted in B pre¬
cursor and memory cell activity, but to be enriched with T cells
having helper and cytotoxic effector cell functions. (Julius
et al., 1973; Handwerger and Schwartz, 1974; Trizio and Cudkowicz,
1974). Nylon-adherent cells provide a B cell enriched fraction that
can be recovered by agitation and thorough washing of the wool
(B!andwerger and Schwartz, 1974). The relative numbers of Ig-
bearing cells in the two separated populations and in the original
untreated spleen populations were assessed using an indirect immuno¬
fluorescence staining method for cells carrying surface immunoglobu¬
lin light chains (table 14).
Table 14
Spleen cell fraction
io cells bearing Ig light chains
Normal spleen cells C. parvum spleen cells
Untreated 35 39
B cell depleted 8 7
B cell enriched 60 60
B cell depleted and B cell enriched fractions were compared
with unseparated spleen cells in the activation assay. It was
found that depletion of the spleen B cell population greatly reduced
macrophage-mediated cytotoxicity (table 15). It was also found that
the nylon-adherent (B cell enriched) cells had retained the capacity
to induce macrophage-mediated cytotoxicity. These results thus
strongly implicated a role for B cells in the activation process.





Spleenc lls + Macrophages + C .parvum
None Bcelldepletion Bcellenrichment




Spleenc lls + Macrophages
None Bcelldepletion Bcellenrichment




Spleenc lls + C.parvum
None Bcelldepletion Bcellenrichment
25,669(23,993-27,14-62) 22,0214.(21,320-22,751 23,502(23,031-23,982)












(a)Comparisonfs leecellsfromuntr atedand.p rvum-treatic .Pvalu greaterthan0.05wereconsider dnotsignificant.
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However, since the separated fractions were not pure populations of
T cells and B cells it could not he concluded that B cells were
involved to the exclusion of other cell types.
A valid criticism of these results would he that no functional
tests were performed for B cells or T cells. It was assumed from
the work of others (vide supra) using similar methods and materials
that nylon wool separation did not affect the immunological compe¬
tence of lymphocytes. However, as a recent report has shown, some
changes do occur,at least in nylon wool treated thymocytes, such as
altered surface morphology and depressed cyclic adenosine monophos¬
phate levels (Zwock, Lin and Wallach, 1976).
Possible mechanisms by which B cells could induce macrophage-
mediated cytotoxicity might he that B cells release a macrophage
activating lymphokine or that they produce antibody in response to
C. parvum which then either activates macrophages through the forma¬
tion of antigen/antibody complexes, or binds to tumour cells, thus
allowing an antibody-dependent macrophage killing of target cells.
James and his colleagues (1976, 1977), have shown that immunoglobulins
produced in C. parvum-treated mice are capable of binding to MC-
induced fibrosarcoma cells in vitro. The implications of these B
cell results are explored further in the discussion.
5.5 Macrophage activation mediated by factors from spleen cells
It was not clear whether the co-operation between G. parvum-
sensitised lymphocytes and normal macrophages was a process requiring
cell-to-cell contact or could be mediated by a soluble factor or
factors released into the culture medium. To resolve this, non-
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glass-adherent spleen cells from normal and C. -parvum-treated mice
were cultured at 37°C with or without washed C. parvum. Cell free
supernatants were prepared after 24 hours culture, by passage through
0.22pm Millipore filters. 0.2 ml volumes of these supernatants
were added to normal macrophage monolayers. 0.7 pg washed C. parvum
was added to some of the microculture wells. 24 hours later macro¬
phage monolayers were washed once and tumour cells added to assess
cytotoxicity.
Macrophages treated with supernatants from C. parvum-immune
spleen cells alone showed slightly increased cytotoxicity compared
to those treated with normal spleen cell supernatant, but this was
not significant in a Student's 't'-test (Table 16). Thus, only the
supernatant derived from C. parvum-immune spleen cells cultured with
C. parvum was able to activate normal macrophages. The presence of
C. oarvum was not required in the microculture wells for activation
to occur. This apparent non-requirement for the addition of the
specific antigen during activation has also been reported by Evans
et_al., (1972) using BCG stimulated lymphoid cells. This is in
contrast to the lymphoma system described by Evans and Alexander in
which macrophages, exposed to supernatant factors derived from
the in vitro interaction of lymphoma-immune lymphocytes and the
specific lymphoma cells used for immunisation, were subsequently
cytotoxic to that particular lymphoma only. But if macrophages
were exposed to both the supernatant factors and the specific lym¬
phoma cells, then a state of non-specific cytotoxicity was induced
in which any target cell could be affected. (Evans and Alexander,
1970; 1972a, b). A likely explanation for this apparent discrepancy
TABLE16
STIMULATIONOFANTI-TUMOURCYTOTOX CITYINRMALMAC PH GES
BYSUPERNATANTSFROMCULTUREOFSPLEENCELLOM.PA VUM-TR ATEDMIC
C.parvumDu ing Macrophage Activation




































(a)Comparisonfthesupernatantfromculturesfnormalsple ncellwiththsup rn tant fromculturesfsple ncellfroC.parvum-treatedic .
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between the lymphoma system and the BCG and C. parvum systems would
be that, in the latter systems, culture supernatants also contain
soluble BCG (or C. parvum) antigens which then serve in the acti¬
vation process.
However, in similar experiments Christie and Bomford (1975)
found that C. parvum-immune spleen cells when cultured produce a
factor which would activate macrophages, but that the greatest cyto¬
toxic effects were achieved when C. parvum had been present, both
in the spleen cell cultures, and during activation. These differences
with the above results might be ascribed to differences in culture
media and culture conditions,and in the route of C. parvum injection,
which was intravenous in their experiments.
The results described here, and those of other workers mentioned
above, demonstrated that cell-to-cell contact was not necessary for
the co-operation between immune lymphoid cells and macrophages leading
to activation of cytotoxicity in the macrophages. In addition, the
results negated a possible criticism of the preceding experiments
that spleen cells persisting in the microculture wells might be the
cytotoxic effector cells.
6. M HMTOOLOGICALLY SPECIFIC COMPONENT OF THE IN VITRO ACTIVATION
OF MACROPHAGES
An immunologically specific component of the in vitro acti¬
vation system was demonstrated by replacing C. parvum strain CN6134
in vitro with various other bacteria and conversely, by attempting
to stimulate macrophages in the presence of C. parvum by lymphocytes
from mice treated with other adjuvants known to stimulate the reticulo-
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endothelial system.
6.1 Comparison of Two Other Anaerobic Coryneform Bacteria with
C. Parvum CN6134
In vitro activation was attempted using washed preparations of
C, parvum strain NCTC 10390 and Propionibacterium freudenreichii
RCTC 10470 in place of C. parvum CN6134. Table 17 illustrates that
some anti-tumour cytotoxicity was obtained with strain 10390 but
not with strain 10470. This result was not unexpected in view of
the reported serological and other biological properties, including
anti-tumour activity, of these bacteria (McBride et al., 1975a).
Strains 10390 and 6134 exhibited antigen cross-reactivity, induced
splenomegaly and had similar degress of anti-tumour activity in vivo
and in vitro. By contrast, strain 10470 showed no cross-reactivity
with the two C. parvum organisms and caused little splenomegaly or
anti-tumour activity.
6.2 In vitro macrophage activation: Comparison of spleen cells from
mice treated with various adjuvants
Mice were injected i.p. on day -11 with one of the following
adjuvants; C. parvum CN6134, BCG (Glaxo), Bordetella pertussis.
Preund's complete, Freund's incomplete. Spleen cells were tested in
the activation assay in the presence of BCG, B. pertussis or C.
parvum. Results have been summarised in Table 18.
Using spleen cells from C. parvum-treated mice, B. pertussis
was able to mediate activation to some extent, but BCG was ineffectual.






None 6134 10390 10470
17,254(16,420-18,130) 17,845(16,927-18,813) 17,910(16,934-18,941) 16,204(15,135-17,349)
11,285(10,188-12,500) 177(169-185) 4,849(4,194-5,606) 11,510(11,094- 19)
35 99 73 29
<0.01 «0.001 <0.001 <0.005
SpleenCells
None 6134 10390 10470
7,125(5,990-8,475) 7,396(6,485-8,435) 11,953(8,839-16,163) 9,185(7,109-11,867)










It is not known if this reflects an antigenic relationship between
C. parvum and. B. pertussis. No cytotoxicity resulted from using
C. parvum 6134 and spleen cells from animals treated with the other
adjuvants. Negative results were also obtained in the BCG and B.
•pertussis groups in which the particular immunising organism was
also present in vitro. Some activation might have been expected
in these two groups in view of their known macrophage stimulating
and anti-tumour properties (BCG: Evans and Alexander, 1972a; Alexan¬
der, 1973; Cleveland, Meltzer and Zbar, 1974; Hawrylko, 1975.
B. -pertussis: Malkiel and Hargis, 1961; Guyer and Crowther, 1969).
Data from the two experiments above demonstrate an immunologi¬
cally specific component of activation: the antigen used in vivo
to stimulate spleen lymphocytes must also be present _in vitro.
This confirms Christie and Bomford's findings using a similar ex¬
perimental protocol (Christie and Bomford, 1975).
6.3 In vitro activation of macrophages: effect of using tumour-bearer
spleen cells
The reasons why C. uarvum should exhibit such potent anti-tumour
properties are not known. One explanation that has been mooted is
that C. parvum and tumour cells have shared antigens, a relationship
that is known to exist with respect to BCG and hepatocarcinoma
in guinea pigs (Bucana and Hanna, 1974; Minden, McClatchy, Wainberg
and Weiss, 1974) and malignant melanoma in man (Minden, Sharpton
and McClatchy, 1976). There is now evidence pointing to a similar
phenomenon with C. mrvum. James et al. (1976, 1977) have shown
that C. parvum administration to normal and tumour-bearing mice
















































(a)Thequantitiesofadjuvantb cter aus dinvitrop rw lle :C.p rvum,0.7J g; BCG,9x10organisms;.pertussis,I4.10rganisms (b)Pvaluesgreat rth n0.05wereconsider dnotsig ificantN S.)
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results in the production of immunoglobulin of all classes and sub¬
classes which will bind in vitro to tumour cells, syngeneic em¬
bryonic fibroblasts and syngeneic kidney and spleen cells. However,
the significance of this is not clear in terms of C, parvum's
in vivo anti-tumour activity since tumour cells coated with such Ig
did not exhibit reduced growth following s.c. or i.v. transplantation.
These results suggested the existence of cross-reacting antigens on
C. parvum and mouse tissue or tumour cells. Another explanation,
not mutually exclusive to this, is provided by the finding that
increased or cLe novo synthesis of autoantibodies occurs following
C. parvum administration (McCracken, McBride and Weir, 1971 ; Cox
and Keast, 1974; James, Clunie, Woodruff et al., 1975).
In view of these results an experiment was set up in which
spleen cells from tumour-bearing mice were used in the activation
assay. Antigen cross-reactivity between C. parvum and tumour cells
might be expected to result in activation of cytotoxicity. Three
5
mice were injected subcutaneously with 1x10 viable cultured
tumour cells and their spleens were harvested 28 days later when the
tumours averaged 18mm in diameter. Results indicated that there was
a slight but significant increase in cytotoxicity using spleen cells
from tumour-bearing mice (table 19). However, the presence of C♦
•parvum in vitro had no effect on the level of cytotoxicity which
implied that there was no evidence in this experiment of cross-
reactivation between tumour cells and C. parvum♦






Spleen+MacrophageC. arvum Spleen+Macrophage Spleen+C. arvum Spleen
18,526(17,968-19,101) 16,669(16,059-17,302) 9,138(8,167-10,225) 9,853(9,380-10,3^9)







(a)Miceinje t dsub utaneouslyleftth ghwi1x10v̂ ablcult reumourells suspendedin100piPBSoday-28. (b)Comparisonfeffectss l enfromnor alicew thltum u -bearing mice.Pvalu sgreaterth n0.05w rconsider dnotsig ificant. (c)Althoughtherearsignificantdifferen sbetween rm lpl endtumou -b aring spleens,thpres nceofC.parvuminotcontributoryanti-tumo rytotoxicity (compareline1with2).Thus,t sexperimentdootsu porthyp the i thatC.parvum'santi-tumo rpropertiesm ybdutigenssh redetwe.parvum andtumourcells.
RESULTS - PA R T 2
IN VITRO BEHAVIOUR OF C. PARVUM-ACTIVATED
CYTOTOXIC MACROPHAGES
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IN VITRO BEHAVIOUR OF C. PARVUM-ACTIVATED CYTOTOXIC
MACROPHAGES
It was observed that macrophages activated with C. uarvum
in vivo quickly lost their anti-tumour cytotoxicity during _in vitro
cultivation. This loss of activity, generally complete by 24 hours,
was measured by incubating macrophages for various periods before
1 25
the addition of tumour cells. IUDR was added to culture wells
24 hours later to assess cytotoxicity. Typical results have been
summarised in Table 20.
It was further noticed that this loss of anti-tumour cytotoxi¬
city could be delayed by cultivating the macrophages with C. parvum
(Table 21). In these experiments C. -parvum was added to macrophage
monolayers.immediately following the washing procedure to remove
non-adherent PE cells, and, at various times later, tumour cells
were added. High macrophage cytotoxicity was sustained by the
presence of C. parvum for the first 24 hours of culture but by
48 hours anti-tumour activity was again declining (Experiment 2,
Table 21). In some experiments it was sometimes possible to regene¬
rate lost cytotoxicity after 24 hours by the addition of C. -parvum
along with tumour cell targets (line 4> Experiment 1; Table 21).
However, this phenomenon of reactivation following prolonged culture
was not observed in all experiments (e.g. line 4, Experiment 2),
and never following culture in excess of 50 hours (Experiments 1
and 2, Table 21).
Added C. riarvum thus seems to provide a continuing stimulation
maintaining anti-tumour activity. This effect has been summarised
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TABLE 20 ANTI-TUMOUR CYTOTOXICITY OF MACROPHAGES EROM
C. PARVUM-TREATED MICE.LOSS OF









Counts per Minute in








ko 18,124-5 195 99 <0.001
3 20 18,31)8 14-28 98 <0.001
10 11).,071 2,637 81 <0.001
l)-0 12,368 1 ,919 81). <0.001
18 20 13,250 5,601 58 <0.001
10 11,682 19,693 Neg -
20 20,709 23,138 Neg -
2k 20 16,829 1 9,109 Neg -
20 11),1)29 13,163 9 N.S.
ko 26,973 35,583 Neg -
kQ 20 22,931 27,391). Neg -
10 20,571) 26,890 Neg —
(a) 0.2ml C. parvum i.p. 10 days previously
(b) Time of incubation of macrophages in vitro before the
addition of tumour cells
(c) Geometric mean of 5 cultures. Limits of 1 standard
error have been omitted
(d) Comparison of C. parvum-treated group with normal group;
P values greater than 0.05 were considered to be not
significant (N.S.) . Results have been summarised from
3 experiments.
TABLE21





















































































(a)1.IpngCparvuminjectedi.p.0d ysreviously (b)P.E.cellmonolayerswash dnceefordditionfC.p rvum (c)G.S.I.=CytotoxicStimulationIndex (d)Comparisonofgroupsincubatedwi hrw thoutC.p rvum Pvaluesgreaterth n0.05w reconsiderednotsig ificant(N.S.) (e)Inthisgrouponly,C.parvumwasremovedbt washesb f rethdditionfu ourcells
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in the tables as a cytotoxic stimulation index (CSl). (See Materials
and Methods).
Loss of anti-tumour activity with in vitro culture and its
prevention by the addition of C. narvum was also observed in
in vitro activated macrophages. However, because of the ease with
which they are obtained, only in vivo stimulated macrophages have
been used in the following experiments, designed to assess the
effects of various treatments on the restimulation phenomenon.
Effect of x-irradiation of:■.macrophages
Peritoneal exudate cells from normal and C. parvum-treated
mice were subjected to various doses of x-irradiation prior to
seeding in microculture plates. 90 minutes later wells were washed
to remove non-adherent cells, and C. parvum or growth medium added.
24 hours later wells were again washed to remove the bacteria and
tumour cells added to assess cytotoxicity. The results (Table 22)
clearly indicated that x-irradiation (up to 800 rads) did not inter¬
fere with the maintenance of cytotoxicity by _in vitro C. parvum.
This experiment fails to exclude the possible contribution to re-
stimulation of activated T cells or plasma (b) cells which are known
to be radioresistant (Anderson and Warner, 1976).
Effect of sodium aurothiomalate
The C. parvum-induced retention of cytotoxicity in cultures of
in vivo-stimulated macrophages was markedly inhibited when sodium
TABLE22











None 200 14.00 800
22,959(21,382-21].,6^2} 20,6214.(18,161^-23,)̂ 20,503(19,129-21,976) 23,088(20,8)4.7-25,569
19,735(18,137-21,14-73) 21,14.06(1900-2lp,116), 22,163(20,290-21}.,09) 17,513(15,956-19,221)
























(a)PEcellsirr diatedpriortos edingnulturelat (b)1-g-hoursafterplating,PEcellmonolayerswash dcdC.arvumdd ; 2lj.hourslaterthw llsreashedwicremoveCp rvumbefoaddition oftumourcells (c)Comparisonfgroupsin ubatedwi hrithout.parvum.Pv lure rth n 0.05wereconsiderednotsign ficant(N.S.).



















1 ,0214.(912-1,150) 20,61414.(19,766-21,562) 26,183(2^,996-27,1425)
96 21 Neg
£0.001 <0.01
(a)Comparisonfgroupsincubatedw horith ut.parvum.Pv l esgreater than0.05wereconsiderednotsignificant(N S.).
-118.
aurothiomalate was added to the cultures (Table 23). This result
parallels the effects of gold salt on the in vitro activation system
(vide supra, Part 1.).
Effect of T cell deprivation of macrophage donor
The T cell dependency of C. parvum-mediated maintenance of
cytotoxicity in cultured macrophages was investigated using macro¬
phages from C« parvum-treated B mice (thymectomised, irradiated,
bone-marrow reconstituted mice). It was apparent from this experiment
that cytotoxicity was not fully retained, in the presence of C.
parvum, in macrophages harvested 3 or 6 days post-C.parvum injection,
regardless of thymic function. Restimulation was only apparent in
macrophages obtained 12 days post-C. -parvum from immunologically
intact mice. The equivalent thymectomised group did not have macro¬
phages which could be restimulated. It would thus appear that the
phenomenon is a T cell dependent event. This might also explain the
delay in the appearance of the capacity for restimulation in macro¬
phages from intact mice - the T cell reaction to C♦ parvum is
perhaps not fully developed until after the sixth day post-injection.
This is also similar to the delay of about 6 days in the appearance
of lymphocytes capable of activating macrophages in vitro.
Specificity of restimulation
To determine whether the maintenance of cytotoxicity in activated
macrophages by C. parvum was immunologically specific, two other










1l+,1+29(13,323-15,628) 15,291(1 +,31+9-16,291+) 10,52i+(9,518-11,636) 13,163(12,123-%,29 )
13,633(12,629-11+,716) 9,1+13(8,562-10,31+8) 6,899(6,1+71-7,356) 3,21+6(3,080-3,1+20)
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(a)SeeM terialsandetho sford taifthproce ure (b)Comparisonfgroupsincubatedw horith ut.rvum.Pvaluesg eaterth 0.05wereconsiderednotsignificant(N.S.)
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anaerobic coryneform bacteria, C. narvum NCTC 10390 and Propioni-
bacterium freudenreichii NCTC 10470, were compared with C. carvum
CN6134 in the test system. Table 25 shows that a restimulation
effect could be obtained with all bacteria tested but that the degree
of cytotoxicity depended on the strain. The antigenically related
strains CN6134 and NCTC 10390. (McBride et al., 1975a) gave maximal
cytotoxicity and P. freudenreichii was much less effective. The
restimulation effect is thus partially specific. (See also the
results using these organisms in the _in vitro activation assay in
Part 1).
Summary of experiments on the maintenance of cytotoxicity of cultured
C. parvum-activated macrophages
In conclusion, the maintenance, by C. narvum, of the cytotoxicity
of cultured, activated macrophages has been shown to be radioresis¬
tant, sensitive to gold salt, and at least partially specific. In
addition, the results using 'B' mice suggested that T cells were
involved but whether in vitro or _in. vivo or both, was not clear.
However, the fact that activated, cytotoxic macrophages could be
recovered from C. parvum-treated 'B' mice as well as from thymically
intact mice (see table 13), would suggest that the failure to restimu-
late 'B * mouse macrophages reflected a lack of appropriately stimulated
peritoneal T cells in the culture wells rather than some in vivo
T cell-dependent alteration of macrophage function. The results of
the irradiation experiment require that these T cells be radioresis¬
tant. It would be interesting to see if anti-9 treatment of PEC
monolayers had any effect on restimulation. There is no evidence of
TABLE25












None 613I+ 10390 101+7
19,109(18,032-20,251) 61+8(611-687) 1,223(1,11+9-1,302) 5,865(5485-6,270)
97 9li 69
<0.001 <0.001 <0.001
(a)0.70 xgstrain613l|-perw llandthequivalent ityfo10390+70 (b)Comparisonwithline5
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B cell involvement in the process but this could be resolved by using
an anti-B cell serum. It has been postulated (Ghaffar and Cullen,
1976) that the loss of cytotoxicity with culture might be due to the
loss or degradation of macrophage-bound macrophage activating factor
(MP) and that the addition of C. -parvum to culture wells stimulates
the regeneration of MAI1 by peritoneal lymphocytes.
Hibbs (1975b) came to a similar conclusion using BCG-activated
macrophages which, he found, lost their tumoricidal potential when
cultured for 48-72 hours. Cytotoxicity could be retained, however,
if specifically sensitised peritoneal lymphocytes and tuberculin
protein were added to the macrophage cultures. Hibbs also reported
that macrophages occasionally retained some cytotoxicity when tuber¬
culin protein alone was added to cultures, a finding which mirrors
the C. narvum results described above.
Some of the results presented in Part 2 have been published




This thesis has attempted to elucidate the mechanisms underlying
the anti-tumour effects of C. parvum particularly with respect to
the production of cytotoxic macrophages, believed to be important
anti-tumour effector cells. Two approaches were made; a direct one
attempting to stimulate non-cytotoxic macrophages with C. parvum and/
or with serum containing C. parvum antibodies, and secondly an indirect
one using lymphocytes, or their mediators, from C. parvum-treated
animals. The latter approach, only, was to give macrophages with
in vitro anti-tumour activity. As the work developed it became
clear that in addition to this mechanism involving lymphocyte medi¬
ation, there must also be another, unknown, mechanism operating in
vivo to account for the early appearance of cytotoxic macrophages
following C. parvum administration. It was also observed that cyto¬
toxic macrophages rapidly lost the ability to inhibit the growth of
tumour cells when cultured in vitro but that this loss of activity
could be delayed by adding C. parvum to the macrophage cultures.
This implied that continuous stimulation of macrophages was required
in vivo to explain the prolonged anti-tumour effects of a single
C. parvum injection. These mechanisms are discussed below in relation
to the literature on the anti-tumour and other biological effects of
C. narvum.
1. MACROPHAGES AS ANTI-TUMOUR EFFECTOR CELLS
1.1 Throughout this work the anti-tumour effector cell has been
assumed to be the macrophage. This assumption was based largely on
the observation that the predominant cell type in the adherent peri-
-1 22-
toneal cell monolayers had the characteristics of the macrophage,
as determined by morphology under phase contrast microscopy, staining
properties, phagocytosis of C. parvum, and trypsin-resistant adher¬
ence to glass and plastic.
Following incubation with C. parvum and lymphoid cells from
C. parvum-treated mice peritoneal macrophages exhibited the morpho¬
logical characteristics of activated macrophages as described by
others of spreading amoeboid appearance with pseudopodia and ruffling
membrane, and containing many phase-dense lysosomes and phase-lucent
vacuoles (Cohn, 1968; Fedorko and Hirsch, 1970; Adams, Biesecker
and Koss, 1973). Further evidence that such activated macrophages
were responsible for the in vitro anti-tumour effect, was shown by
the sensitivity of cytotoxicity to the addition of sodium aurothio-
malate to the culture wells, either during peritoneal cell adherence,
or during the activation process itself (vide infra). In addition,
the ineffectiveness of prior x-irradiation of peritoneal cells to
affect cytotoxicity also lends support to this macrophage evidence
(vide infra).
1.2 Nature of the anti-tumour effect of C. narvum-activated
macrophages
Macrophages from mice treated with reticuloendothelial stimu¬
lants such as BCG and C. parvum are generally regarded as being non-
specifically cytotoxic. Peritoneal exudate cells and spleen cells
from mice treated i.p. with C. parvum have been shown to inhibit the
in vitro growth of methylcholanthrene-induced fibrosarcomas of both
CBA and A/Hej mice and also of murine embryonic fibroblasts (Cullen
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and G-haffar - unpublished observations). This non-specific cyto¬
toxicity has also been reported by others (Jones, McBride and Weir,
1975). However, the question of an antigenic relationship between
C. narvum and tumour cells or normal murine tissue, throws some
doubt on whether these results truly indicate a non-specific effect
(see discussion on specificity below).
Although the design of the anti-tumour assay used in this study
was such that it could not distinguish between growth inhibition
and killing of tumour cells, observation of the culture wells using
trypan blue and phase contrast microscopy showed that death of target
cells did occur in many experiments.
By harvesting tumour cells with trypsin following incubation on
monolayers of cytotoxic macrophages and then transferring them to
a fresh plate for further culture, it was possible to show that both
cytostasis and killing of tumour cells was occurring. Results from
an experiment of this type are given on the next page (Table 26).
In this case tumour cells had been added to C. parvum-activated
peritoneal macrophages in a Petri dish, and 48 hours later adherent
and non-adherent tumour cells were harvested with the aid of trypsin
and washed in growth medium. Viable cell counts were made using the
trypan blue exclusion test (see appendix for details). Tumour cells
were then repla ted in fresh Petri dishes. After a further 72 hours
the total cell content (adherent and non-adherent) of each dish was
harvested and viable counts again performed.
It can be seen that in the untreated control and the unactivated
macrophage control plates the total number of viable cells increased
with time, whereas, in comparison, the tumour cell population exposed
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to activated macrophages was virtually static. The percentage of
dead cells from the activated group was also considerably higher.
Experiments of this type have several failings. For example, it
is impossible to assess the number of cells that may have lysed during
the incubation periods. Another criticism is that cytotoxic macro¬
phages could have been carried over from the first harvest to the
second incubation. However, this would be unlikely to affect growth
of tumour cells because the numbers of macrophages involved would be
small and they would probably have lost their cytotoxicity after the
initial 48 hours of culture, (see Results - Part 2). The experiment
does show, nevertheless, that tumour cells exposed to activated macro¬
phages fail to. recover (at least within 72 hours) even when removed
from those macrophages. The increase in the percentage of dead cells
with time also suggests that some tumour cells experienced an initial
cytostasis, followed at a later time by death.
This experiment also illustrates an observation, frequently made,
that normal macrophages can promote tumour growth in vitro. This has
also been noted by other workers (Keller, 1976a). The sinister possi¬
bility must be considered that the macrophage content of many tumours
may in fact be stimulating tumour growth within the tumour mass.
Prehn (1972, 1976) has argued that the immune system may actually
promote tumour growth. Such a phenomenon may account in part for
the anti-tumour action of C. narvum since one of its effects is T
cell suppression thereby blocking any immunostimulation of tumour
growth.
The actual mechanism by which C. uarvum-activated macrophages
exert their in vitro cytostatic or cytotoxic effects is not known for
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certain. Prom the work of others several possibilities exist.
Bennet, Old and Boyse (1964) described a system in which target
tumour cells were phagocytosed and killed intracellularly provided
that an opsonic antibody were present. Extracellular killing by
labile, lytic factors released into the culture medium have also
been described (Kramer and Granger, 1972; Currie and Basham, 1975;
Melsom, Sanner and Seljelid, 1975; Sethi and Brandis, 1975). These
factors could be complement cleavage products such as C3a, which has
also been shown to be cytolytic (Ferluga, Schorlemmer, Baptista and
Allison, 1976). A third system requires macrophage-target cell
contact (Granger and Weiser, 1964; Evans and Alexander, 1970; Hibbs,
1974). Hibbs (1974) was able to demonstrate that this type of
macrophage-mediated killing occurred by the transfer of lysosomes to
the cytoplasm of target cells which subsequently underwent hetero-
lysis. It is likely that C. narvum-activated macrophages also
exert their anti-tumour effects in this way since these effects can
be abrogated by gold salt (tables 8 and 9) which is known to inhibit
lysosome hydrolases (Persellin and Ziff, 1966; Ennis et al.. 1968).
Administration of C. narvum leads to an increase in macrophage
lysosomal enzymes (McBride, Jones and Weir, 1974).
1.3 The retention of macrophage cytotoxicity in cultures by
C. -parvum
As described in Results - Part 2, activated macrophages lose
their anti-tumour cytotoxicity within the first 24 hours of culture,
a loss which has also been observed by others in a lymphoma system
(Evans and Alexander, 1970) and with BCG-activated macrophages (Hibbs,
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1975b). The addition of C. parvum to the macrophage cultures
delayed this loss of activity, or even regenerated it in some
experiments. Analysis of this effect showed the process to he T
cell dependent, radioresistant and at least partially specific.
Since cytotoxic macrophages could be recovered from both T cell-
deprived mice and thymically intact mice (Ghaffar et al.. 1975 )> the
inability of cytotoxic macrophages from 'B' mice to respond to added
C. parvum in culture implied that the _in vitro restimulation process
required T cells, rather than that the macrophages from 'B * mice were
functionally different from those of thymically intact mice. It is
not yet known whether B cells are involved in the phenomenon of
restimulation.
It has been postulated (Ghaffar and Cullen, 1976) that the loss
of cytotoxicity with culture might be due to the loss or degradation
of macrophage-bound macrophage activating factor (MAP) and that the
addition of C. parvum to culture wells stimulates the regeneration
of MAP by the few peritoneal lymphocytes persisting in the wells.
In this respect it is interesting that Hibbs (1975b) using cytotoxic
macrophages from BCG-infected mice could cause the retention of cyto¬
toxicity in culture by the addition of tuberculin protein and sensi¬
tised lymphocytes, the addition of either agent alone being without
effect.
Possibly of some relevance to these■observations are the recent
immunological studies using anti-alpha-2-macroglobulin sera showing
that peritoneal macrophages from C. parvum-treated mice exhibit a
different pattern of intracellular staining to those from untreated
mice, and that most of this staining is lost within 16 hours of
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culture (T.A. Varley - personal communication). Alpha-2-macro-
globulin may be a carrier for MAP (McDaniel, Laudico and Papermaster,
1976; see also section below on activation of macrophages by lympho¬
cyte culture supernatants).
2. IN VITRO ACTIVATION OF MACROPHAGES BY SPLEEN AM) LYMPH
NODE CELLS
It was found that spleen cells obtained from mice injected with
C. narvum. either intraperitoneally (i.p.) between 6 and 21 days
before, or intravenously (i.v.) between 6 and 14 days before, could
stimulate anti-tumour cytotoxicity in normal macrophages, but only
in the presence of C. narvum. The effect was never present until
after day 6 (data not presented) despite the fact that spleen and
peritoneal exudate cells from mice given C. parvum systemically,
contain a population of cytotoxic cells by day 4 (Ghaffar et al.,
1974) or even by day 2 (Jones, McBride and Weir, 1975). This dis¬
crepancy suggests that _in vivo macrophage activation occurs very
rapidly following C. narvum injection and by a mechanism other than
that involving sensitised lymphocytes. It could be argued that with
the i.p. route macrophages are being activated by peritoneal lympho¬
cytes in the early stages, although the lack of activation before
day 6 with the intravenous route makes this less likely. Possible
mechanisms accounting for the early activation of anti-tumour cyto¬
toxicity are discussed later.
Subcutaneously administered C. -parvum was largely ineffective
in producing spleen cells capable of in vitro activation.
These results parallel remarkably closely the development of
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cytotoxic peritoneal exudate cells in C. parvum-treated mice as
assessed by in vitro tests (Ghaffar and Cullen, 1977).
Peripheral lymph node cells from i.p. treated mice could also
activate macrophages but to only a limited extent, and only then if
the lymphocyte to macrophage ratio was increased four-fold. Cells
from nodes draining the site of a subcutaneous C. -parvum injection
were the most effective, but again it required four times the number
of cells than would have been the case using spleen cells. The
effect of i.v. injection of C. oarvum on the macrophage-activating
capacity of lymph node cells has not yet been investigated.
This variation in expression of anti-tumour effects between the
routes of C. parvum administration has been demonstrated repeatedly
in in vivo studies. Both the i.p. and the i.v. routes are generally
regarded as being effective therapeutically (Scott, 1974c; Milas ert
al., 1974a; Woodruff and Dunbar, 1975), whereas the subcutaneous
route is only of value when the injection is at, or close to, the
tumour site (Scott, 1974b; Likhite and Halpern, 1974; Woodruff and
Dunbar, 1975). In addition , C. parvum given by the s.c. route
has little effect on circulating immunoglobulin levels including
antibodies to C. -parvum which is in marked contrast to the increases
in mice treated by the i.p. route (Woodruff, McBride and Dunbar,
1974; James et al.. 1976).
3. SPECIFICITY OF TEE IN VITRO MACROPHAGE ACTIVATION
The immunologically specific nature of the in vitro activation
was demonstrated by replacing C. parvum 6134 with other bacterial
adjuvants both in vitro and _in vivo. The use of Glaxo strain BCG
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and P. freudenreichii 10470 _in vitro with C. parvum-immune lympho¬
cytes was completely ineffective. However, C. parvum 10390 and, to
a lesser extent, B. pertussis did mediate some activation. 10390 is
antigenically related to 6134 and, in addition, exhibits similar
reticuloendothelial stimulating and anti-tumour properties (McBride
et_al., 1975a). It is not known whether C. parvum 6134 cross-reacts
with B. pertussis. These results, therefore, strongly indicate an
immunologically specific component in in vitro macrophage activation.
An alternative explanation might be that the activation obtained with
10390 and B. -pertussis was due simply to the biologically active
nature of these bacteria. This is unlikely since 10390 was not as
effective as 6134 in the assay although both strains appear to have
similar anti-tumour properties (McBride et al., 1975a). The conclusion
that in vitro macrophage activation is an immunologically specific
phenomenon is supported by the work of Christie and Bomford (1975)
using a similar protocol.
Attempts to activate macrophages with BCG or B. pertussis and
spleen cells from mice previously injected with these organisms were
unsuccessful although both agents have known anti-tumour properties
(Evans and Alexander, 1972a; Hawrylko, 1975; Guyer and Crowther,
1969). James, Wilmott, Milne and Cullen (1977) using the same B.
pertussis and BCG preparations used in this study found that B. pertussis
had some slight in vivo anti-tumour activity but that the BCG prepa¬
ration had none. The inactivity of the Glaxo BCG strain used here
may reflect its reported lower virulence and lack of persistence in
mice as compared to other strains (Evans and Alexander, 1976). Fortner,
Hanna and Coggin (1974) compared the Glaxo BCG with the Phipps strain
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of BCG in guinea pigs, and found significant differences in terms
of growth, kinetics and in anti-tumour activity.
It has been postulated that C. parvum's anti-tumour activity
might be due to the stimulation of a specific anti-tumour immune
response, either directly through cross-reacting antigens on tumour
cells and C. uarvum. or merely by close association of tumour and
C. -parvum in vivo. Evidence for this is discussed below.
Sharing of antigenic determinants has been demonstrated between
BCG and hepatocarcinoma cells in guinea pigs (Borsos and Rapp, 1973;
Minden, McClatchy, Wainberg and Weiss, 1974; Bucana and Hanna, 1974)
and recently between BCG and human malignant melanoma cells (Minden,
Sharpton, and McClatchy, 1976). The existence of a similar anti¬
genic relationship between C. -parvum and tumour cells might explain
the observations of James and his colleagues (1976, 1977) that admin¬
istration of adjuvant-like bacteria such as C. uarvum, P. freudenreichii
and B. pertussis in the mouse resulted in a significant increase in
certain serum immunoglobulins which could bind in vitro to both
tumour cells and normal mouse cells. However, other equally plausible
explanations might be: a) an increased or de novo synthesis of
autoantibodies (McCracken, et al., 1971; Cox and Zeast, 1974; James
et_al., 1975); b) an increase in preexisting anti-tumour antibodies
(Martin and Martin, 1974); c) the production of unique anti-tumour
antibodies. A fourth possibility that the results were due to binding
of cytophilic Ig via Fc receptors was excluded on two counts; firstly,
that the cultured tumour cells were virtually devoid of Fc receptors
(James et al.. 1976; Szymaniec and James, 1976) and secondly, that
binding could not be blocked with aggregated IgG. The significance
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of these _in vitro Ig-binding experiments was not clear since incu¬
bation of tumour cells in sera rich in these immunoglobulins did
not affect their growth when subsequently transplanted.
The question of shared antigens between C. narvum and fibro¬
sarcoma cells was investigated using the in vitro macrophage acti¬
vation assay. Activation was attempted using spleen cells from mice
bearing tumours of about 18mm diameter (table 19). Spleen cells
from such mice have been shown to be cytotoxic to tumour cells in
vitro (Cullen - unpublished observations) and also to have elevated
K cell cytotoxicity (Ghaffar, Calder and Irvine, 1976a).
Although some increase in macrophage anti-tumour activity was
observed, it was unaffected by the presence of C. parvum. This
experiment thus failed to support the hypothesis of shared antigenicity.
It might be worthwhile to repeat this experiment using spleen cells
from mice with varying sizes of tumour, or with the cells from lymph
nodes draining the tumour site.
C. parvum-enhanced or C. parvum-initiated tumour-specific res¬
ponses have been reported in two experimental systems, one in which
C. parvum was injected intratumour, and the other in which C. -parvum
was administered together with irradiated tumour cells. Intratumour
inoculation of C. parvum can result in partial or complete regression
of the tumour with consequent strong, specific anti-tumour immunity
(hikhite and Halpern, 1974; Scott, 1974b). This effect is T cell-
dependent (Scott, 1974b; Woodruff and Dunbar, 1975; Woodruff and
Warner, 1977), and partly dependent on a specific immune response
to C. parvum (Scott, 1974b). Intratumour injection of BCG can also
cause regression and seems to be associated with the development of a
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delayed hypersensitivity reaction to the bacteria in the bed of the
tumour as well as generation of a tumour specific response (Zbar,
Bernstein and Rapp, 1971; Zbar, Bernstein, Bartlett et_al., 1972;
Hawrylko and Mackaness, 1973).
T cell-dependent augmentation of tumour-specific immunity has
also been achieved in the mouse by injection of mixtures of C. parvum
and irradiated tumour cells subcutaneously into the footpad but not
by intravenous or intra-peritoneal injections (Scott, 1975; Bomford,
1975; Tuttle and North, 1976a; Scott and Bomford, 1976). Injection
of C. -parvum and irradiated tumour cells at separate sites also gave
tumour immunity provided the sites had common lymphoid drainage (Scott,
1975). In contrast to the intratumour experiments this process
was not dependent on the development of a specific immune response
to C. parvum (Scott, 1975).
It can be seen, therefore, that, depending on circumstances,
C. parvum administration can give rise to a non-specific anti-tumour
effect or a specific anti-tumour response. It would be interesting to
know if lymphoid cells from mice with a strong C. parvum-enhanced
tumour-specific immunity could activate macrophages in vitro and
whether the presence of C. parvum would be required. Scott (1975)
demonstrated that such specific immunity could be transferred to
normal animals by transfer of lymphocytes. Adoptive transfer of
immunity in a similar model was shown to be mediated by short-lived
T cells (Tuttle and North, 1976b).
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4. CHARACTERISATION OF TEE CELLS INVOLVED IN ACTIVATION
Various approaches utilising x-irradiation, anti-macrophage
serum and sodium aurothiomalate were made to the problem of confir¬
ming that the activating cells were lymphocytes. Since the biological
effects, particularly in vivo, of x-irradiaticn and sodium auro¬
thiomalate are complex, the nature of these effects with regard to
the immune system have been expounded in some detail below.
4.1 Effect of x-irradiation*on macrophage function
Certain macrophage functions such as phagocytosis and migration
(Muramatsu, 1966) are generally regarded as being resistant to ioni¬
sing radiation. Histological studies of irradiated macrophages
failed to find evidence of damage (Brecher, Endicott, Gump and
Brawner, 1948). Radiation does, however, induce several biochemical
changes. Geiger and Gallily (1974) reported that DNA and RNA
synthesis were elevated and choline uptake was enhanced in irradiated
macrophages. Lysosomal enzyme levels in such cells are also elevated
(Geiger and Gallily, 1974; Meyer and Dannenberg, 1970; Schmidtke and
Dixon, 1973).
Phagocytosis, as assessed by clearance from the blood of bacteria
(Benacerraf, I960; Geiger and Gallily, 1974) and in vitro uptake of
sheep red blood cells (Perkins, Nettesheim, and Morita, 1966) and
radioiodinated protein antigens (Schmidtke and Dixon, 1972), is
particularly insensitive to x-irradiation. However, post-phagocytic
retention and degradation of antigen do appear to be affected in some
*N.B. X-irradiation dose can be expressed in Roentgens (r) or rads (r).
There is a slight difference in value between the two systems.
Irradiation doses have been quoted as presented in the original
papers in R or r.
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studies (Donaldson, Marcus, Gyi and Perkins, 1956; Kakurin, 1959)°
In contrast, Perkins et al. (1966) found that digestion of sheep
red blood cells by macrophages was unimpaired by irradiation and
Schmidtke and Dixon (1973) found that in vivo irradiation 1 to 3
days before harvest of peritoneal macrophages did not affect the in
vitro performance of these cells in handling keyhole limpet haemocya-
nin.
The capacity of macrophages to present antigen in a manner suitable
for the induction of antibody formation is radioresistant for antigens
such as sheep erythrocytes (Roseman, 1969; Goldie and Osoba, 1970;
Gershon and Feldman, 1968) and with protein antigens the immunogenic
capability of macrophages can even be heightened following irradiation
(Schmidtke and Dixon, 1972). However, in studies with Shigella
infection in mice the immunosuppression observed following sub-lethal
(550r) x-irradiation was shown to be due in part to the inability of
macrophages to process antigen (Gallily and Feldman, 1967). Similar
studies by Pribnow and Silverman (1967) in rabbits, and by Mitchison
(1969) in mice also showed impairment in the capacity of irradiated
antigen-containing macrophages to transfer an immune response in vivo.
L
In studies using lymphoma eels, Den Otter, Evans and Alexander
(1974) found that in vitro macrophage cytotoxicity was either radio¬
resistant (not affected by doses in excess of 500R) or radiosensitive
(activity abolished by 500R) depending on the manner in which the
macrophage donor mice had been immunised. Radioresistant cytotoxic
macrophages were obtained by immunising mice with living allogeneic
lymphoma cells or, in a syngeneic system, by first immunising mice
with radiation-killed tumour cells followed by challenge with live
-135-
tumour cells which, are then rejected. Radiosensitive macrophages
were found in hoth syngeneic and allogeneic mice immunised with
radiation-killed lymphoma cells. In addition, the cytotoxicity of
macrophages non-specifically activated in vitro by endotoxin or
lipid A was resistant to doses up to 5,000R.
4.2 Irradiation and antibody production
The effects of in vivo x-irradiation on antibody production
depend on a) the antigen, b) dose of irradiation and c) time of
irradiation with respect to the antigenic challenge or infection. In
general, immune responses are depressed when irradiation is given
at or before antigenic challenge (Anderson and Warner, 1976). How¬
ever, following antigen administration irradiation can lead to
enhanced antibody production (Dixon and McConahey, 1963; Taliafero,
Taliafero and Jaroslow, 1964). Taliafero et al., (1964) proposed
that this enhancement be classified as two types: type A, found with
low doses (25-200r) and associated with heightened peak titre and
shortened latent period; and type B, requiring exposure usually greater
than 400r and associated with increased peak titre but lengthened
latent period. Various mechanisms may be operating, not necessarily
mutually exclusive, which may account for such enhancement. For
example, lymphoid organs may be disproportionately repopulated with
antigen-stimulated cells (Dixon and McConahey, 1963). The T cell
suppressor system is particularly sensitive (vide infra)and this
could lead to enhancement (Tada, Taniguchi and Okumura, 1971). A
further mechanism which may contribute to this phenomena may lie in
the observation of Sljivic (l970a, b) that following irradiation there
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can be a transient bacteraemia by gut microbes leading to endotoxin
stimulation of the reticuloendothelial system. This effect was
not apparent in any of the thesis experiments using whole-body
irradiation.
4.3 Irradiation and T cell helper and T cell suppressor function
There has been controversy in recent years over the sensitivity
of T cell helper activity to x-irradiation. It is now clear, however,
that the discordant results of different groups were due to funda¬
mental differences in their experimental assays. In vitro assays
using primed T cells indicate radioresistance whether irradiation
is administered in vitro (Zettman and Dutton, 1971), or in vivo
(Zatz and Unanue, 1973). Adoptive transfer assays with primed T
cells, on the other hand, generally indicate radiosensitivity of
helper functions (Anderson et al., 1974; Hamaoka et_al., 1972;
Janeway, 1975). The discrepancy between the two assay systems is
explained by changes in the _in vivo migratory capacity of irradiated
lymphocytes which fail to home to lymphoid organs (Anderson et al.,
1974; Hamaoka et al., 1972). Studies utilising an in situ irradi¬
ation procedure in which homing is not required also show radiores¬
istance of helper activity. Non-antigen-specific T cell-mediated
help is also radioresistant (Hirst and Dutton, 1970; Gershon,
Leibhaber and Ryu, 1974). Unprimed T cells have invariably been
found to be radiosensitive (Miller and Mitchell, 1968; Ito and
Cudkowicz, 1971).
Suppressor T cells appear to be radiosensitive (Basten et ah,
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1974; McCullagh, 1975). However, some experimental models suggest
that once activated, suppressor cells are more resistant. For
example, the in vitro suppression of antibody formation to sheep
erythrocytes by concanavalin A-activated T cells was resistant to
2,000R (Dutton, 1972; Rich and Pearce, 1973) but irradiation of
the T cells before exposure to mitogen abrogated the appearance of
suppressor effects. This would suggest that there are suppressor T
cell sub-populations consisting of radiosensitive precursors and
radioresistant effectors. However, suppressor activity is not
sensitive to mitomycin C treatment (McCullagh, 1974; Basten et al.,
1975) indicating that cell proliferation does not follow suppressor
cell activation. An alternative explanation of radioresistance of
suppression is that it is mediated by macrophages passively armed
by activated T cells (Asherson and Zembala, 1974; Bash and Waksman,
1975).
4.4 Irradiation and cytotoxic lymphocytes
As with cytotoxic macrophages (vide supra) cytotoxic lymphocytes
comprise two categories: one sensitive to irradiation doses of about
500r, and the other resistant to doses up to 2000r (Denham et al.,
1970). Antigen-stimulated lymphocytes appear to be more radioresistant
(Grant et al., 1972; Denham et al.. 1970).
4.5 X-irradiation and in vitro macrophage activation
In the light of the foregoing brief review on the effects of
ionising radiation on the immune response, the following interpre-
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tations have been made on the results of experiments using x-irradi-
ation to analyse the in vitro activation of macrophages.
The in vitro irradiation of spleen cells prior to their addition
to adherent PE cells showed that the activating cell population(s)
was sensitive to even the lowest dose used, 200r. Small lymphocytes
in general are radiosensitive and in vitro doses of as little as
2-5R can result in changes in motility and morphology (Stefani and
Schrek, 1964). Most, if not all, irradiated cells are subject to
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mitotic death at the first or second post-irradiatiom mitosis but
some such as non-activated small lymphocytes, including B cells,
are subject to interphase death. These effects can be manifest
very soon (within one hour) following irradiation (Cronkite, Chanana,
Joel and Laissue, 1974; Bari and Sorenson, 1964; Jordan, 1967).
Thus the macrophage activating cells could comprise a population of
non-activated precursor cells which may require cell division to
mediate their effects. B cells or monocyte precursors could be
involved.
This radiosensitivity of the activating cell population also
confirmed that the observed anti-tumour effects were not due to cyto¬
toxic spleen cells persisting in culture wells since Woodruff et al.
(l976b) demonstrated that the _in vitro anti-tumour cytotoxicity of
spleen cells from C. -parvum-treated mice was resistant to 800r.
In vitro irradiation of PE cells prior to seeding in culture
plates had no effect at the lower doses, 200r and 400r, although
there was a slight depression of activation at 800r. This supported
the view that the mature macrophage population of adherent PE cells
was the source of anti-tumour effector cells in the assay. Other
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radioresistant cells such, as activated cytotoxic T cells or helper
T cells may also have been present in the wells but it is difficult
to see how they could significantly aid the activation of macrophages
by lymphoid cells from C. parvum-treated animals.
In the experiments investigating the maintenance of cytotoxicity
of C. parvum-stimulated adherent PE cells, _in vitro irradiation of
PEC also had no effect (Table 22). However, in this situation the
presence of a population of C. narvum-primed helper cells (and,
therefore, radioresistant) could be involved in the reactivation
of macrophages.
The experiments using in vivo irradiation proved more difficult
to analyse. Whole-body x-irradiatian doses of 200r and 400r given
just before i.p. C. parvum, reduced the capacity of spleen cells
to activate normal macrophages in vitro 8 days later. A third group
of mice given 800r died or were too sick to use. It would be interes¬
ting to know if activation could be completely abrogated by other
irradiation protocols such as using higher doses or irradiating
at different times with respect to C. parvum administration. A
complication of the above experiment was that the 8 day delay following
irradiation would allow some recovery of the mouse's response to
C. parvum.
Other workers have also studied the effects of x-irradiation
on the anti-tumour activity of C. -parvum. Woodruff et al., (1976b)
using similar experimental conditions and materials to those used
here, found that whole-body x-irradiation doses of 400r given either
just before, or 4 days before C. parvum, abolished the in vitro
cytotoxicity of PE cells. Similarly with spleen cells, cytotoxicity
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could be ablated by 400r when, given 4 days before C. parvum, but
800r was required for this effect when given just before C. parvum
injection. In addition, it was observed that the cytotoxicity of
spleen and PE cells was resistant to whole-body irradiation given
after activation of cytotoxic cells had occurred.
In the same study, (Woodruff et al.. 1976b) it was also shown
that the effects of systemic C. uarvum on a growing tumour nodule
could be greatly reduced by irradiating the mice either 4 days before
or 4 days after C. parvum injection. Even the strong anti-tumour
effect which follows injection of C. parvum at the site of a tumour
was ablated by 500r irradiation 4 days prior to C. parvum. Simi¬
larly, Milas et al. (l974d) showed that irradiation prior to, but
not following, treatment with Corynebacterium granulosum abrogated
this organism's _in vivo anti-tumour effects.
These results thus confirm that the anti-tumour activity of
C. parvum is dependent on a population of radiosensitive cells, a
population which could include macrophage precursors, and unprimed
T cells and B cells. Radiation effects on the function of non-
dividing cells, such as the degradation and presentation of G. parvum
antigens, could also play a part.
4.6 Effect of gold salt on macronhage activation
Gold compounds have been shown to have several effects on
macrophages. Sodium aurothiomalate is rapidly taken up by phagocytic
cells resulting in the inhibition of lysosomal enzyme activity in
these cells (Persellin and Ziff, 1966), apparently by reversibly
binding to sulphydryl groups (Ennis et al.. 1968). Phagocytosis
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and migration of macrophages are also suppressed "by this compound
(jessop et al., 1973; Vernon-Roberts et al.t 1973).
Sodium aurothiomalate has been shown to abrogate the protective
effect of C. -parvum treatment in mice to tumour challenge (McBride
et al., 1975b; James et al., 1976). Multiple gold salt injections
also reduced the in vitro anti-tumour capacity of peritoneal exudate
cells from mice treated with C. parvum 4 days previously and to a
lesser extent 7 days previously (Ghaffar et al., 1976b). The
recovery of cytotoxicity in the peritoneal cell population between
day 4 and day 7 may have been due to the continuing stimulation of
the reticuloendothelial system by C. parvum, known to persist in
the lymphoid organs of the mouse for periods up to a month following
injection (Sadler, Cramp and Castro, 1977; Scott and Milas, 1977;
Dimitrov, Greenberg and Denny, 1977).
That this interference with the anti-tumour activity of C.
parvum by sodium aurothiomalate was directed atthe effector level
and not at the process leading to macrophage stimulation was illus¬
trated by the fact that anti-tumour cytotoxicity Df in vivo C♦ parvum-
stimulated macrophages could be blocked by the presence of gold salt
in vitro (Ghaffar et al., 1976b). This effect was also noted in
this thesis where the presence of gold salt either during macrophage
adherence or during activation abrogated the anti-tumour effects
(Table 9). It is also relevant that the continuous stimulation of
cytotoxic macrophages by the addition of C. parvum in vitro was
sensitive to the presence of gold salt (Part 2, Table 23).
This result and those of others discussed above suggest that
macrophage lysosomal enzymes contribute to the anti-tumour effects
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of C. carvum. Furthermore, the observation that in vivo administration
of sodium aurothiomalate prevented the appearance of spleen cells
capable of activating macrophages in vitro indicates that intact
macrophage function is necessary in this process, presumably via the
phagocytosis of C. parvum and presentation of its antigens to lympho¬
cytes. Several other immunological consequences of treatment have
been reported that may involve the macrophage. For example, it
prolongs survival time of skin homografts in mice (Scheiffarth,
Baenkler and Islinger, 1970) and inhibits the PHA response of
lymphocytes (Cahill, 1971). Multiple injections of sodium auro¬
thiomalate also prevent the appearance of serum immunoglobulins
capable of binding to tumour cells in both tumour-bearing and C.
narvum-treated tumour-bearing mice (James et al., 1976). This study
also recorded that gold treatment prevented the elevation of serum
levels of IgM, IgG2a and IgG2b that follow systemic C. -parvum admin¬
istration. Similarly, McBride et al. (1975b) reported that multiple
injections of sodium aurothiomalate partially inhibited the immune
response to sheep red blood cells and to C. narvum itself in C.
parvum-treated mice. Gold has been shown to bind to serum proteins,
principally albumin and, at higher serum concentrations, also to
immunoglobulin and complement, a phenomenon which may aid the uptake
of gold by macrophages (horber, Bovy and Chang, 1972). As discussed
below immunoglobulin, complement and antigen-antibody complexes may
play a significant role in C. -parvum's anti-tumour activity as
mediated by macrophages.
In contrast to the above results several immune mechanisms,
which are probably macrophage independent, are either unaffected by
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or stimulated "by gold treatment. For example, although there is
an increased plaque-forming cell response to sheep red blood cells
(Scheiffarth, Baenkler and Pfister, 1971; Measel, 1975), there is
no effect on antibody response to Semliki Forest virus (Allner,
Bradish, Fitzgeorge and Hathanson, 1974),and no effect on the delayed
hypersensitivity response of guinea pigs (Persellin, Smiley and Ziff,
1967).
4.7 Anti-macrophage serum (AMS)
The finding that anti-macrophage serum (AMS) treatment of spleen
cells failed to affect their capacity to activate normal macrophages
in vitro, provided further confirmation that the activating cells
were not macrophages (table 7a). On the other hand, the same batch
of AMS was able to abrogate the direct in vitro anti-tumour cyto¬
toxicity of unseparated spleen cells from C. narvum-treated mice
(table 7b). This demonstrated that, under the conditions of the
former experiment (table 7a), splenic macrophages carried over into
the culture wells and persisting there, could not be contributing
significantly to the observed cytotoxic effects following the
activation process.
5. FURTHER ANALYSIS OF THE MACROPHAGE-ACTIVATING LYMPHOCYTES
The lymphocytes involved in in vitro macrophage activation were
further characterised in a series of experiments which provided evi¬
dence for the participation of both T cells and B cells.
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5.1 T cell evidence
The capacity of spleen cells from thymically-intact mice and
from T cell-deprived mice to activate macrophages was investigated
at various times following i.p. injection of C. narvum. In agree¬
ment with the work of Bomford and Christie (l975), the results
indicated that T cell deprivation severely restricted the development
of spleen cells capable of activation, although the slight anti-
tumour activity at day 12 suggested that such development may only
be delayed in T cell-deprived mice. It is possible that greater
cytotoxicity would have ensued if spleen cells had been harvested
at some time later than day 12.
Thymectomised, irradiated, bone marrow reconstituted mice are
probably not totally devoid of T lymphocytes and so the result at
day 12 may reflect expansion of a residual host T cell population
in the donor bone marrow under the stimulus of the C. narvum injec¬
tion. Alternatively, there may be what Howard, Scott and Christie
(1973) have termed a 'T cell bypass'mechanism operating in these mice.
The stimulation of B cells in T cell-deprived mice, together with
retention of some T cell helper activity, may be sufficient for
the macrophage activation process to occur. It would be interesting
to repeat this experiment using an extended time course in both
'B' mice and nude mice.
In contrast, there have been many reports demonstrating the
apparent non-T cell dependency of the anti-tumour action of C. uarvum
in vivo (Woodruff et al.. 1973; Sadler and Castro, 1976; Woodruff
and Warner, 1977). In vitro assessment of spleen ana peritoneal
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exudate cell cytotoxicity has also shown that C. parvum is as
effective in T cell deprived mice and homozygous nude mice as in
thymically intact mice. The problem of residual T cell activity
also plagues analysis of these experiments.
Another observation which may be important in an analysis of
mechanisms is that although cells cytotoxic for tumour cells in vitro
appear in peritoneal exudate by day 4 in thymically intact mice,
'B' mice and homozygous nude mice (Ghaffar et al., 1975), the cyto¬
toxic capacity of spleen cells from T cell-deprived mice is more
fully developed at day 5 than that of intact mice (table 15). This
earlier appearance of cytotoxic spleen cells in the 'B' mouse may
have been due to a lack of suppressor cells in these mice. A glass-
adherent splenic population of cells which suppressed responsiveness
to FHA, concanavalin A and the mixed lymphocyte reaction, has been
isolated from rats by Folch and Waksman (1974a, b). The suppressor
activity was absent in spleens from T cell-deprived rats and it was
concluded that the suppressor cells were T cells or were dependent
on the presence of T cells for their activity. Splenic suppressor
cells, believed to be macrophages, and which inhibited proliferation
of T cells in the presence of PHA, have been detected in C. narvum-
treated mice (Scott, 1972a, b; Kirchner, Holden and Herberman,
1975). Suppression in tumour-bearing hosts has been attributed to
T cells (Pujimoto, Greene and Sehon, 1976a, b) and to macrophages
(Kirchner, Glaser, Holden et al., 1976). Gorczynski (1974) has
attributed suppressor activity to B cells. It has been suggested that
suppression may in fact be mediated by macrophages in response to a
T cell signal (Taylor and Basten, 1976). Whatever the mechanism,
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suppressor systems must play an important part in the modulation
of the host's response to C. -parvum or a growing tumour.
Experiments in which spleen cells were treated with anti-9
serum and guinea pig complement provided no conclusive support for
the involvement of T cells in macrophage activation. Interpretation
of results was made difficult by the abrogating effect of the normal
serum controls, despite their known low anti-9 activity (table 10).
This effect was also found in a recent experiment (data not shown)
using, as a control, anti-9 serum which had been neutralised by
absorption with C^H mouse brain. The reduction in activation by
serum treatment (control and anti-9) may have been due to non¬
specific blocking of B cell Fc receptors. Antigen-antibody complexes,
for example, can inhibit the antibody response both in vitro and
in adoptive transfer experiments (Sinclair, Lees, Abrahams et al.,
1974; Hoffmann, Kappler, Hirst and Oettgen, 1974). Antibody-dependent
cell mediated cytotoxicity can be inhibited by antigen-antibody com¬
plexes (MacLennan, 1972b), normal serum (MacLennan, Loewi and
Harding, 1970), Ig (Scornik, Cosenza, Lee, Kohler and Rowley, 1974;
Greenberg, Shen, and Roitt, 1973), and heat-aggregated IgG (MacLennan,
1972b). The sera used in this study had not been ultracentrifuged
or refined in any way, and so aggregates and complexes may have been
present.
It should be noted that Christie and Bomford (l975) found that
anti-9 serum treatment of spleen cells from C, parvum-treated mice
did abrogate their capacity to activate macrophages in vitro.
Several other workers have found that in vitro macrophage activation
was T cell dependent (Evans et al., 1972; Lohmann-Matthes and
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Fischer, 1973; Lohmann-Matthes et_al. ,1973).
5.2 B cell evidence
The observation that normal AKR serum, together with guinea
pig serum, could block the macrophage activating capacity of spleen
cells suggested that B cells may also be involved in activation.
Further evidence supporting this idea derived from experiments in
which spleen cells were separated on nylon wool columns into B cell
enriched and B cell depleted fractions. Depletion of B cells (more
precisely, Ig-bearing cells) in spleen cell suspensions greatly
reduced the level of cytotoxicity in the subsequent assay. Use
of the nylon adherent, B cell enriched population in the assay re¬
sulted in almost the same degree of activation as obtained with
unfractionated spleen cells.
No functional T cell and B cell tests were carried out on the
separated fractions and it was assumed from the work of others
(Julius et al.. 1973; Handwerger and Schwartz, 1974; Trizio and
Cudkowicz, 1974), that such functions would be unaffected by incu¬
bation in nylon wool. However, as a recent report has shown, some
changes can occur, at least in nylon wool treated thymocytes, such
as altered surface morphology and depressed cyclic adenosine mono¬
phosphate levels (Kwock et al.. 1976).
This involvement of B cells in macrophage activation has been
demonstrated by other researchers (Wilton, Rosenstreich and Oppen-
heim, 1975). A macrophage-B cell cooperation has also been described,
in a syngeneic tumour system, in which macrophages lysed tumour cells
in the presence of an anti-tumour antibody of the IgG2a class (Yamazaki,
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Shinoda and Mizuno, 1975, 1976; Yamazaki, Shinoda, Suzuki and
Mizuno, 1976). Antibody-dependent macrophage-mediated cytotoxicity
presents an interesting possibility as an alternative explanation
for the observations in this thesis. In the experiments using
supernatants from spleen cell cultures, antibody to C. narvum may
have been produced and could therefore mediate a cytotoxic effect
by binding to macrophages or, as suggested by the recent work of
James et al. (1976, 1977) to tumour cells. Direct binding of immuno¬
globulins to tumour cells would be less likely since supernatants
are removed and the culture wells washed before tumour cells are
added. However, without being able to formally exclude the possi¬
bility, it seems unlikely that antibody-dependent macrophage-mediated
cytotoxicity can account for the observed results in view of the
inability of sera from C. -parvum-treated mice to confer any cytotoxic
potential on normal macrophages.
6. MACROPHAGE ACTIVATION BY FACTORS RELEASED BY LYMPHOCYTES
Experiments using supernatants from cultures of spleen cells
established that macrophage activation could be effected by a factor,
or factors, released by C. narvum-immune spleen cells in response to
the presence of C. oarvum in the cultures. Such factors are generally
referred to in the literature as macrophage activating factors (MAE)
although some authors have used the abbreviations MCF (macrophage
cytotoxicity factor) (Lohmann-Matthes et al., 1972) or SMAE (specific
macrophage arming factor) (Evans and Alexander, 1972a, b). Treatment
of macrophages with SMAE resulted in a state of preactivation called
"arming" and only subsequent exposure of such macrophages to the
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sensitising antigen resulted in activation (Evans and Alexander,
1972a, b).
Normal (non-cytotoxic) macrophages have been rendered cytotoxic
to tumour cells by incubation with MAE derived from cultures of
syngeneic (Evans and Alexander, 1971; Pidler, 1975; Churchill,
Piessens, Sulis and David, 1975), allogeneic (Evans and Grant, 1972;
Lohmann-Matthes, Ziegler and Fischer, 1973; Pels and Den Otter,
1974), or xenogeneic (Fidler, 1975; Pidler, Darnell and Budmen,
1976) lymphocytes. MAP has also been described in an allograft
model (Dimitriu, Dy, Thomson and Hamburger, 1975) and in studies on
the anti-microbial ±ole of macrophages (Patterson and Youmans, 1970;
Krahenbuhl and Remington, 1971; Godal, Rees and Lamvik, 1971). MAF-
rich supernatants were generally obtained in these studies from
cultures of sensitised lymphocytes incubated with the sensitising
antigen, and treatment of macrophages with the supernatants resulted
in stimulated macrophages which were specifically, or non-specifically
cytotoxic depending on the system studied. It would appear that
previous exposure of animals to pathogens results in a state of
preactivation such that only non-specific MAP is produced (Evans and
Alexander, 1972a; Lohmann-Matthes, 1976) and severe infection can
lead to the production of macrophages which are cytotoxic without the
need for further in vitro activation (Hibbs et al.. 1971, 1972;
Krahenbuhl and Remington, 1974; Keller and Jones, 1971; Evans and
Alexander, 1972a). Thus specific pathogen free animals ought to be
used to ensure production of specific macrophage activating factor.
Non-specific MAP has also been obtained from mixed lymphocyte cultures
(Godal et al.. 1971; Dimitriu et al.. 1975) and from concanavalin
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A-stimulated lymphocyte cultures (Pidler, Darnell and Budmen,
1976).
Fractionation of MAF-containing supernatants by column gel-
filtration has been performed by several groups, and the molecular
weight determinations all fall within the same range: 35*000-55,000
Daltons (Nathan et al., 1973), about 30,000 Daltons (Lohmann-Matthes,
1976) and in an allograft situation, 45,000-55,000 Daltons (Dy,
Kamoun, Dimitriu and Hamburger, 1976). Evans et al. (1972) reported
that in addition to a low molecular weight fraction (50,000-60,000)
MAF activity was also associated with a fraction containing material
of a size greater than 300,000 Daltons. The lower molecular weight
material elutes in the same band as other non-antibody lymphocyte
mediators called lymphokines (Dumonde et al.. 1969, 1975). Nathan,
Remold and David (1973) found that macrophage migration inhibitory
factor eluted from Sephadex G-1 00 in the same fraction as MAF, and
in fact these authors were unable to distinguish between MIF and
MAF, concluding that they may be the same material. MIF/MAF activity
could be differentiated from other lymphokines eluting in this fraction
such as lymphotoxin and macrophage chemotactic factor (Nathan et al..
1973). This association between MIF and MAF has also been observed
by others (Rocklin, Winston and David, 1974b; Lohmann-Matthes, 1976)
although further analysis is required to determine whether they are
indeed the same substance.
Another lymphokine which is potentially capable of mediating
the cytotoxic effects in the anti-tumour assay is interferon, known
to activate macrophages (Schultz, Papamatheakis and Chirigos, 1977a)
and to inhibit cellular proliferation (Gresser, Brouty-Boye, Thomas
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et al., 1970). Interferon is produced in vitro by non-adherent
spleen cells, possibly B cells, from C. parvum-treated mice and,
provided that C. parvumjypresent, also from untreated mice (Hirt,
Kochen and Kirchner, 1977). This production of interferon by normal
spleen cells makes this lymphokine a less likely candidate for the
mediator molecule in the system described in this thesis since normal
spleen cells did not activate macrophages.
There have been several attempts to identify the lymphocyte
responsible for the production or release of MAT1. Studies using
anti-9 serum (Evans et al.. 1972; Grant et al., 1973; Lohmann-
Matthes et al.. 1973), T cell-deprived mice (Evans et al., 1972), and
cell separation on cotton wool columns (Lohmann-Matthes and Fischer,
1973) indicated that the macrophage activating factor was T cell-
dependent and may have been a T cell product. However, other workers
have attributed MAF production, as assessed by the enhanced incor-
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poration of C-labelled glucosamine into macrophages in culture
(Hammond and Dvorak, 1972; Wilton, Rosenstreich and Oppenheim, 1975),
to both T and B cells, following stimulation with antigens or mitogens
(Wahl, Wilton, Rosenstreich and Oppenheim, 1975). Wahl and Rosen¬
streich (1976), however, believe that antigen-specific lymphokine
synthesis by B cells requires help by a soluble factor from antigen-
activated T cells. Wahl et al. (1975) also observed that whereas
T cell production of monocyte chemotactic factor and MAF required
the cooperation of macrophages, B cell production of these lymphokines
could occur in the absence of macrophages. The possible role of
macrophages in the release of mediators by lymphocytes has yet to
be assessed in the in vitro C. parvum anti-tumour assay.
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Other mediators once thought to be solely of T cell origin
have now also been demonstrated to be elaborated by B cells:
macrophage migration inhibitory factor (MIF) (papageorgiou, Henley
and Glade, 1972; Rocklin, MacDermott, Chess et al.. 1974a); osteo¬
clast activating factor (Mundy, Luben, Raisz et al., 1974); inter¬
feron (Epstein, Kreth and Herzenberg, 1974; Wallen, Dean and Lucas,
1973); and lymphotoxin (Granger et al., 1970). Of particular interest
is the finding that antigen-antibody complexes and bacterial products
such as LPS and tuberculin PPD could stimulate B cell enriched popu¬
lations to produce a macrophage chemotactic factor (Wahl, Iverson
and Oppenheim, 1974). It is thus conceivable that C, narvum, known
to be a B cell mitogen (Zola, 1975) would also stimulate B cell
production of macrophage-regulating lymphokines.
The nature of the specific component of specific MAF has been
the subject of much speculation. The discovery of Evans et al..
(1972) that SMAF activity was also associated with a large molecular
weight ( 300,000 Daltons) substance suggested that specificity could
be due to an immunoglobulin. Indeed SMAF can be absorbed from
culture supernatants by macrophages or the immunising tumour cells
in an antibody-like manner (Evans et al., 1972; Pels and Den
Otter, 1974). However, Lohmann-Matthes and Fischer (1973) demon¬
strated that the specificity of their activating factor was not due
to conventional IgG or IgM, to antigen/antibody complexes, or to
cooperation between a non-specific T cell product and antibody.
Furthermore, a recent analysis of a non-specific MAF, which also
gave two active fractions, one of 60,000 Daltons and one greater
than 300,000 Daltons, failed to detect IgM in the larger molecular
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weight material (McDaniel, Laudico and Papermaster, 1976). MAP
activity in the two fractions was associated with albumin and alpha-
2-macroglobulin (alpha-2-M) respectively, and it was mooted that these
proteins were acting as carriers for the activating factor. It should
be noted that this particular MAP was obtained from a human cultured
lymphoid cell line and thus may not be typical of MAP produced by
lymphocytes responding to antigen or mitogen. Nevertheless, the
idea that alpha-2-M may be associated with macrophage activation is
very interesting in light of the diverse range of homeostatic and
immunological functions already attributed to this serum protein
(James, 1975; Home, Thomson, Towler et_al., 1975; Debanne, Bell and
Dolovich, 1976; Blumenstock, Saba, Weber and Cho, 1976; Harpel, 1973).
Owing to the lack of positive evidence for a role for B cell
antibody in specific MAP preparations, and because of its T cell-
dependency, the possibility was considered that T cell immunoglobulin
could be involved. Evidence has accumulated showing that T cells
carry, on their surface, immunoglobulin determinants (Bankhurst, Warner
and Sprent, 1971 ; Marchalonis, Haustein, Harris and Miller, 1975)
known to resemble the monomeric subunits of IgM pentamers (Marchalonis,
Cone and Atwell, 1972), and which can act as antigen receptors (March¬
alonis.and Cone, 1973). In this respect it is intriguing that the
operation of specific MAP can resemble the stimulation of B cell
responses to antigen by T cells, a cooperation which is mediated by
macrophages which have absorbed complexes of T cell-Ig and antigen
released from the surface of the activated T cells (Peldmann, 1972;
Cone, Peldmann, Marchalonis and Nossal, 1974). It is also relevant
that the T cell-Ig in this work was cytophilic for macrophage whereas
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33 cell monomeric IgM was not (Cone et al., 1974). MAP is cytophilic
for macrophages (Lohmann-Matth.es and Fischer, 1973; Evans and Alexan¬
der, 1976).
The question of whether C. -parvum-elicited MAF is of the specific
or non-specific variety is difficult to determine, at least from the
evidence presented in tliis thesis. Since the mice used were from an
open colony it might he expected that the MAF produced would he non¬
specific (Lohmann-Matthes, 1976). Indeed non-specific activation
appears to occur in that once macrophages have been incubated in
MAF-containing supernatant, C. parvum need not be added to achieve
anti-tumour cytotoxicity. A similar result was reported by Evans
et al., 1972 using BCG, but unfortunately, in both studies soluble
BCG or C♦ parvum antigens may have been present in the supernatants
used. On the other hand Christie and Bomford (1975), although
obtaining some activation using C. parvum-elicited MAF alone, found
that the greatest anti-tumour effect resulted when macrophages were
exposed to MAF in the presence of C. parvum. or even unrelated
ba.cteria such as Proteus vulgaris and Escherichia coli. These authors
thus demonstrated that the production of C. parvum-MAF was a specific
event but that once exposed to MAF macrophages could be activated
to full cytotoxicity by other (non-specific) bacteria.
The question of the specificity of C. parvum-MAF must remain an
open one particularly in view of the evidence (discussed more fully
in an earlier section on specificity) that both specific and non¬
specific anti-tumour responses occur following the systemic adminis¬
tration of C. parvum.
Although MAF production can be demonstrated easily in vitro it
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doesn't necessarily follow that it is an important effector mechanism
in vivo. The inability of sera from C. -parvum-treated mice to acti¬
vate macrophages _in vitro suggests either that it did not contain
MAP or that it was present in insufficient quantities. Thus in
vivo MAP production may only be a local phenomenon, possibly confined
to lymphoid organs, and requiring close association of lymphocytes,
macrophages and C. parvum. In this respect it would be important to
know the distribution of C. parvum following its injection. Three
recent studies (Dimitrov et al., 1977; Sadler et al., 1977; Scott
and Milas, 1977) using fluorescein-labelled and/or radio-labelled
C. -parvum showed that following i.p. or i.v. injection C. parvum
could be located in the liver, spleen, gut and, to a lesser extent,
in bone marrow, lungs and lymph nodes. Subcutaneous administration
of C. parvum resulted in a persistence of the bacteria at the site
of inoculation, thus probably accounting for the poor efficacy of
this route of administration in treating any but local tumour nodules.
These studies were also able to throw further light on the
mechanism of C. parvum's anti-tumour effects, and are worth elaborating
in more detail. Scott and Milas (1977) found that in contrast to a
biologically inactive strain of C. parvum. (CM 5888) which was rapidly
broken down and cleared, C. parvum 6154 persisted in organs, and
could be detected after more than a month following injection. This
resistance to degradation of C. parvum 6134 is probably important in
its anti-tumour effects, and would also account for its hyperplastic
effect on liver and spleen (Adlam and Scott, 1973).
Labelled C■ parvum could also be located in the body of solid
tumours (Sadler et al.. 1977; Scott and Milas, 1977) although there
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was no correlation between the amounts found, and the susceptibility
of tumours to i.v. administered C. narvum. Autoradiographic studies
confirmed that labelled C« narvum was only present in the cytoplasm
of phagocytic cells in the various organs examined (Sadler et al.,
1977).
These results, therefore, show that macrophage activation could
occur locally and over an extended period of time. It is also inter¬
esting that although no C. -parvum was found in peritoneal exudate
cells after i.v. injection, the peritoneal macrophages had, neverthe¬
less, been activated and could inhibit tumour growth in vitro
(Scott and Milas, 1977). Presumably macrophages, or their precursors,
were being activated elsewhere before migrating into the peritoneal
cavity. Furthermore, the absence of labelled C. narvum in these
cells meant that, either phagocytosis of the bacteria was not required
in this process, or that they were digested very rapidly following
activation. It has been observed that bone marrow-derived macrophages
can be activated in vitro by MAF (Meerpohl, Lohmann-Matthes and
Fischer, 1976).
In conclusion, there are various areas for further research
with respect to C. parvum-MAF. It is not known whether the producing
lymphocytes are B cells, or T cells or both and, although the spleen
cells in this study were depleted of glass-adherent cells, this pro¬
cedure is not rigorous enough to exclude the possible involvement of
macrophages in MAF release. The specificity of C. -parvum-MAF could
be explored further by replacing C. narvum 6134 with other strains
and other organisms. MAF-rich supernatants should also be fraction¬
ated on Sephadex columns to determine the molecular weight of the
active moiety.
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7. DIRECT ACTIVATION OF MACROPHAGES BY C. PARVUM
The experiments attempting to activate normal, non-cytotoxic
peritoneal macrophages by culturing them with. C. parvum, serum from
C. narvum-treated mice or with mixtures of both to give antigen-
antibody complexes, all proved unsuccessful. This approach had been
prompted by reports of direct activation in vitro of macrophages by
various agents; a fraction extracted from Mycobacterium smegniatis
(juy and Chedid, 1975), double-stranded RITA, the lipid A fraction of
endotoxin, synthetic poly(l).poly(c) (Alexander and Evans, 1971; Parr,
Wheeler and Alexander, 1973), and possibly tumour antigen-antibody
complexes (Evans, 1975). Nevertheless, the failure to demonstrate
a direct activation by C. parvum in vitro does not rule out the -
possibility of such a mechanism operating in vivo, possibly mediated
by humoral factors such as complement and antibodies to C. parvum.
C. parvum has been shown to activate both the classical and
alternate (properdin) pathways of complement when added to guinea
pig serum (McBride, Weir, Kay et al., 1975c). Activation of both
pathways can also occur in patients receiving C. parvum immunotherapy
(Biran, Moake, Reed et al., 1976). Activation of the alternate path¬
way (Gotze and Muller-Eberhard, 1971) has also been described for
endotoxic lipopolysaccharides exhibiting anti-tumour activity (Okuda,
Yoshioka, Ikekawa et al., 1972).
The importance of the lipid or lipopolysaccharide content of the
anaerobic coryneform bacteria is now also recognised as it apparently
accounts for many of the biological properties of these organisms:
increased blood clearance of carbon (Otu, Russell and White, 1977) and
virulent organisms (Pauve and Hevin, 1974); increased resistance towards
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infection (Fauve and Hevin, 1974); anti-tumour activity (leBride,
Dawes and Tuach, 1976); chemoattractant for macrophages (Russell,
Mclnroy, Wilkinson and White, 1976). It has been proposed that the
biological activities of endotoxic lipopodysaccharides are mediated
by the complement system (Gewurz et al., 1968). Such a system might
explain why such a great diversity of agents and microorganisms can
have similar effects on macrophages.
Thus a mechanism of macrophage stimulation can be envisaged during
C. parvum treatment requiring activation of the alternate pathways or,
following formation of C. parvum-C. parvum antibody complexes, of
the classical pathway and probably involving binding of complexes
at macrophage C3 receptors. Also of great relevance to the activation
of macrophages by C. parvum is the observation of Ogmundsdottir
and Weir (1976) that C. parvum NCTC 10390 binds to mouse peritoneal
macrophages via plasma membrane receptors having specificity for
sugar determinants in the cell wall of C. parvum bacteria, whereas
r fthe biologically inactive anaerobic coyneform Propionibacterium
freudenreichii RCTC 10470 exhibited only slight binding. Trypsin
treatment of the macrophages failed to affect this binding indicating
that the receptors were not cell-bound antibody.
The association of complement and the activation of anti-tumour
activity in macrophages by C. parvum can be extended further. Attach¬
ment of the C3 cleavage product, C3b, to mouse macrophages in vitro
results in a release of lysosomal enzymes. Such enzymes can also
cleave C3 thus generating more C3b and creating an amplification
system (Schorlemmer, Davies and Allison, 1976). In addition a
fragmentation product of the fifth component of complement C5a, has
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been shown to be an important chemotactic factor for guinea pig
macrophages and polymorphonuclear leukocytes (Snyderman, Shin and
Hausman, 1971). C5 can be cleaved by macrophage-derived proteinase
to give several chemotactic fragments thereby providing amplifi¬
cation (Snyderman, Shin and Dannenberg, 1972).
Activation of both the alternate pathway and, by virtue of
the presence of naturally occurring antibodies to C.- parvum in the
mice used in these studies (Woodruff, McBride and Dunbar, 1974;
James et al., 1976), the classical pathway could occur soon after
C. parvum treatment. Thus complement may play an essential role in
the earlier effects of C. parvum on the reticuloendothelial system.
Among such early consequences is a stimulation of macrophage colony-
forming cells from bone marrow in normal mice (Wolmark et al., 1974;
Baum and Breese, 1976) and in tumour-bearing mice (Wolmark and
Fisher, 1974). The numbers of colony-forming cells reached a maximum
48 hours following C. parvum treatment. However, in a similar study,
Dimitrov, Andr^, Eliopoulos and Halpern (1975) found that the effect
was not apparent until 5 days after inoculation. Macrophages derived
from the bone marrow of tumour-bearing mice exhibit specific anti-
tumour cytotoxicity in vitro (Fisher, Wolmark, Coyle and Saffer,
1976c). Bone marrow macrophage-precursors from normal mice can also
be rendered cytotoxic by a macrophage cytotoxicity factor derived
from cultures of immune lymphocytes (Meerpohl, Lohmann-Matthes and
Fischer, 1976). (vide su-pra).
Another early effect following systemic C. naryum treatment is
the appearance, by day 3 or 4, in the spleen and peritoneal cavity,
of macrophages cytotoxic for tumour cells in vitro (this thesis, G-haffar
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et al.t 1974).
It is of interest that a recent publication describes a biphasic
activation of murine macrophages, as assessed by carbon clearance,
following i.p. C. uarvum treatment (Otu et al., 1977). There was a
peak of activity at 2 days, attributed to the lipid content of the
bacteria, followed by a late phase of activation with maximal ac¬
tivity at 14 days, the reasons for which were less clear. This later
peak of stimulation may be explained by the production of macrophages
activated by lymphocytes responding to the C. oarvum injection as
described in this thesis.
8. MECHANISMS OF MACROPHAGE ACTIVATION
It is easy to forget in immunobiology that when studying an
arm of the immune system in isolation, that that arm is, in reality,
only part of a complex, but integrated, balanced whole. Administra¬
tion of immunopotentiators such as C. narvum result in an alteration
of the balance, and all aspects of the immune system are affected:
the reticuloendothelial system is stimulated, there is a strong
adjuvant effect on B cells, many T cell-mediated phenomena are de¬
pressed and both specific and non-specific anti-tumour responses
augmented. This thesis has been primarily concerned with the anti-
tumour effects of C. parvum as mediated by activated macrophages
and in the mechanisms underlying the production of such macrophages.
A picture has emerged of two processes leading to the development
of macrophages with in vitro anti-tumour potential, one an early
phase, possibly involving direct activation of mature macrophages
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or macrophage precursors, and the other, a later phase of activation,
mediated by lymphocytes sensitised to C« parrom. The first mechanism
possibly operates concurrently with the second once it becomes esta¬
blished. These proposed mechanisms have been outlined below and
are shown diagrammatically in fig. 7. Direct activation could occur
by binding and/or ingestion of C. -parvum or of C. narvum-antibody
complexes. No in vitro evidence was obtained for such a concept.
However, in vivo activation of the complement system by the classical
or alternate pathways could be associated with such a mechanism.
Complement activation would also result in the production of com¬
plement derived macrophage chemotactic and macrophage stimulatory
factors as well as cleavage products of C3 known to be cytolytic
for tumour and other cells.
A known early effect of C. narvum is the stimulation of bone
marrow colony formation. Whether this effect is mediated by C♦ narvum
directly or by humoral factors such as antibody and complement is
not known. It would be interesting to see if bone marrow cells
could be stimulated to form colonies in vitro by C. parvum alone or
whether serum from C. narvum-treated mice was required. The in
vitro cytotoxicity of such colony cells could also be assessed. Bone
marrow-derived macrophage precursors have been activated in vitro
by a MAP preparation (Meerpohl et al., 1976).
Early activation of macrophages may be mediated by the lipid
component of C. parvum. as suggested by Otu et al.. (1977).
Spleen cell-mediated macrophage activation did not appear until
day 6 or 7 post i.v. or i.p. injection of C. narvum which implied
that an immunological process was involved. This was also shown
Figure7.
MECHANISMSOFMACROPHAGEA TIVATIONFOLLOWINGSYSTE ICADMINIS RATIONF.PARVUM Notethatactivatedmacrophagesyt ems lvemplifyrregulatethff ct .
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by the earlier activation obtained in mice presensitised to C.
-parvum (Bomford and Christie, 1S75). The apparent delay between
the first appearance of cytotoxic peritoneal macrophages by day 2
or 3, and the development of activating cells in the spleen, could
indicate that activation in vivo is mediated by another lymphocyte
population such as that in the peritoneal cavity, and which responds
at a different rate. However this explanation also has to account
for the similar activation kinetics following i.p. or i.v. injection
of C. parvum. Of relevance to this was the finding of Scott and
Milas (1977) that although C. parvum was not detectable in peritoneal
macrophages following i.v. administration, these cells were still
cytotoxic, implying that activation either occurred outside the
peritoneal cavity, or was mediated by sensitised lymphocytes migrating
into it. An alternative explanation of the delay in appearance of
activating cells may simply be that there were insufficient numbers,
of sensitised spleen cells before day 7 to be detectable in the
activation assay.
Macrophage activation by splenic lymphocytes could be mediated
by a factor, or factors released from the lymphocytes in the presence
of C. parvum. It was not known whether activation in the presence
of lymphocytes was also mediated by MAP. The nature of MAP was not
investigated. It was thought possible that the C. -parvum-mediated
in vitro retention or regeneration of macrophage cytotoxicity may
be caused by a regeneration of MAP, in the culture wells, by a small
residual population of peritoneal lymphocytes. Macrophages could
participate in MAP production although their involvement was excluded
to a large extent by prior removal of glass adherent cells from
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spleen cell suspensions. It would "be interesting to know if activated
macrophages could activate other non-cytotoxic macrophages. This
may occur indirectly, anyway,through release and cleavage of com¬
plement products.
The relative roles of T cells and B cells in MAP production and
macrophage activation have not "been established unequivocally.
The above outline of possible macrophage activation models
leaves many questions unanswered. For example, the question whether
T cells or B cells, or both, are required for MAP release and macro¬
phage activation ought to be investigated using homozygous nude mice
and anti-B cell serum to supplement the methods used in this project.
In individuals with C. -parvum-augmented specific tumour immunity
(see Scott, 1975; Bomford, 1975) T cells presumably play an important
part, either directly, or in cooperation with macrophages, in the
expression of cytotoxic effects. It would be interesting to know
if lymphocytes from such Individuals could activate normal macro¬
phages to express specific cytotoxicity, as in the SMAP system
described by Evans and Alexander (l972a, b).
Another area of work which could be extended would be the inves¬
tigation into C. -parvum-MAP to discover its nature and its relationship
both to lymphokines and to serum proteins such as albumin, and alpha-
2-macroglobulin. Sephadex gel column separation of lymphocyte culture
supernatants ought to provide some of the answers.
Experiments using bone marrow colony formation techniques would
determine whether C♦ parvum can activate macrophage precursors
directly, or through the complement-antibody system. The possible
role of complement products in the mediation of C. -parvum's biological
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and anti-tumour effects ought also to be studied.
Finally, the possible role of natural killer cells as effectors
of C. -parvum' s in vivo and in vitro anti-tumour activity ought to
be considered. It seems unlikely that the in vitro phenomena de¬
scribed in this thesis were mediated by such cells unless they dis¬
played many of the physical and biologicalcharacteristics of macro¬
phages such as adherence, phagocytosis, susceptibility to gold salt,
and radioresistance. However, in the in vivo situation natural killer
cells could be augmented by C. parvum treatment and thus play a
significant role in anti-tumour effects. Confirmation of such an
effect will probably have to await a suitable cell separation pro¬
cedure.
9. CONCLUDING REMARKS
In conclusion, this thesis confirms that macrophage cytotoxicity
can be induced in vitro by direct incubation, either with sensitised
lymphocytes in the presence of C. -parvum, or- with culture supernatant
containing lymphocyte-derived MAF. The results also affirm the nece¬
ssity to administer C. parvum by the i.p. or i.v. routes in order to
obtain a systemic anti-tumour effect. The subcutaneous route remains
only of value for local effects.
Discounting the artificiality inherent in any in vitro model,
it is likely that the activation system described is operative _in vivo
in the C. uarvum-treated animal. This was supported by experiments
assaying the in vitro cytotoxicity of PE cells from C. -parvum-treated
mice (Ghaffar and Cullen, 1977) which showed a similar pattern and
time course of anti-tumour activity to that of the development of splenic
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lymphocyte capacity to activate macrophages in vitro. Both these
studies illustrated that the anti-tumour protection afforded by a
single i.v. or i.p. injection of C. parvum declined with time. This
decline may be akin to the loss of cytotoxicity of macrophages when
cultured, and probably reflects the eventual elimination of C. uarvum
organisms from the body. This would prevent continued, new activa¬
tion of macrophages as well as restimulation of lost macrophage
activity.
In a clinical situation where it is desirable to sustain a
maximal anti-tumour effect over a prolonged period, C. parvum would,
with the possible exception of- intratumour treatment, probably have
to be administered at regular intervals. The parameters of dose,
route, and timing of injections which would give optimal anti-tumour
effects are still being evaluated. The high doses of C. parvum
administered in the earlier animal studies had several undesirable
consequences. Many T cell functions were suppressed (Scott, 1974c)
with consequent increased risk of infection and the possible loss of
the specific component of C. -parvum's anti-tumour response. It should
be noted that the dose of 1 .4mg used in my experiments is now regarded
as a large one and thus it would be interesting to repeat the acti¬
vation experiments using smaller doses. High doses can also result
in undesirable toxic effects (Scott, 1974c). Thus in animal studies
C. parvum is now often given in "human equivalent" smaller doses.
Scott and Warner (1976) demonstrated that weekly small doses of i.v.
injected C. parvum gave an anti-tumour response as assessed in vivo
and in vitro and had the added bonus of avoiding impairment of T
cell function.
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The nonspecific anti-tumour protection afforded by systemic
C. parvum injection is probably of particular importance to patients
in the later stages of cancer who may have a depressed immune system.
Possibly of greater value in immunocompetent patients would be the
augmentation of a long-lasting specific response to their own tumour.
This can be achieved by either injecting C, parvum into, or close
to, the tumour, or by injecting C. -parvum together with irradiated
tumour cells subcutaneously. (Scott, 1975; Bomford, 1975). A
successful outcome using the latter therapy requires use of the correct
doses of C. parvum and irradiated tumour cells (Bomford, 1975; Woodruff
and Whitehead, 1977). Large doses of C. parvum administered as a
mixture with irradiated tumour cells abrogated the normal immunising
effect of such irradiated tumour cells (Woodruff et al.. 1976a).
Recent work on this phenomenon points to the induction of specific
immunological tolerance resulting from the injection of a' large dose
of C, parvum mixed with irradiated tumour cells (Woodruff and White¬
head, 1977). Bomford (1977) has recently described further conditions
which allow promotion rather than inhibition of the growth of MC-
induced tumour cells in the footpads of C. -parvum-treated mice.
Promotion occurred with low doses of tumour cells (around the TD50),
or with high doses of C. parvum given before tumour challenge, except
when i.v. C. -parvum was used in conjunction with very small numbers
of tumour cells. Bomford argued that these findings were due, not
to the presence of C. parvum-induced suppressor cells, but to the
trapping of anti-tumour effector cells at the site of C. narvum
deposition. C. -parvum given before the tumour challenge would thus
pre-empt the migration of such effector cells to the tumour site.
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These studies demonstrate that considerable caution must be
exercised when using C, narvum as a tumour immunotherapy agent and
that further research into the mechanism of its action .is required.
Nevertheless, C. parvum, whether administered on its own or in
conjunction with chemotherapy, radiotherapy or specific tumour immuno¬
therapy, still promises to be of value in the treatment of residual
or disseminated cancer. Just how promising it proves to be will
depend on the outcome of the many current C. oarvum clinical trials.
A P P E N D IX
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APPENDIX
Dulbecco's Phosnhate Buffered Saline (PBS)








This formulation can be obtained in tablet form from Oxoid Ltd.,
London. Ten tablets are dissolved in 1 litre of distilled water
This can be obtained in 5ml sterile ampoules from Oxoid Ltd.,
London. Add 5 ml of solution B to 1 litre of solution A to make
up the complete Dulbecco PBS of pH 7.4.
Assessment of cell viability by trypan blue exclusion
The following method for the assessment of cell viability is
based on that described by Waithe and Hirschorn (1973). 0.1 ml of
cell suspension is added to 0.1 ml of 0.16 per cent (w/v) solution







of trypan blue in RPMI-1640. The suspension is then mixed and
incubated for 5 minutes at 37°C. Viable (non-blue) cells are then
counted immediately. The trypan blue assessment of viability was
always compared with that obtained by phase-contrast microscopy
in this study.










Pyridoxine HCL 1 .0
Riboflavin 0.2
Thiamine HCL 1.0







































L-tyrosine (Na salt) 20.0
L-valine 20.0
This is the formulation for RPMI-1640 medium as it appears in the
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